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Introduction
In the late 1980s there was a true turnabout on the important issue of neonatal pain. 
Then, Anand and co-workers [1, 2], published a trial on preterm infants randomly al-
located to fentanyl with a muscle relaxant or muscle relaxant only during surgical patent 
ductus arteriosus (PDA) closure. This provided evidence, for the first time, that preterm 
infants  have a capacity to feel pain from a very early age (24-26 weeks gestation) and 
that early repetitive pain gives rise to short-term and long-term consequences [3, 4]. 
Nowadays pain management has become an essential part of the standard of care 
in NICUs worldwide, and pain is considered ‘the fifth vital sign’. The degree of distress 
associated with the treatment of preterm infants is reflected by the, on average, 11.2 
painful procedures per day at our NICU [5]. Studies from NICUs in other countries have 
shown a similar trend with 6 to 17.3 procedures per newborn per day [6-11]. It has been 
found also that neonates receive comparatively less pain medication than older children 
and adults in similar painful procedures [12]. Caregivers may be reluctant to prescribe 
analgesics to neonates for fear of adverse effects, drug tolerance and dependence [13]. 
Moreover, there are few dosing guidelines and pharmacokinetic data on common drugs 
for neonates of different gestational ages and birth weights. On top of this, more than 
90% of the currently prescribed drugs to neonates are not licensed for or are used in an 
off-label manner in this age group — and pain medication is no exception. 
Animal and human studies have shown significant risks for neurological impairment, 
besides adverse learning, cognitive and behavioral effects after exposure to pain early 
in life [14, 15]. Painful skin-breaking procedures in very preterm infants, for example, 
have been related to impaired brain development characterized by reduced maturation 
of white matter and subcortical grey matter [16], and reduced brain size in the frontal 
en parietal regions [17]. The necessity to carefully manage painful procedures in very 
preterm infants is not debated, but the question how to do this most effectively and 
safely is still open. 
Analgesia is necessary to protect the newborn against the negative short and long term 
consequences of pain. Long acting opioids, such as morphine, are not effective to reduce 
procedural pain, such as that from heel sticks, in preterm infants [18]. Even anaesthesia 
is not without risks as neuroapoptosis is described in human and rodent studies [19-21]. 
Routine administration of morphine in ventilated neonates did not show a benefit in 
terms of neurological outcome and mortality and was associated with a higher inci-
dence of hypotension and other adverse effects [22-24]. Opioid administration even 
has more long-term consequences. De Graaf et al. showed negative effects on cognitive 
functioning in 5-year-old children who had been treated with morphine as a neonate 
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[25] and magnetic resonance imaging (MRI) in these children at the age of 14-17 years 
showed  less brain volume [26]. The effectiveness of sucrose to reduce procedural pain 
has also been questioned although it is still standard of care in many NICUs [27-29]. 
Safe and adequate dosing of analgesic medication is inextricably linked to proper pain 
assessment. Quite a few multidimensional pain assessment tools are available but only 
a limited number is recommended for neonates. The most used ones are the Premature 
Infant Pain Profile (PIPP) and the Neonatal Infant Pain Scale (NIPS). In 2001, a prospective 
study in our NICU found that neonates were subjected to a mean of 14.3 procedures 
per day  with the highest exposure to painful procedures (63.6%) during the first day 
of admission [6]. This was reason to implement an individualized pain management 
protocol providing for pain assessment with the COMFORTneo scale and pain treatment 
(both pharmacological and non-pharmacological such as NIDCAP and sucrose) guided 
by a decision tree.
Many  painful procedures are performed without analgesics, not only in the Netherlands 
[5] but also in Europe [30]. Our quest for new analgesic opportunities in neonatal pain 
management continues. Apart from the classic approach with opioids such as morphine, 
fentanyl, studies suggest a potential role for alternative drugs such as paracetamol. In 
other words, Paracetamol and Preterm infants: a painless liaison?
Paracetamol (N-acetyl-p-amino-phenol) was introduced by von Mering in 1893 but not 
widely used until the 1950s. Nowadays it is the most used analgesic and antipyretic 
drug in children and is even prescribed to neonates to treat mild to moderate pain. In 
addition it is increasingly used in combination with opioids to treat severe pain [31-33]. 
Paracetamol is less potent than opioids and probably induces fewer side effects, 
although hepatotoxicity has been described [15, 34-37]. In Europe there is no labeled 
use of paracetamol for neonates younger than 10 days of age. Term neonates and older 
children usually receive paracetamol via the intravenous, oral or rectal route, and there 
is limited evidence on the use of intravenous paracetamol in preterm neonates, espe-
cially those with a gestational age of less than 28 weeks [38]. Developmental changes in 
distribution, metabolism and elimination determine the appropriate dosing regimen of 
paracetamol for neonates with different gestational and postnatal ages [39]. Currently 
there are no dosing guidelines of intravenous paracetamol for very low birth weight 
(VLBW) infants.
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Working mechanism
The mechanism of action of paracetamol analgesia is multifactorial: not only does it 
influence the central nervous system by inhibiting the prostaglandin synthesis (COX3, 
COX 2b) but it also acts peripherally through metabolites of paracetamol that stimulate 
TPRA1 (Transient receptor potential ankyrin1), a protein found on the surface of nerve 
cells [40]. When TPRA1 is activated, it interferes and reduces the transmission of informa-
tion from pain-sensing nerves to the brain.
Furthermore paracetamol exerts its analgesic effects by inhibitory action on spinal nitric 
oxide mechanisms and serotonergic pathways by antagonizing N-methyl-D-aspartate 
and substance P induced spinal hyperalgesia [33].
Metabolism
The three pathways by which paracetamol is metabolized in the liver are sulphation, 
glucuronidation and oxidation. In neonates the most important route of metabolism is 
sulphation and the rate constant of sulphate formation in neonates is larger than in adults 
Figure 1. Metabolic pathways of paracetamol
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[41]. Neonates have an immature glucuronide conjugation system. When paracetamol is 
administered in therapeutic doses the major part is excreted as non-toxic metabolites in 
the urine after sulphation or glucuronidation. Approximately 5% is excreted unchanged 
in the urine and the remainder is metabolized by cytochrome P-450 in the liver, of which 
CYP2E1 is the most important iso-enzyme. The product of oxidation is a highly reactive 
metabolite, N-acetyl-p-benzoquinone imine (NAPQI). 
Dosing
Maturational changes in developmental physiology require age-specific doses, intervals 
and serum drug concentrations: the distribution volume of paracetamol is probably 
larger in preterm infants compared to term infants but seems to be similar in term neo-
nates and older children [32, 42-44]. Reduced clearance in preterm infants necessitates 
multiple doses treatment of paracetamol with a longer time interval or adjusted total 
daily doses to prevent progressive increasing plasma concentrations. Still, the optimal 
loading dose of paracetamol for VLBW infants is unknown and simply extrapolating 
dose recommendations for less preterm infants is inadvisable. We should remain cau-
tious, especially since high dose paracetamol treatment in preterm infants for PDA in the 
first days of life seems to win ground as drug of choice.
Paracetamol hepatotoxicity is caused by NAPQI, produced by the oxidative enzyme 
CYP2E1 and normally detoxified by glutathione reserves. Paracetamol concentrations 
associated with increased NAPQI in neonates have not been reported, and the activity 
of CYP2E1 is still not quantified [45, 46]. Whether hepatotoxicity by formation of NAPQIs 
and other metabolites in neonates is of lesser importance needs to be elucidated. 
Aims and outline of this thesis
The studies described in this thesis aim to improve our knowledge on the use, indica-
tions, effects and adverse effects of paracetamol in VLBW infants (pharmacokinetics). 
Furthermore they also address the use of pain assessments tools to quantify the pain-
relieving effect of paracetamol (pharmacodynamics).
In Chapter 2 we tested the psychometric qualities of a modified version of the COMFORT 
behavioral scale tailored for use in premature neonates, called the COMFORTneo scale.
In 2011 we prospectively evaluated the degree of compliance of our NICU medical 
and nursing staff with the protocolized pain assessments and treatment. As secondary 
outcome reasons for non-compliance were investigated (Chapter 3).
In Chapter 4 we evaluated whether the introduction of a new pain assessment pro-
tocol and pharmacological guidelines lowered the number of painful procedures and 
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our previous study in 2001. 
To gain more insight in the pharmacokinetic and pharmacodynamics aspects of intrave-
nous administered paracetamol, we conducted a multicenter, blinded and randomized 
trial in preterm infants (n= 60) with a gestational age between 24 and 32 weeks who 
were randomly allocated to three different single loading doses of intravenous para-
cetamol (10, 15, 20 mg/kg) before central venous catheter insertion in the first week 
of life. Plasma concentrations of paracetamol and its non-toxic and toxic metabolites 
were determined.  Furthermore we investigated the relation between an infant’s DNA 
and the formation of toxic metabolites of paracetamol with a possible threat to hepa-
totoxicity. The target was a polymorphism of CYP2E1, an important oxidative enzyme 
that can form a toxic metabolite of paracetamol called N-acetyl-p-benzoquinone imine 
(NAPQI) (Chapter 5). The effects of the three different loading doses of intravenous 
paracetamol were analysed with two different pain assessment tools: the PIPP score 
and the COMFORTneo scale. Scores in the study population were compared with scores 
in age-matched neonates (n = 20) who underwent central venous line placement with 
only sucrose as analgesia (Chapter 6). 
More recently paracetamol has been suggested to be effective for patent ductus arte-
riosus (PDA) closure [47]. More than 10 observational and retrospective studies have de-
scribed oral or intravenous high dose paracetamol treatment with varying effectiveness 
[48-50]. In Chapter 7 we describe, in a prospective observational single center study, 
the evaluation of the efficacy of intravenous paracetamol on PDA closure.  We included 
33 VLBW infants with hemodynamically significant PDA (hsPDA) who did not respond 
to ibuprofen or had a contraindication for ibuprofen treatment and received high dose 
paracetamol (15mg/kg/6h) for 3-7 days.
The results of our studies are addressed in the general discussion in Chapter 8, followed 
by future perspectives in research.
Chapter 9 contains the summary of this thesis.
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Abstract
Objectives
Pain assessment is essential to tailor intensive care of neonates. The present focus is on 
acute procedural pain; assessment of pain of longer duration remains a challenge. We 
therefore tested a modiﬁed version of the COMFORT-behavior scale – named COMFORT-
neo – for its psychometric qualities in the Neonatal Intensive Care Unit setting.
Methods
In a clinical observational study, nurses assessed patients with COMFORTneo and 
Numeric Rating Scales (NRS) for pain and distress, respectively. Interrater reliability, 
concurrent validity, and sensitivity to change were calculated as well as sensitivity and 
specificity for different cut-off scores for subsets of patients.
Results
Interrater reliability was good: median linearly weighted Cohen κ 0.79. Almost 3600 
triple ratings were obtained for 286 neonates. Internal consistency was good (Cronbach 
α 0.84 and 0.88). Concurrent validity was demonstrated by adequate and good correla-
tions, respectively, with NRS-pain and NRS-distress: r = 0.52 (95% conﬁdence interval 
0.44-0.59) and r = 0.70 (95% confidence interval 0.64-0.75). COMFORTneo cut-off scores 
of 14 or higher (score range is 6 to 30) had good sensitivity and speciﬁcity (0.81 and 0.90, 
respectively) using NRS-pain or NRS-distress scores of 4 or higher as criterion.
Discussion
The COMFORTneo showed preliminary reliability. No major differences were found in 
cut-off values for low birth weight, small for gestational age, neurologic impairment risk 
levels, or sex. Multicenter studies should focus on establishing concurrent validity with 
other instruments in a patient group with a high probability of ongoing pain.
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Introduction
Daily pain management in the Neonatal Intensive Care Unit (NICU) continues to be far 
from ideal according to surveys in Australia,1 France,2-4 and Italy.5 Yet, pain should be 
considered the 5th vital sign, recommends the American Pain Society, and accordingly 
be given due attention. Adequate dosing of analgesics in neonates must inevitably rely 
on proper pain assessment. The available pain measurement instruments mostly target 
acute procedural pain, such as caused by heel lance or postoperative pain. An interna-
tional expert group recommended the Premature Infant pain Profile (PIPP), Neonatal 
Infant Pain Scale, Neonatal Facial Coding Scale, and Crying; requires increased oxygen 
administration; increased vital signs; Expression; Sleeplessness for procedural pain as-
sessment.6
Acute pain measures include behavioral indicators of pain, of which facial expression is 
considered the most sensitive.7 Its sensitivity may be questioned however. Slater et al 
recently compared PIPP scores with cortical pain responses detected by near infrared 
spectrograph during 33 heel lance procedures in 12 infants. Surprisingly, in 10 out of 
these 33 procedures scores on the facial expression did not indicate pain, whereas 
cortical pain responses were present. Physiological indicators such as increased heart 
rate and decreased oxygen saturation also proved useful for acute, procedural pain as-
sessment.8 Heart rate changes and oxygen saturation changes are both incorporated 
in the PIPP.9 This instrument has been extensively applied in studies comparing pain 
treatments for procedural pain10-13 and in psychometric studies comparing PIPP with 
other instruments.14-16
Prolonged pain, for example, due to extended artificial ventilation or diseases such as 
necrotizing enterocolitis (NEC), is much more difficult to assess. Because it is not easy 
to differentiate it from other sources of distress. In 2006 the Neonatal Pain task Force, 
(appointed by the Food and Drug Administration and the National Institutes of Health), 
pointed out that pain instruments for ongoing pain in preterm and term infants are 
lacking. Assessing pain of longer duration remains a challenge as Stevens and Pillai Rid-
dell18 and Anand19 recently emphasized. Boyle et al20 asked clinical staff ﬁrst to guess 
whether preterm ventilated babies were receiving morphine or placebo, and next asked 
what made them think so. As staff associated facial expressions, high activity levels, poor 
response to handling, and poor ventilator synchrony with the effects of placebo, the 
authors suggest these factors are useful markers for persistent pain in preterm infants.
But are they indeed?
To date, 2 instruments designed to measure prolonged pain in neonates are avail-
able, the neonatal Pain, Agitation, and Sedation Scale (N-PASS)15 and Echelle Douleur 
Inconfort Nouveau-Né (EDIN).21 Hummel et al15 recently validated the N-PASS, analyzing 
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72 paired assessments before and after intervention in 46 infants. The N-PASS aims to 
assess both pain and sedation. It includes vital signs as 1 of 5 items. Interrater reliability 
between nurses was good and both beginning construct and concurrent validity were 
demonstrated. Internal consistency was good. There are no other studies investigating 
the usefulness of vital signs for prolonged pain assessment in neonates. The EDIN, a 
behavioral pain instrument widely used in French NICU’s, was validated in 76 neonates.21 
Interrater reliability, has been internal consistency, and sensitivity to change was estab-
lished. The EDIN incorporates ‘‘a blank face’’ and ‘‘paucity of movements,’’ features often 
seen in neonates, for instance those with NEC. Both instruments include consolability 
(the extent to which a child can be consoled), an aspect that goes beyond clinical obser-
vation we feel, and may require nursing interventions.
The Neonatal Task Force furthermore elaborated on behavioral distress, as shown during 
for instance mechanical ventilation. The creators of the COMFORT scale provided the 
following deﬁnition: behavioral distress encompasses all behaviors of negative affect as-
sociated with pain, anxiety, and fear.22 they added that distress may occur in the absence 
of pain. The question is how can we tell if a child is in distress, pain, or both? A neonate 
is like an “emotional black box” and caregivers find it very difficult to decide whether it is 
in pain or distressed, or both.
Disentangling both states requires emphasis on contextual factors as well. This is a uni-
versal challenge in all preverbal and nonverbal human beings, for example, neonates, 
cognitively impaired children and demented elderly. Although difficult, we have to 
make a serious attempt to address both.
In an earlier randomized controlled trial comparing morphine and placebo in ventilated 
premature neonates we used PIPP, Neonatal Infant Pain Scale, and COMFORT behavioral 
scale to assess pain/distress around endotracheal suctioning.23 After this trial, which run 
for almost 3 years, we asked nurses to choose an instrument for future application in 
situations other than acute pain. They were given a choice of 15 validated pain instru-
ments and chose the COMFORT behavior scale, provided it was slightly modiﬁed to 
make it more useful for preterm neonates.24 The COMFORT behavior scale had earlier 
been validated for postoperative pain in 0 to 3-year-old infants in our institute25 and for 
distress and sedation in children with a median age of 17 months.26
In this study, we tested the modiﬁed scale, which we named COMFORTneo scale. Two 
research questions were addressed: (1) Are the psychometric properties of the COM-
FORTneo scale adequate in terms of reliability, validity, and sensitivity to change? (2) Are 
different cut-off scores needed for different subpopulations in the NICU?
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Materials and methods
Patients and Settings
In this clinical observational study, all neonates admitted to the Erasmus MC-Sophia 
NICU in the period October 2005 to August 2006 were eligible, except those treated 
with continuous neuromuscular blocking agents. This NICU is a regional 28-bed tertiary 
care unit with 650 admissions yearly and a Neonatal Individualized Developmental Care 
and Assessment Program training center since 2003.
Procedure
In October 2005, the digital Patient Data Management System (PDMS) replaced paper 
recording. COMFORTneo scores and numeric rating scores for pain and distress, data 
on analgesics and sedatives were entered and later retrieved from the system. Nurses 
indicated if a patient’s assessment was ‘‘standard,’’ or performed on suspicion of pain or 
on suspicion of oversedation. Standard assessments were those performed at least once 
every shift to monitor the patient.
Acute painful procedures are not scored. Pain assessment is part of daily care and be-
cause of its noninvasive and observational character institutional review board approval 
of the study was waived.
Scales
The COMFORTneo scale was modiﬁed from the COMFORT behavior scale25 as follows. 
The item alertness was rewritten to bring it in line with Prechtl’s27 behavioral state cri-
teria. Muscle tone was no longer scored by touch, but by observation of toes and fists 
(clenched or not), ﬁngers played or not, and legs or arms (stretched or relaxed). The ‘‘no 
movement’’ response to body movement became ‘‘no or minor movement’’ because pre-
mature neonates are seldom without movement.28,29 Like the COMFORT behavior scale, 
the COMFORTneo scale is composed of 7 behavioral dimensions (Fig. 1). As respiratory 
response applies to ventilated neonates only, and crying to spontaneously breathing 
neonates only (including those requiring continuous positive airway pressure), the rater 
will actually rate 6 dimensions. Alertness, calmness/agitation, facial tension, muscle 
tone, body movement are rated for all neonates. As responses are on a 1 to 5 Likert scale, 
total scores ranges from 6 to 30−with higher scores indicating more pain. Before scoring, 
the rater will observe the patient for 2 minutes and next rate each individual item for its 
most extreme manifestation observed during this period.
The COMFORTneo was introduced in 2004 and its effectiveness was evaluated 6 months 
later by 6 nurses, a neonatologist (D.R.) and psychologist (M.v.D.). It was then decided 
to include a Numeric rating Scale (NRS) for distress as well because nurses felt that high 
COMFORTneo scores were often due to distress rather than pain. Nurses also were con-
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cerned that without a treatment algorithm pain assessment would be less effective and 
pain and distress would stay untreated. The data of 1164 assessments in 209 infants in 
the period March 2004 until September 2005 were used to calculate cut-off scores for a 
treatment algorithm.24-30 Internal consistency was good and concurrent validity with the 
NRS pain and NRS distress adequate.
A NRS for pain replaced the Visual Analogue Scale used with the COMFORT behavioral 
scale, as it fits in better with PDMS. Both NRS were used for ongoing validity testing.24 
Both NRS pain and NRS distress are scored after the COMFORTneo score by the caregiv-
ing nurse as representing the expert opinion of the nurse. Rating is on a scale of 0 to 10, 
with 0 representing no pain or distress and 10 worst imaginable pain or distress. Scores 
4 to 6 are considered to reflect moderate pain or distress and 7 to 10 severe pain or 
distress.31
Reliability
All nurses followed a 2-hour training program. The program includes 10 assessments in 
different patients, together with but independently from a qualified nurse. Agreement is 
assessed from the weighted Cohen32 κ calculated from these 10 paired assessments. If it 
was below 0.65, the nurse was asked to repeat 10 assessments until the required κ value 
had been reached. The linearly weighted κ corrects for chance agreement and gives 
greater weight to larger disagreements. As a rule of thumb, both Cohen and Fleiss33 
indicate that a κ of 0.61 or higher is adequate.
Internal consistency was calculated separately for spontaneous breathing versus 
mechanically ventilated neonates, using Cronbach α and minimum and maximum cor-
rected item – total correlation. Because the COMFORTneo scale is highly comparable 
with the COMFORT behavior, we did not repeat structural equation modeling. The previ-
ous analysis had shown that the COMFORT behavior scale could be represented by a 
single factor which was stable across repeated assessments.25
Concurrent Validity
Concurrent validity of the COMFORTneo scale was determined on the basis of the NRS-
pain and NRS-distress scores. The Pearson product moment correlation coefficients 
between the COMFORTneo and the 2 NRS scores are presented. As these correlations 
were found to violate the assumption of independence (repeated measurements), we 
also calculated the mean COMFORTneo, mean NRS-pain, and mean NRS-distress scores 
for each patient.34 The Pearson product moment correlation coefficients of these mean 
values are presented with 95% confidence intervals (CI) and p values.
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Sensitivity to Change
Sensitivity to change was determined by comparing scores before and after a pain or 
distress reducing intervention. Secondly, assessments indicated as standard in PDMS 
were compared with “suspected for pain” assessments in the same patients.
Patients with at least 1 assessment for each condition were included in the analysis. In 
addition, mean scores for the 2 conditions per patient were calculated. And finally, as-
sessments on “suspected for oversedation” were compared with standard COMFORTneo 
scores for the same patients. For all 3 types, sensitivity to change was tested using the 
paired t test for parametric data.
Cut-off Scores
The expert opinion of the nurses represented by both NRS-distress and NRS-pain was 
used as the gold standard against which cut-off scores for COMFORTneo were evalu-
ated. Cut-off scores are useful for clinical practice, because they can guide analgesic 
treatment. When either NRS-pain or NRS-distress scores were 4 or higher, a value of 1 
was assigned. Values below 4 were assigned 0. Different cut-off scores COMFORTneo 
were tested against this classiﬁcation.
Derivation of cut-off scores was as follows. First the combinations of speciﬁcity and sen-
sitivity for different cut off scores of COMFORTneo were calculated and presented in a 
receiver operating characteristic curve. Then, of the cut-off scores closest to the top left-
hand corner in the chart, the most ‘‘conservative’’ one of 14 was chosen as to prevent too 
rapid pharmacologic interventions. Sensitivity and speciﬁcity for speciﬁc cut-off scores 
were also calculated for subpopulations of extreme low birth weight (ELBW <1000 
grams), very low birth weight (1000 to 1499 grams), different gestational age groups (24 
to 28 weeks, etc.), and small for gestational age (SGA ≤ 2SD) infants. We also classified 
the sample by the level of risk of neurologic impairment (NI) into 3 groups according to 
Stevens et al.35 At high risk for NI are neonates with perinatal asphyxia, intraventricular 
hemorrhage grade III or IV, congenital syndrome, or chromosomal anomaly (group A). 
At moderate risk for NI are neonates with persistent pulmonary hypertension, severe 
meconium aspiration, meningitis, and NEC (group B). At low risk for NI are neonates 
with respiratory distress requiring ventilation and sepsis (group C). Finally, boys and girls 
were compared, because sex may influence pain response.36-38
Statistical methods
Three aspects of analgesic and sedative treatment are presented. First, the maximum 
hourly dosages per kilogram of body weight for continuous midazolam and morphine; 
second, duration of administration in days; and third, number of dosages for oral or 
intermittent bolus medication.
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Nominal variables of different groups were compared with the w2 test or Fisher Exact 
tests when cell values were small. Kruskal-Wallis test was used to compare nonpara-
metric continuous variables between more than 2 groups. Data are given as median 
(interquartile range, IQR) for nonparametric data and as mean (SD) for parametric data.
Correlational analyses were done with the mean of repeated assessments per patient as 
summary statistic39 to avoid statistical testing across nonindependent observations. In 
addition, the summary statistics were correlated with each other to determine the level 
of association.
Results
Patients and Assessments
In the study period, 488 neonates were admitted to the NICU. One or more COMFORT-
neo observations were performed in 286 neonates (gestational ages from 24.6 to 42.6 
weeks). Twenty-one percent were (ELBW <1000 gram) and 18.2% were SGA infants. 
Seventy-seven infants (26.8%) were at high or moderate risk for NI. The median number 
of assessments was 6 (IQR 2 to 13). Characteristics for the sample and for the infants 
not assessed are listed in Table 1. This latter group left the NICU significantly sooner 
(median stay 2 d opposed to 9 for the assessed patients) A significantly lower proportion 
of patients in the non assessed group received analgesics or sedatives.
COMFORTneo scores of 14 or higher were recorded for 23.1% of all 3596 assessments. 
Nurses sometimes failed to record NRS ratings in PDMS, so we could retrieve no more 
than 2684 and 2668 NRS ratings for NRS pain and NRS distress respectively. Moderate 
pain (NRS 4 to 6) was seen in 5.8% and severe pain in 1.3% (NRS 7 to 10) of assessments. 
Moderate distress (NRS 4 to 7) was scored in 12.6% and severe distress in 5.4% of assess-
ments (NRS 7 to 10). Figure 2 gives a boxplot with COMFORTneo scores grouped by type 
of assessment. For 143 assessments (4% of all assessments) made, as nurses suspected 
the neonate to be oversedated the median score was 10 (IQR 9 to 11). For standard as-
sessments, the median score was 11 (IQR 9 to 13), with 16.5% of the scores 14 or higher, 
requiring intervention. The highest median score is seen for the 290 assessments on 
suspicion of pain that is 18 (IQR 15 to 21).
Pharmacologic treatment
Forty-one percent of the assessed neonates received no analgesics (opioids or 
paracetamol at all during NICU stay. Almost half of the assessed patients (46.9%) received 
continuous morphine at a maximum dosage of 15 mg/kg/h (IQR 10.0 to 19.9) for a me-
dian duration of 5 days. Midazolam was given to 26.6% of all patients with a maximum 
dosage of 103mg/kg/h (IQR 100 to 10 As to classification by level of risk of NI, morphine 
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Table 1. Characteristics assessed (n = 286) and non assessed patients (202)
N (%)
Sample
N (%)
Not assessed
p-value
Boys/Girls 174/112 (60.8 
/39.2)
110/92 (54.5/45.5) 0.16
GA groups N=197
24.2 - 28.0 wk 58 (20.3) 9 (4.6)
28.1 - 32.0 wk 86 (30.1) 50 (25.4) <0.0001
32.1 - 37.0 wk 49 (17.1) 62 (31.5)
37.1 - 42.6 wk 93 (32.5) 76 (38.6)
Birth weight in grams N=192
ELBW < 1000 g 60 (21.0) 13 (6.8) <0.0001
VLBW 1000 to 1499 g 57 (19.9) 33 (17.2)
> 1500 g 169 (59.1) 146 (76.0)
SGA 52 (18.2) 33 (16.5) 0.63
Primary diagnosis
Respiratory insufficiency 153 (53.5)
Prematurity and/or SGA 41 (14.3)
Congenital cardio(vascular) defects 25 (8.7)
Perinatal asphyxia 25 (8.7)
Other1 42 (14.8)
Neurological outcome2
A=At high risk for NI 52 (18.2)
B=At moderate risk for NI 25 (8.7)
C=At low risk for NI 209 (73.1)
Postnatal age in days, median (IQR)
At first assessment 1 (0 to 3)
At last assessment 7 (2 to 19)
One month survival 88.5% 96.5 0.001
Mechanical ventilation during study period
Ventilated all the time 68 (23.8)
Part of the time 126 (44.0)
not at all during the study period 92 (32.2)
Total hospital stay in days
Median (IQR) 11 (4 to 28)
NICU stay 9 (4 to 23) 2 (1 to 6) <0.0001
Patients receiving opioids, benzodiazepines or 
barbiturates
148 (51.7) 19 (9.4) <0.0001
Patients receiving paracetamol 74 (25.9) 4 (2.0) <0.0001
1 Others: sepsis, cerebral abnormalities, metabolic problems and congenital anomalies
2 A; perinatal asphyxia, IVH grade III or IV, syndrome or chromosomal anomaly, B; persistent pulmonary hy-
pertension of the newborn, severe meconium aspiration, meningitis, necrotising enterocolitis C; respiratory 
distress requiring ventilation, sepsis (Stevens et al 2007)
abbreviations ELBW: extreme low birth weight; VLBW; very low birth weight SGA; small for gestational age; 
NI; neurological impairment IQR: interquartile range
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was significantly more often given to patients in the ‘moderate risk for NI” group (Fisher 
exact test, p = 0.001) in higher dosages (Kruskal-Wallis, p=0.032). Midazolam was given 
to 50% of the “high risk for NI” group, to 72% of the moderate risk for NI group, and 
to 15,3% of the minor risk for NI group. These percentages were significantly different 
(Fisher exact test, p=0.001). the highest dosages were noted for the high risk group for 
NI (Kruskal-Wallis test, p=0.012)
Phenobarbital was needed in 41 patients (14.3%) with a median of 1 dosage (IQR 1 to 
2). More than half of these patients were in the high-risk group. Patients in the ‘‘minor 
risk for NI’’ group required signiﬁcantly less phenobarbital than the other groups (Fisher 
exact test, p≤0.001). There was no statistically significant effect of sex on prescribed 
analgesics or sedatives.3
Psychometric Properties
Reliability
In total 141 nurses and 3 researchers followed the training program. Linearly weighted 
κ’s ranged from 0.65 to 0.97 with a median of 0.79. With Cronbach α of 0.88 in 1149 
scores, internal consistency of the COMFORTneo items for the nonventilated neonates 
was good. Corrected item total correlations ranged from 0.52 for muscle tension to 0.80 
for calmness. For mechanically ventilated neonates, 2447 scores yielded a Cronbach α of 
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0.84. Corrected item total correlations ranged from 0.49 for respiratory response to 0.72 
for calmness.
Concurrent Validity
The Pearson product moment correlation coeffi  cient between COMFORTneo and NRS-
pain was 0.54 in 2684 paired assessments. The Pearson product moment correlation 
coeffi  cient between mean COMFORTneo and mean NRS-pain per patient was r = 0.51 
(95% CI 0.43-0.59, p <0.0001) in 253 neonates. The Pearson product moment correlation 
coeffi  cient between COMFORTneo and NRS-distress was 0.83 in 2668 paired assess-
ments. Using the mean values of COMFORTneo and NRS-distress per patient gives a 
Pearson product moment correlation coeffi  cient of 0.75 (95% CI 0.70-0.79, p <0.0001) 
in 250 neonates.
Sensitivity to Change
For 110 paired assessments (in 76 neonates), we compared COMFORTneo scores 
before and after interventions to reduce pain or distress (Fig. 3). Mean scores before 
intervention (mean 19.8, SD 3.8) were signiﬁcantly higher (paired t test, t = 14.99, df = 
75, p ≤0.001) than after intervention (mean 12.0, SD 3.4). Interventions to reduce pain 
were administration of opioids (55 observations) and paracetamol (19 observations). 
Interventions to reduce distress were administration of sedatives (benzodiazepines, 
antiepileptics in 25 observations) and nonpharmacologic intervention (9 observations 
Figure 3. Boxplot of COMFORTneo before and after intervention, clustered by intervention type
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including swaddling, paciﬁer, and consoling). Two observations resulted in administra-
tion of both opioids and sedatives.
Assessments both in standard and suspected for pain conditions were made for 102 
patients. The mean COMFORTneo score was 11.4 (SD 2.6) for the standard condition and 
18.4 (SD 3.8) for the suspected for pain condition. The mean difference of 6.9 points 
(95% CI 6.1-7.8) is highly signiﬁcant (paired t test, t= 16.6, p ≤ 0.001) and indicates 
good sensitivity to change. For 66 patients mean COMFORTneo score during suspected 
oversedation was 9.7 (SD 1.7). This was signiﬁcantly lower than the standard mean score 
of 10.9 (SD 1.8) for these patients (paired t test, t = 4.45, p ≤0.001).
Cut-off Scores for COMFORTneo
Cut-off scores for COMFORTneo were calculated against NRS-pain or NRS-distress (or 
both) of 4 or higher. Sensitivity and specificity for COMFORTneo cut-off scores of 14 or 
higher were 0.81 and 0.90, respectively.
43 
 
Figure 4. Receiver operator characteristic (ROC) curve for COMFORTneo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Receiver operator characteristic (ROC) curve for COMFORTneo.
32 Chapter 2
Figure 4 gives the receiver operating characteristic curve showing sensitivity and 
speciﬁcity results for cut-off values close to the upper left-hand corner. Table 2 gives 
sensitivity and speciﬁcity at a cut-off score of 14 or higher for the different subgroups. 
Sensitivity ranged from 0.75 to 0.85 and speciﬁcity from 0.87 to 0.95 for the different 
subgroups. These ﬁndings do not support the need to apply different cut-off scores for 
these subgroups. Both sensitivity and specificity were comparable for the 3 groups at 
differing risk for NI. When using the NRS-pain of 4 or higher separately for these analyses, 
we would obtain 0.72 sensitivity and 0.80 specificity at COMFORTneo cut-off scores of 
14 or higher. For the NRS-distress of 4 or higher, sensitivity would be 0.81 and specificity 
0.90.
Discussion
Psychometric Properties
This psychometric study of 286 neonates includes as many as almost 3600 assessments. 
The results indicate that COMFORTneo can be assessed reliably after a 2-hour training 
session, has good interrater reliability, concurrent validity, and sensitivity to change. The 
calculated cut-off scores facilitate the design and implementation of treatment algo-
rithms, thus enhancing its clinical utility. To test concurrent validity, most psychometric 
Table 2. Sensitivity and specificity for COMFORTneo cutoff scores of 14 or higher for different subgroups
Subgroups N Number of assessments Sensitivity Specificity
COMFORTneo combined with NRS 256 2751 0.81 0.90
Gestational age
24 - 28 wks 49 935 0.76 0.91
28.1 - 32 wks 75 531 0.83 0.91
32.1 - 37 wks 46 436 0.78 0.89
>37 wks 86 849 0.84 0.90
Birth weight
< 1000 grams 53 915 0.78 0.90
1000-1499 grams 47 548 0.77 0.94
1500 or more 156 1288 0.83 0.89
Small for Gestational Age 46 703 0.76 0.90
Neurological outcome
A=At high risk for NI 45 508 0.85 0.95
B=At moderate risk for NI 25 443 0.75 0.90
C=At low risk for NI 186 1800 0.80 0.87
Gender
Girls 100 963 0.77 0.92
Boys 156 1788 0.82 0.89
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studies use other existing behavioral pain instruments to compare with a newly devel-
oped one. We did not choose this approach because we feel the large overlap in items in 
neonatal behavioral pain instruments results in an artiﬁcially inﬂated correlation. Other 
ways to test validity should be considered.
Recent near-infrared spectroscopy studies for example showed that painful stimuli acti-
vate the cortex of preterm neonates.38-40 Future research protocols to validate clinically 
applicable tools could well include near-infrared spectroscopy or other neuroimaging 
methods, thus providing an objective, observer-independent evaluation of validity.38-42
Cut-off Score
We set a rather conservative cut-off score of 14, because we feel there is a thin line 
between harmful pain and drugs harmful to the developing brain. In other words, 
to prevent that potentially harmful drugs are prescribed too soon. For that matter, a 
number of neonatal studies have shown the limited effects of morphine to reduce acute 
pain.12-43 A recent study in neonatal rats repeatedly exposed to morphine reported 
prolonged pain hypersensitivity, decreased morphine antinociception, and decreased 
stress-induced analgesia.44 Earlier rat studies suggest that anesthetic agents such as 
midazolam enhance neuro-apoptosis.45 In contrast, there is substantial evidence from 
clinical studies that pain and distress are harmful in the short and long run. We therefore 
advice to assess pain frequently during analgesic treatment to facilitate optimal dosing 
of, for instance, opioids.
As pain scores for neonates of different gestational ages or for SGA neonates did not 
differ greatly, we conclude tailored cut-off scores are not needed.
This does not imply, however, that gestational age is of no consequence.
Clinical practice, for that matter, suggests that more immature babies need more time to 
recover after interventions; they show brief behavioral responses because they are more 
easily exhausted than the term neonates. In contrast, term neonates admitted to the 
NICU typically will have serious problems, such as asphyxia and meconium aspiration 
syndrome, which may dampen their pain responses.19
No substantial differences were found between the COMFORTneo scores for the groups 
distinguished by risk of NI, with comparable sensitivity and specificity for cut-off scores 
of 14 or higher. However, patients at moderate to high risk for NI seem to require more 
sedation and analgesia46 as was confirmed in this study. They can show irritability, 
restless behavior, inconsolability, or convulsions, and may require benzodiazepines for 
sedation or for treating convulsions. Preterm neonates with severe NI may also have 
lower levels of consciousness. For daily practice, it is important to take all such informa-
tion into account.
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Pain and Distress
Pain and distress can occur simultaneously, may inﬂuence each other and present with 
comparable responses in neonates. It is difficult therefore to discriminate between the 2.
The most sensible way to address this challenge is to carefully observe the effects of 
pain-reducing or distress-reducing interventions. In addition, caregivers should be open 
to the impact of other factors that affect the neonate’s level of pain and distress.
There are environmental factors such as noise and light levels, circumstantial factors, 
for example, postoperative state, having undergone painful procedures shortly before 
assessment, or analgesic and sedative treatment just started, and patient related factors. 
The latter category includes temperament, illness severity, behavioral signs impeded by 
specific conditions (e.g. NEC or sepsis), or NI.35
Nurses more often rated 4 or higher for NRS-distress than for NRS-pain, 18% versus 8%. 
We hypothesize that nursing staff may consider distress a more frequent problem than 
pain.
The prevalence of pain of longer duration in the NICU is unknown and not many stud-
ies have deﬁned its clinical manifestations in NICU patients. Pain of longer duration 
may result from surgery (extending beyond the acute postoperative period), from 
inﬂammation (caused by NEC, or meningitis, or thrombo-phlebitis), from skin burns 
(heated transcutaneous sensors or chemicals), birth trauma, or extended mechanical 
ventilation. Prolonged pain may be associated with the signs of low-grade distress 
because of the neonate’s poor energy reserves. It would seem important to educate 
nurses on the relevance of contextual factors, the complexities of pain and distress, and 
situations when prolonged pain is likely to occur.
On the other end of the pain and distress continuum is the challenge of potential 
oversedation. Nurses suspected oversedation once or more in 66 neonates. However, it 
might very well be that the real incidence is higher because lack of behavioral signs is 
less alarming to nurses than the presence of behavioral signs suggesting distress. The 
NICU treatment algorithm dictates that dose reduction should be considered, when 
COMFORTneo scores is 8 or lower.
Remaining in deep sleep for a considerable time (>12 h) even during handling should 
in most instances be reason to decrease morphine in small steps. But comfortable sleep 
during nighttime may result in a low COMFORTneo score, which does not necessitate 
change of therapy.30
Methodologic Limitations
This study had limitations, largely related to the fact that we used data from clinical prac-
tice. First, the nurse involved assessed both the COMFORTneo scale and NRS distress and 
NRS pain. It would be ideal to have a separate caregiver score 1 of the 3 independently, 
provided this person has the same contextual insight as the caregiving nurse. Second, 
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another instrument to compare the COMFORTneo against was lacking at the time. The 
N-PASS was not yet published and the EDIN had some items which nurses found difficult 
to assess. For instance the item ‘‘quality of contact with nurses.’’ Response categories for 
the items range from 0, ‘‘smiles, attentive to voice,’’ to 3 ‘‘refuses to communicate with 
nurses, no interpersonal rapport’’. This item was judged not applicable to very preterm 
neonates. Another EDIN item focuses on quality of sleep in preceding hours, which was 
considered difficult to assess reliably with the current practice of incubator covers.
In future studies, should independent observers score the N-PASS or PIPP or even EDIN 
simultaneously with the nurses’ scoring of the COMFORTneo. In this way a better esti-
mate of concurrent validity could be obtained.
Ratings before and after pain relieving interventions were rare. A possible explanation 
is that nurses tend to put trust in the prescribed therapeutic interventions and forget 
to check its effectiveness or deem this unnecessary, when the child responds to the 
prescribed drug as expected. More attention to oversedation could have given more 
insight into the extent of this undesired state and ways to prevent it.
Finally, although interrater reliability was satisfactory for all nurses when they took up 
scoring, it would have been better to reassess interrater reliability after 6 months so as 
to ensure quality of scoring.
Conclusions
We report the initial validation of a modiﬁed measure, the COMFORTneo scale, designed 
to assess persistent or prolonged pain in the NICU. It shows clinically acceptable reli-
ability, internal consistency, beginning concurrent validity, and sensitivity to change, 
and provides a uniform cut-off value applicable to different subpopulations (ELBW, very 
low birth weight, SGA, term neonates, different NI risk levels, or sex).
Staff found that the COMFORTneo scale to be a clinically useful pain instrument for the 
NICU environment, with cut-off scores introduced in a useful treatment algorithm.30 
Preferably, interventions should be based on repeated assessments performed routinely 
and on suspicion of (prolonged) pain, distress, or oversedation. Such an approach, per-
haps coupled with independent neuroimaging techniques, may help reﬁne the mea-
surement of persistent pain, thus providing a scientiﬁc framework for optimal comfort 
care in the NICU.
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Abstract
Background
A pain management protocol was implemented in our Neonatal Intensive Care Unit 
in 2005, including individual pain assessments and pain treatment guidelines with a 
decision tree.
Objectives
To prospectively evaluate the degree of compliance of medical and nursing staff with 
the pain protocol.
Methods
Prospectively recorded pain scores (COMFORTneo score) and all prescribed analgesics 
and sedatives for the calendar year 2011 were retrieved. The primary outcome is the 
degree of compliance to the protocol with respect to pain assessments and treatment; 
the secondary outcome consists of reasons for non-compliance.
Results
Of the 732 included patients, 660 (90%) received fewer than the stipulated 3 assess-
ments per day. Eighty-six per cent of all assessments yielded a score between 9 and 
14, suggesting a comfortable patient. In cases of high pain scores (≥14), reassessment 
within 60 minutes took place in 31% of cases and in 40% treatment was started or ad-
justed. In cases of low pain scores (≤8) during treatment, 13% of the 457 assessments 
were reassessed within 120 minutes and in 17% a dose reduction was performed.
Conclusions
Although the majority of pain assessments suggested comfortable patients, there is 
room for improvement with respect to reassessments after adjustment of analgesic/
sedative treatment. Some protocol violations such as oversedation in palliative patients 
are acceptable but should be well documented.
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Introduction
Exposure to pain in early life may alter the central pain pathways, neuronal responses to 
noxious stimulation, and neuroendocrine and physiological stress responses [1-4]. This, 
in turn, may affect the neonate’s pain processing and long-term development [1, 5]. Pain 
prevention and adequate pain treatment should therefore be part of daily care in the 
Neonatal Intensive Care Unit (NICU).
Preterm infants in the NICU undergo around ten to fourteen painful or stressful proce-
dures per day[6-8]. Current pain management in most NICUs consists of pharmacologi-
cal and non-pharmacological treatment. Non-pharmacological interventions to treat 
procedural pain consist of swaddling, containment by parent or care giver, non-nutritive 
sucking with or without a pacifier, facilitated tucking, decreased stimulation, and ad-
ministration of sucrose [9, 10]. Most frequently used systemic analgesics are opioids 
(e.g. morphine and fentanyl) and paracetamol. However, standard use of opioids has not 
been proven effective during mechanical ventilation [11] or to reduce procedural pain 
[12]. Also, concerns have been expressed about the safety of sedatives as midazolam 
and phenobarbital in preterm neonates[13]. To prevent neurotoxic effects of anaesthetic 
and analgesic agents[14, 15], these medications should be individually titrated, based 
on outcome of assessment with validated pain assessment scales [16].
Between 15% and 65% of European and Australian NICUs have written guidelines for 
pain treatment; i.e. for acute pain, prolonged pain or both [17-21]. From 6% to 70% of 
the units use a pain assessment tool. Deindl et al showed that the introduction of pain 
and sedation protocols in two NICUs resulted in increased use of opioids and other 
pharmacological interventions [22]. In 2005, our NICU implemented an individualized 
pain management protocol that includes pain assessment and pain treatment guided 
by a decision tree (Figure 1). So far, it was never studied if this protocol provides for 
adequate analgesia in children overall. Also compliance with the protocol of medical 
staff and nurses was never evaluated.
The aim of this study was to evaluate the degree to which the medical and nursing staff 
comply with the standardized pain management protocol. A secondary aim was to 
identify reasons for non-compliance.
Methods
Patients and setting
This study was conducted in the level 3 NICU of the Erasmus MC – Sophia Children’s 
Hospital, Rotterdam, the Netherlands. All neonates (postnatal age < 28 days) admitted 
longer than 8 hours were eligible for inclusion. The performed study was purely obser-
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vational; no additional tests or interventions were done. According to the institutional 
review board no informed consent was necessary in this observational trial. (MEC-2012-
260).
Study design and procedure
We retrospectively determined to what extent nurses and physicians complied to the 
unit’s neonatal pain protocol in calendar year 2011. Data on pain scores (COMFORTneo 
score and analgesic/sedative medication) prospectively recorded in the electronic 
patient’s chart were retrieved from the Patient Data Management System® (PDMS). 
Patients’ sex, gestational age, birth weight, date of death, ICU length of stay, any surgical 
procedures, and diagnosis were retrieved from the hospitals’ data system. If medica-
tion should have been prescribed according to the protocol but was not recorded, the 
nursing notes in the PDMS were consulted for a possible reason or for information on 
non-pharmacological interventions.
COMFORTneo score
The COMFORTneo score is a modified version of the COMFORT behavioural scale 
validated for NICU patients and tested for its psychometric qualities in our level 3 NICU 
[23]. It consists of behavioural items: alertness, calmness/agitation, respiratory response 
(only in mechanically ventilated patients) or crying (only in spontaneously breathing 
patients), body movements, muscle tone and facial tension (observation only).
The six are rated from 1 to 5. Summating the six ratings leads to a total score ranging from 
6 to 30. A COMFORTneo score between 9 and 13 suggests ‘comfort’, between 14 and 30 
indicates ‘pain or distress’ and between 6 and 8 may suggest ‘oversedation’ during intrave-
nous analgesics or sedatives. The COMFORTneo score can be assessed reliably after a 2-hour 
training session, has good interrater reliability, concurrent validity and sensitivity to change 
[23] All nurses were trained to perform COMFORTneo assessments before the introduction 
of the pain management protocol in 2005. The COMFORTneo item scores are entered in an 
electronic form (in the PDMS) at the bedside in the PDMS. The system then provides a total 
score.
Pain management protocol
In 2005 we introduced a pain management protocol dictating that nurses assess pain 
with the COMFORTneo score in all patients three times every 24 hour (once every 8-hour 
shift). Extra assessments with the COMFORTneo score are required in case of suspected 
pain or distress, after an acute painful procedure, in case of suspected oversedation and 
in case of prolonged use (≥ 5 days) of analgesics and/or sedatives. The final decision 
whether treatment should be started, maintained, increased or tapered off is made by 
the attending physician guided by a decision tree (Figure 1).
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If the COMFORTneo score is between 9 and 13, no further action is required until next as-
sessment. If the score is between 6 and 8 no further action is required unless analgesics 
or sedatives are already prescribed. Then, medication should be tapered down. If the 
score is between 14 and 30, the nurse must consider if factors other than pain might be 
responsible, such as uncomfortable posture, wet diaper, hunger, and insufficient respi-
ratory support with hypercapnia. The effect of adjusted treatment should be assessed 
within 60 minutes. However, as the PDMS displays the data on the whole hour only, it 
was decided to accept 120 minutes in the current study.
Table 1. Patient characteristics
Patients with 
assessments
(n = 648)
Patients without 
assessments
(n = 84)
p-value
Boys, n (%) 350 (54.0) 47 (56.0) 0.74
Length of stay (in days), median (IQR) 5 (3 to 11) 1 (1 to 1) < 0.001
Gestational age at birth (in weeks), n (%)* < 0.001
23.6 – 26.6 weeks 76 (11.7) 3 (3.6)
27.0 – 31.6 weeks 210 (32.5) 4 (4.8)
32.0 – 36.6 weeks 128 (19.8) 17 (20.2)
>=37 weeks 233 (36.0) 60 (71.4)
Weight at birth (in g), mean (sd) 2061 (1039) 2769 (888) < 0.001
Small for gestational age, n (%) 102 (15.7) 13 (15.5) 0.95
Mortality during NICU stay, n (%) 42 (6.5) 2 (2.4) 0.14
Surgical patients, n (%) 80 (12.3) 0.001
Patients receiving opioids, benzodiazepines or 
paracetamol, n (%)
224 (34.6) 5 (6.0) <0.001
Diagnosis, n (%)
Pre- and/or dysmaturity 297 (45.8) 25 (29.8)
Respiratory insufficiency 79 (12.2) 9 (10.7)
Asphyxia 51 (7.9) 2 (2.4)
Congenital anomalies 46 (7.1) 7 (8.3)
NEC 37 (5.7)
Observation 36 (5.6) 5 (6.0)
Suspect for infection 30 (4.6) 16 (19.0)
PDA surgical closure 25 (3.9)
Hyperbilirubinemia 10 (1.5) 9 (10.7)
Convulsions 8 (1.2) 1 (1.2)
Pneumothorax 7 (1.1)
Miscellaneous 22 (3.4) 10 (11.9)
* one missing value (n = 731)
abbreviations: IQR; interquartile range, NICU; neonatal intensive care unit, NEC; necrotizing enterocolitis, 
PDA; patent ductus arteriosus
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Outcome measures
The primary outcome is the degree of compliance of medical and nursing staff with the 
pain management protocol. Compliance is understood to be at least 3 times daily pain 
assessments done by the nursing staff, reassessment within 120 minutes and performing 
a pharmacological intervention when indicated. First day of admission and discharge 
days were left out of consideration.
The secondary outcome consists of potential reasons for non-compliance; i.e. provid-
ing no treatment after a high COMFORTneo score or failure to reduce in case of low 
COMFORTneo scores.
Data analysis
In table 1 patient characteristics are presented as medians (interquartile ranges) in case 
of non-normally distributed variables and as means (standard deviations) in case of 
normally distributed variables. Two patient groups were distinguished: patients whose 
pain had indeed been assessed and patients who had not been assessed. Background 
characteristics were compared using the t-test or Mann-Whitney U-test in case of con-
tinuous variables. Chi square tests or Fisher exact tests were used in case of categorical 
variables. Data analyses were performed with Statistical Package for the Social Sciences 
(SPSS) version 20.0 (SPSS Inc.). A p-value of 0.05 was deemed statistically significant.
Results
Of the 778 patients admitted in 2011, n=46 were excluded because they had been 
admitted for less than 8 hours. Of the 732 included patients, 660 (90%) received fewer 
than the stipulated 3 assessments per day and in total 84 patients (11%) had not been 
assessed at all. Patients who were not assessed had a median length of stay of 1 day (IQR 
1 to 1); assessed patients had a median of 5 days (IQR 3 to 11) (p < 0.001). The former 
were significantly more often born at term age (p < 0.001). All the surgical patients (n = 
80) were assessed (p < 0.001).
Of all 732 included patients, one-quarter received opioids either as a bolus or continu-
ously. A total of 159 (22%) patients received continuous morphine with a mean dose of 
11.9 mcg/kg/hr. (SD 4.9). Main reasons for opioids use (more than one reason possible) 
were postoperative pain (n=59), distress or irritability (n=33), chest drain (n=22), pallia-
tive end-of-life care (n=14), distress (n=13), cooling due to asphyxia (n=11), conservative 
treatment of NEC (n = 9) and fractures (n=3). Hundred and four (14%) patients received 
sedatives, which consisted of midazolam in 78 (75%) patients.
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Compliance to standard pain assessments
The total number of 24 hour admission days was 6858; full nursing staff compliance 
would therefore have required at least 3 x 6858 = 20,574 assessments. However, as only 
12392 assessments were documented; the compliance rate was 60.2%. The assessments 
were evenly distributed among the shifts; 5409 (37%) during the day shift, 4827 (33%) 
during the evening shift and 4306 (30%) during the night shift.
Assessment and treatment compliance on high COMFORTneo scores
Eighty-six per cent of the pain assessments in 2011 suggested ‘comfort’ and required no 
further action (Figure 2). High COMFORTneo scores (between 14 and 30) were assigned 
in 1578 (11%) assessments and 31% were reassessed within 120 minutes. Pharmacologi-
cal interventions were performed after 633 of these 1578 assessments (40%); analgesics 
in 77.4%, sedatives in 6.6% and a combination of the two in 16.0% assessments. In 
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Figure 2. Flow Chart
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27.5% of cases of non-compliance reasons were documented in the medical records; for 
example maximum analgesia reached, restlessness related to respiratory failure, hunger, 
obstipation, withdrawal syndrome or irritability.
Compliance after low COMFORTneo scores
Low COMFORTneo scores (between 6 and 8) in patients receiving continuous analgesics 
and/or sedatives were assigned in 3% of assessments and 13% were reassessed within 
120 minutes. In 77 assessments (17%) medication was tapered according to protocol. If 
not, documented reasons were: sedatives used as anti-convulsant therapy, NEC or other 
painful disorder (e.g. skin lesions), chest tube, discomfort on the ventilator, end-of-life 
care and total body cooling in case of asphyxia.
Discussion
Overall, compliance with the pain management protocol was low but nevertheless some 
two thirds majority of the Comfort neoscores suggested comfortable patients despite 
a relatively limited use of morphine and sedatives. When morphine or midazolam was 
prescribed, a reason was well described in the medical records. Comparing this with 
years of routine continuous morphine infusions to ventilated neonates, we can be satis-
fied with this progress.
Daily pain assessments were introduced in 2003 in our unit because neonatal pain might 
be otherwise unrecognized and undertreated. In our study and in contrast to what we 
expected, 86% of all assessments suggested comfortable patients. The unassessed 
patients (11%) had a short length of stay in our NICU (median of 1 day) which indicates 
stable, not severely sick children who are most likely not in pain. This raises the question 
whether all patients should be strictly assessed three times a day. Perhaps an individu-
alised strategy should be considered including a special focus on the high-risk patients. 
Patients at risk of pain that might need more intensive pain monitoring are extreme 
preterm infants enduring frequent painful procedures, postoperative patients, patients 
with necrotizing enterocolitis, patients with chest drains, and patients with rare painful 
skin diseases such as epidermolysis bullosa. A three times a day strategy would probably 
fit for septic instable or invasively ventilated newborns. This individualized approach 
could be less time consuming than standardised assessments in all patients and might 
enhance compliance to pain assessments. On the other hand, standard pain assess-
ments may decrease the risk of missing patients who suffer pain. One way to stimulate 
better compliance to pain assessment could be introducing an alert to assess pain at a 
set time in each shift. Why standard pain assessment is so difficult to adhere to remains a 
question, already raised by Franck and Bruce in 2009[24] and others[25]. One reason we 
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could think of, is the fact that a gold standard for pain assessment is lacking in preverbal 
infants which is in contrast to vital signs such as ‘heart rate’ and ‘blood pressure’. Nurses 
might feel that therefore pain assessment is less important than temperature taking for 
instance. In adults where self-reported pain is considered the gold standard it is easier 
to introduce pain assessment as the fifth vital sign as suggested by many international 
medical societies.
Articles on compliance and an acceptable level of compliance with pain protocols are 
largely lacking in literature. A percentage of 80% seems clinically feasible but compli-
ance level of reassessment after interventions or readjustment of analgesics/sedative 
treatment should preferably be 100%. Ceelie et al also evaluated the compliance with a 
prescribed pain protocol [26]. This study looked at a post-operative pain protocol on the 
paediatric intensive care unit (PICU) in our institute. They found the same level of compli-
ance, i.e. in approximately 15% the nurses and physicians followed the protocol of both 
treatment and reassessment. Deindl et al successfully implemented a Neonatal Pain 
and sedation Protocol and showed an increase in opiate prescription, pharmacologic 
interventions and staff satisfaction without affecting time on mechanical ventilation, 
length of stay on intensive care and adverse outcome [22]. However, one could question 
if increase in opiate prescription is necessarily an improvement bearing in mind the 
adverse long-term effects of opioids described in animal studies [27-31].
A limitation of our study is that nurses and physicians work in different electronic docu-
mentation systems for their clinical notes and there is no connection between these 
systems. Data might get lost or remain unread. Furthermore, medical and nursing staff 
do not always document the possible reasons for deviating from the treatment protocol. 
The retrospective nature of the study makes it more difficult to have complete access to 
these reasons.
Compliance with protocols and guidelines in health care is challenging in many set-
tings [32, 33]. Dutch physicians considered the fact that protocols often do not match 
the individual patient as an important barrier to compliance. This also seems to apply 
in our patient group. Some patients are deeply sedated to provide optimal comfort in 
end-of-life care and therefore we accept low COMFORTneo scores. High COMFORTneo 
scores may also be accepted as maximum therapy is provided and further increase of 
medication will add more adverse effects e.g. on blood pressure, motility of the gut and 
bladder function. These exceptions may imply that 100% compliance is not feasible. A 
paradigm shift may be warranted here, in which working according to protocol also of-
fers leeway to deviate from protocol in justifiable cases. A prerequisite is, however, that 
these justifiable violations are well communicated with co-workers and recorded in the 
patient data management system.
As this study was conducted in a single NICU, the generalizability of the results of our 
study is unclear. The fact the pain is a special point of interest in our center probably even 
Pain management in Neonatal Intensive Care 49
Ch
ap
te
r 3
overestimates the pain and analgesia evaluation on other non-pain centers. Another 
matter of debate is the appropriateness of reassessment within 120 minutes after dose 
reduction, bearing in mind that drug clearance in neonates is slower than in adults and 
that clearance is altered in critically ill patients[34-38]. This suggests that reassessment 
after tapering off drugs should be performed more than once and preferably after 30 
minutes of an alteration in medication.
Conclusion
This study reveals that the majority of pain scores suggested comfort, however pain 
assessments 3 times daily were not always performed. Compliance to pain assessment 
and treatment was far from perfect. Pain is insufficiently scored and decision making 
around treatment poorly reported.
Recommendations
All protocols should be routinely evaluated for their applicability. Justified and in-
dividualized adaptation might help increase compliance and get rid of useless and 
time-consuming procedures not resulting in adjustment of treatment. For neonatal pain 
protocols we recommend to tailor the number of pain assessments to the individual 
patient. Selecting critically ill patient groups for standardized pain assessment and leav-
ing the stable patients aside is not commendable in NICU patients: a pitfall could be 
that stable non assessed patients are forgotten when their clinical situation deteriorates.
We recommend that nurses and physicians should be better instructed to identify 
and document reasons for deviating from the pain protocol and emphasize the roll of 
reassessments. A recommendation for future research is studying the effect of monthly 
feedback about the compliance to reassessments as well as involving parents in pain 
assessment of their own child comparing to health care givers. For the current COM-
FORTneo score a 2 minutes observation is necessary. Future studies should also focus on 
the reliability of shorter, more efficient, pain observations. This would probably increase 
the compliance rate and would identify patients at ’risk’ for pain.
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Abstract
Objective
To study whether new pharmacological and non-pharmacological guidelines lowered 
numbers of painful procedures in neonates and changed the amount and frequency of 
analgesic therapy as compared to the results of our previous study in 2001.
Design
A prospective observational study.
Setting
Level III NICU of the Erasmus MC-Sophia Children’s Hospital, Rotterdam.
Participants
Neonates admitted at postnatal ages less than 3 days with length of stay at least 72 
hours.
Main Outcome Measures
Number of all potentially painful procedures and analgesic therapy recorded at the 
bedside during the first 14 days of NICU stay.
Results
A total number of 21076 procedures were performed in the 175 neonates studied 
during 1730 patient-days (mean 12.2). The mean number of painful procedures per 
neonate per day was 11.4 (SD 5.7), significantly lower than the number of 14.3 (SD 4.0) 
in 2001 (p<0.001). The use of analgesics was 36.6% compared to 60.3% in 2001. Sixty-
three percent of all peripheral arterial line insertions failed vs. 37.5% in 2001 and 9.1% 
venipuncture’s failed vs. 21% in 2001.
Conclusions
The mean number of painful procedures per NICU patient per day declined. Non-
pharmacological pain- or stress reducing strategies like NIDCAP and sucrose were fully 
embedded in our pain management. As further reduction of the number of painful 
procedures is unlikely we should apply more non-pharmacological interventions and 
explore newer pharmacological agents.
Eight years later, are we still hurting newborn infants? 55
Ch
ap
te
r 4
Introduction
In 2001 in a prospective study on procedural pain and analgesia in our level 3 NICU, 
neonates underwent a mean of 14.3 painful procedures a day [1]. In 2008, the EPIPPAIN 
study reported a median of 115 procedures during a study period of 14 days; in almost 
80% of cases analgesics were not given [2]. Johnston et al. in 2010 reported a drop in 
the number of tissue damaging procedures in Canadian NICUs over a 12-year period, 
still half of the procedures were performed without analgesics [3]. In our previous study 
60.3% of patients were given analgesics [1]. Care givers may be reluctant to prescribe 
analgesics to neonates for fear of adverse effects, drug tolerance and dependence. 
Moreover, dosing guidelines and pharmacokinetic data on common drugs for neonates 
of different gestational ages and birth weights are often lacking [4].
Neonates can feel pain from 23-24 weeks gestation[5] and early exposure to repetitive 
untreated pain portends immediate and long-term consequences on behavioural and 
neurological outcome [6] [7, 8]. Animal and human studies have shown significant risk for 
neurological impairment, besides learning, cognitive and behavioral effects [8, 9]If this 
holds true for the longer term is not known because longitudinal data are largely lacking. 
De Graaf et al. showed negative effects on cognitive functioning in 5-year old children 
who as a neonate received morphine [10]. In 2001 we introduced NIDCAP on our ward, 
placing a focus on non-pharmacological pain management [11, 12]. Several guidelines for 
procedural painmanagement in neonates have been published since our previous studies 
[1]. As a result of this we routinely administer sucrose 24% orally before painful procedures 
such as heel lancing, line insertion, and retinopathy screening since 2005. Sucrose has been 
proven to alleviate pain in mildly to moderately painful procedures in neonates [13-16].
Based on the results of our former study, current pain management includes repeated 
pain assessments with the COMFORTneo scale (Appendix 1), analgesic treatment ac-
cording to a decision tree (Appendix 2), NIDCAP care, and other non-pharmacological 
pain relieving interventions.
In the current study we evaluated whether these policy changes lowered the number 
of notably painful procedures and investigated what types of procedures often failed. 
Finally, we quantified analgesic therapy and compared findings with those from the 
previous study.
Methods
Data collection
The study design was prospective and observational. From February 6, 2009 to August 
5, 2009, nurses and medical staff collected bedside data on all procedures (successful 
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and failed) children underwent during the first 14 days of admission to the level III NICU 
of the Erasmus MC-Sophia Children’s Hospital Rotterdam, the Netherlands. Patients 
older than 3 days at admission and those transferred or discharged within 72 hours after 
admission were excluded. Data collection for children discharged from the unit between 
4 and 14 days was stopped on the day of discharge.
A procedure was defined as any medical, nursing, surgical, diagnostic or therapeutic 
intervention. Invasive or painful procedures were defined as interventions that cause 
mucosal or skin injury from removal or introduction of foreign material [2]. Pain guide-
lines of our department prescribe sucrose for minimal invasive or mild to moderate 
painful procedures and opioids for invasive and severe painful procedures (chest tube 
insertion). Intubations are performed with propofol. All procedures are conducted with 
parental or caregivers containment (NIDCAP).
Per calendar day data were recorded on a case record form and combined with the 
electronic patient’s chart data in the Patient Data Management System® (PDMS). Data 
included background characteristics, type and duration of respiratory support and CRIB® 
(Clinical Risk Index for Babies) scores [17], as well as administration of pain medication.
Data on analgesics and pain scores during the study days were retrieved from the PDMS. 
Nurses assessed the neonates pain with the Numeric Rating Scale (NRS from 1-10) and 
the COMFORTneo scale at least once during every 8 hour shift [18, 19]. The COMFORT-
neo scale has been validated and its cutoff value for pain is a score of 14 and higher 
combined with an NRS score of 4 and higher. A COMFORTneo score of 14 and higher 
combined with an NRS score below 4 is considered a sign of distress and not pain. Extra 
assessments are performed after administration of sedatives or analgesics, or if pain, or 
over- or under-sedation are suspected.
The performed study was purely observational. No additional tests or interventions 
were done. According to the Dutch law no ethical approval was necessary in this purely 
observational trial.
Statistical analysis
Numbers of procedures were counted per calendar day and corrected for the actual 
length of stay on the first and last study days. Data are presented as mean (SD) for nor-
mally distributed variables and as median interquartile range for non-normally distributed 
variables. Numbers of painful procedures and background characteristics were compared 
between four gestational age groups (24-28 wks, 29-32 wks, 33-36 wks, and 37-42 weeks) 
using ANOVA with Bonferroni correction. Findings from 2001 are compared with those 
of 2009 using the independent t-test for continuous variables and the chi-square test for 
proportions. Analyses were performed with the SPSS statistical program (version 17.0).
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Results
Patients
Table 1 lists the background characteristics of the 175 enrolled neonates. Mean gesta-
tional age was 31.6 weeks (range 24 1/7 to 41 6/7 weeks); 37.1% had a gestational age 
less than 29 weeks; Median birth weight was 1770 gram and 26.3% patients were small 
for gestational age.
The overall CRIB score was 2.7 (SD ±2.6) on a 0 to 10 scale. Sixty percent of all patients 
received conventional ventilation or high frequency oscillation/ventilation as maximum 
ventilatory support. The incidences of IRDS, intraventriculair hemorrhage and patent 
ductus arteriosus were highest (81.5%, 26.2% and 49.2% respectively) in infants with a 
gestational age less than 29 weeks. Asphyxia was diagnosed in 8 patients (26.7%) in the 
age group of 37-42 weeks and in 6 patients (13.1%) with a gestational age less than 37 
weeks. Nine patients (5.1%) died during the study period.
Table 1. Background characteristics
Total 
population
N=175
24-29 wks
N=65
37.1%
30-32 wks
N=49
28.0%
33-36 wks
N=31
17.7%
37-42 wks
N=30
17.1
N (%) N (%) N (%) N (%) N (%)
Male: N(%) 89(50.9) 28(43.1) 23(46.9) 19(61.3) 19(63.3)
Birth weight (grams): 1775 935 1405 2200 3545
Median (IQR) (1080-1380) (710-1110) (1188-1705) (1725-2620) (3277-3962)
Small for gestational age (SGA): N (%) 46 (26.3) 20(30.8) 18(36.7) 7(22.6) 1(3.3)
CRIB Score: Mean(SD) 2.7 (2.6) 4.5(3.0) 1.3(1.7) 1.8(1.9) 2.2(1.6)
Maximum respiratory support:
Mech ventilation 105(60.0) 58(89.2) 18(36.7) 14(45.2) 15(50.0)
CPAP/Non Invasive ventilation 36 (51.4) 7(10.8) 21(67.7) 6(35.3) 2(13.3)
Nasal prongs 16 (47.1) - 5(50.0) 6(54.5) 5(38.5)
No respiratory support 18 (10.3) - 5(10.2) 5(16.1) 8(26.7)
Duration maximum Respiratory support, median(IQR)
Days on mechanical ventilation 4 (1-9) 5(1-13) 2(1-4) 3 (1-4) 4(3-5)
Days on CPAP 4 (2-7) 9 (3-14) 3(4-5) 3 (2-4) 1 day both
Days on Nasal Prongs 3 (1-5) - 5 (2-10) 2 (2-3) 1 (1-8)
IRDS, n (%) 76 (43.4) 53 (81.5) 14 (28.6) 8 (25.8) 1 (3.3)
Asphyxia, n (%) 14 (8.0) 3 (4.6) 1 (2.0) 2 (6.5) 8 (26.7)
Intraventriculair haemorrhage, n (%) 20 (11.4) 17(26.2) 1(2.0) 1(3.2) 1(3.3)
Patent Ductus arteriosus, n (%) 42 (24.0) 32(49.2) 4(8.2) 2(6.5) 4(13.3)
Surgery during study period, n (%) 8(4.6) 6(9.2) - 1(3.2) 1(3.3)
Died during study period, n (%) 9 (5.1) 5 (7.7) 1(2.0) 1(3.2) 2(6.7)
Abbreviations: CPAP, Continuous positive pressure ventilation; IRDS, Infant respiratory distress syndrome
# ANOVA, because of significant difference between the youngest GA group and the other groups
† Fisher exact test, Percentages are column percentages
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Compared to the study population of 2001 the present population included significantly 
more preterm infants (145 /175 versus 104/151 patients in 2001, p = 0.003).
Incidences of procedures
Table 2 shows the incidences of procedures in this study and in the 2001 study, ranked 
in order of frequency established in the 2001 study. The total number of procedures in 
the current study was 21076 during 1730 patient-days; or mean 12.2 per patient-day. 
The mean number of painful procedures per neonate per day equaled 11.4 (SD 5.7) 
versus14.3 (SD 4.0) in 2001 (p<0.001). Broken down for age groups, it was highest in age 
Table 2. Incidences of procedures in 2001 and 2009, with frequencies per infant per day and p-values 
comparing frequencies
Procedure
% of Total 
procedures
Frequency per infant 
per day, Mean (SD) SDM p-value
2001
N = 151
2009
N = 175 2001 2009
Nasal suctioning 31.2 31.6 4.5 (2.3) 3.4 2.2) 0.49 p<0.001
Endotracheal suctioning 23.0 23.0 3.3 (4.0) 2.5 3.5) 0.21 p=0.06
NPT suctioning 9.4 5.7 1.3 (2.4) 0.6 (1.2) 0.37 p<0.001
Heel lancing 7.1 10.7 1.0 (1.6) 1.5 (1.1) 0.36 p=0.001
IV cannula insertion 3.8 3.2 0.5 (0.6) 0.4 (0.3) 0.21 p=0.06
Nasogastric tube insertion 3.8 1.9 0.5 (0.6) 0.2 (0.1) 0.70 p<0.001
IV cannula removal 3.2 2.2 0.5 (0.7) 0.3 (0.2) 0.39 p<0.001
Nasogastric tube removal 3.1 1.0 0.4 (0.5) 0.1 (0.1) 0.83 p<0.001
X-ray 2.9 2.8 0.4 (0.9) 0.3 (0.3) 0.15 p=0.17
NPT insertion 2.4 3.3 0.3 (0.6) 0.4 (0.4) 0.20 p=0.08
Failed IV cannula insertion 1.7 2.0 0.2 (0.9) 0.2 (0.3) 0 p=1.0
Laxative or enema 1.2 1.1 0.2 (0.5) 0.1 (0.1) 0.28 p=0.01
Nasal oxygen cannula insertion 1.0 1.0 0.2 (0.4) 0.1 (0.2) 0.32 p=0.004
Intubation 0.9 0.6 0.1 (0.4) 0.08 (0.08) 0.07 p=0.52
Peripheral arterial line insertion 0.8 0.4 0.1 (0.3) 0.05 (0.07) 0.23 p=0.04
Extubation 0.7 0.5 0.1 (0.3) 0.06 (0.08) 0.18 p=0.09
Peripheral arterial line removal 0.6 0.3 <0.1 (0.3) <0.1 (0.06)
Failed peripheral arterial line insertion 0.5 0.8 <0.1 (0.5) <0.1 (0.06)
Venipuncture 0.4 0.2 <0.1 (0.3) <0.1 (0.1)
Insertion umbilical line 0.4 0.3 <0.1 (0.2) <0.1 (0.05)
Removal umbilical line 0.3 0.4 <0.1 (0.2) 0.1 (0.1)
Failed umbilical line insertion 0.2 0.2 <0.1 (0.2) <0.1 (0.06)
Insertion central line 0.2 0.4 <0.1 (0.2) <0.1 (0.05)
0.2 <0.1 (0.2) <0.1 (0.1)
0.2 <0.1 (0.2) <0.1 (0.09)
0.02 <0.1 (0.2) <0.1 (0.03)
0.2 <0.1 (0.1) <0.1(0.05)
0.07 <0.1 (0.1) <0.1 (0.04)
Abbreviations: IV, intravenous; NPT, nasopharyngeal tube, SDM=standardized mean difference
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group 24-29 weeks at 14.1 (SD 5.2); followed by age group 30-32 weeks at 9.9 (SD 3.8) 
and age group 33-36 weeks at 9.1 (SD 5.7).
Suctioning (endotracheal, nasopharyngeal and nasal) was the most frequent painful 
procedure, comprising 60.3% of all procedures vs.63.6% in 2001.
Second most commonly performed procedure was heel lancing, comprising 10.7% of all 
procedures vs. 7.1% in 2001. Nasal pharyngeal tube insertion accounted for 3.3% of all 
procedures in 2009 vs. 2.4% in 2001; intubation for 0.6% of all procedures vs. 0.9% in 2001.
Sixty-three percent of all peripheral arterial line insertions failed vs. 37.5% in 2001. Um-
bilical arterial line insertions failed in 49.5% of cases; umbilical venous line insertions in 
36.6% of cases (34.6% in 2001. Intravenous cannula insertions failed in 38% of cases vs. 
30.9% in 2001, venipuncture’s in 9.1% vs. 21% in 2001 (Figure 1). Of all intubations 22.5% 
needed more than 1 attempt.
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Fig. 1 Percentages of failed and successful procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Percentages of failed and successful procedures
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Although the present population included significantly more preterm infants, the mean 
number of painful procedures was lower in the age groups of 30-32.6 weeks (12.0 in 
2001 versus 9.9 in 2009) and 33-36.6 weeks (12.3 versus 9.1 in 2009) but not in the more 
premature infants of 24-29.6 weeks (15.2 in 2001 versus 14.0 in 2009).
Analgesics
Sixty-four neonates (36.6%) received one or more doses of analgesics. Twenty-one of 
those (12%) received rectal paracetamol during a median of two days (range1 to 11 
days). Forty-eight neonates (27.4%) received continuous morphine, whether or not 
combined bolus morphine for a median of 3 days (range 1 to 12 days); eight of those 
underwent an operation during the study period. Three neonates received fentanyl as 
bolus medication from 1 to 3 times (Figure 2).
Pain assessments
Almost all patients (169; (96.6%) underwent pain assessment during the study period 
i.e. a median 16 assessments (range 1 to 61) per patient. The number of COMFORTneo 
assessments was 2962 during 1690 patient-days, corresponding to 1.7 per patient-day. 
Out of 2962 assessments 2901 involved complete assessments meaning COMFORTneo, 
NRS pain and NRS distress scores. In 88.9% of the cases all three scores were low or at 
least acceptable. In 4.8% of assessments the COMFORTneo was 14 or higher but both 
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Fig. 2 Pharmacological analgesic treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pharmacological analgesic treatment
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NRS were not > 3. In 3.7 of cases both COMFORTneo and NRS distress were high but NRS 
pain<3. In 1% of the assessments all three scores were too high. Of our complete cases 
of 2901 assessments, 89.2% included standard pain assessments, in 7.1% the reason for 
assessment was suspected pain or distress. 2.8% of assessments were performed after a 
pain or distress reducing intervention. In 0.6% (n=17) the reason to assess was suspected 
oversedation. Finally in only 8 assessments it was after an acute painful procedure. N=90 
infants out of the 169 (53.2%) had at least once a COMFORTneo score of 14 or higher.
Possible reasons for high scores were NEC (n=7), skin-related (n=5), delivery-related 
(n=3, breech and vacuum extraction), thorax drainage (n=2), postoperative (n=2) and 
others (n=8).
Comment
Our analysis revealed that the mean number of painful procedures per patient per day 
had statistically significantly declined from 14.3 in 2001 to 12.2 in 2009. Studies from 
NICUs in different countries likewise have shown a similar trend with a range from 6 to 
17.3 procedures per patient per day [1-3, 19-21]. Suctioning, venous catheter placement 
and heel lancing are most frequent across all settings. In our NICU endotracheal suction-
ing still accounts for 23.0% of all procedures (same in 2001) and is comparable with the 
23.3% reported in the EPIPPAIN study, even though we stopped routine suctioning of 
mechanically ventilated neonates after 2003[2].
The nasopharyngeal tube insertion rate increased from 2.4% in 2001 to 3.3% in the cur-
rent study and the number of intubations dropped from 0.9% (2001) to 0.6% of all pro-
cedures in 2009. This may be due to the introduction of non invasive ventilation in 2008. 
Introduction of propofol as premedication for intubation explains the lesser number 
of failed intubations in 2009. Compared to the 2001 cohort we included more preterm 
infants in the current study but the more preterm infants (24-29.6 weeks) unalterably 
need the highest number of painful procedures due to their unstable condition in the 
first period of life. It remains a source of concern that adequate care for our patients still 
involves on average 11 painful events per day.
In 2001, 60.3% of neonates received analgesics, especially opioids versus 36.6% in 2009. 
This significant drop is the result of study findings showing that routinely administration 
of morphine in ventilated neonates had no beneficial effects on pain expression and 
neurologic outcome [22-24]. A follow up study described negative effects of neonatal 
morphine administration on cognitive functioning at age 5 years [10]. Pre-emptive use 
of opioids in preterm newborns has not been properly studied. Morphine might be ben-
eficial when pain is present, but could be neurotoxic in the absence of pain as suggested 
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in animal studies [9]. Intravenous paracetamol administration might be an alternative 
but is used off label and may be unsafe unless future PK/PD studies prove otherwise. In 
the meantime we should focus on expanding the range of (non)pharmacological and 
non-pharmacological pain treatment. As to the latter, we have already experience with 
sucrose and NIDCAP interventions such as positioning, swaddling, non-nutritive sucking, 
and kangaroo care. Furthermore, our pain management guidelines enabled caregivers 
in the current study to respond immediately when painful procedures were carried out 
or pain was suspected. All above measures together might explain the high percentage 
(89%) of low COMFORTneo scores (<14). In only 2.4% of the pain assessments the child 
was perceived to be in pain, attributable to pain conditions such as NEC and severe 
skin lesions. We have every reason to believe, therefore, that we did not undertreat or 
misdiagnose neonatal pain.
Two study strengths can be identified. First, the second study was conducted in the 
same level 3 NICU. Second, nursing and medical staff participated in both studies using 
the same case record forms.
Strikingly, however, the frequency of failed procedures did not decline over the years. 
An explanation might be that since 2008 more extremely premature infants (gestational 
age < 27 weeks) were admitted and survived on our ward. Nowadays, the critically ill 
patients and extremely premature infants stay on our ward and undergo the highest 
number of painful procedures during the first 14 days of life. The high frequency of failed 
procedures might also be explained by the reduction of the training period for residents 
on the NICU so they have less opportunity to gain experience.
Several limitations of this study should be addressed. First, to compare our results with 
our former study, we did not distinguish between painful and stressful procedures, like 
Carbajal et al. did[2]. A further distinction between skin breaking and non-skin break-
ing procedures would also have been interesting as the first were recently related to 
white matter changes and brain development on MRI scans at term equivalent age of 
ex premature born neonates [25]. Second, during painful procedures we used sucrose 
and containment according to our pain guidelines but no other non-pharmacological 
interventions such as skin-to-skin care or breastfeeding. Thirdly we found that routine 
administration of sucrose was not always documented in the patient’s chart. A detailed 
sucrose prescription is now added in the electronic patient chart safeguarding more 
accurate report of the daily used doses of sucrose. Furthermore, this study was a single 
center study and not a multiple center study like in 2001 which could give limited 
generalizability of this data. And finally, we can’t exclude that (failed) interventions or 
administration of analgesics went unrecorded.
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Conclusions
Our new (non)pharmacological pain management has only minimally but statistically 
significant (p<0.001) reduced the number of daily painful procedures. It might be hard 
to achieve further reduction. The findings from the present study were reason to change 
our policy: only experienced senior neonatal nurses, nurse practitioners and neonatolo-
gists/fellows are allowed to perform procedures on extremely preterm infants in the first 
postnatal period. We also set up an intravenous access team, started a training program 
and introduced new support devices to identify reliable venous and arterial access.
Pain and distress management has become a key issue for the daily care in our NICU. In 
future we should focus on individualized pain management and collect data on pharma-
cokinetics and pharmacodynamics of analgesics in (extremely) preterm neonates.
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Metabolism of intravenous paracetamol in very 
preterm infants: fi rst analyses of plasma levels 
of paracetamol and its metabolites.
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Introduction
Preterm infants are at high risk for repetitive and prolonged pain due to indispensable 
intensive care treatment [28]. Yet, the use of analgesics to alleviate their pain and to 
prevent negative short and long term consequences of pain is still very limited [13]. 
Opioids and NSAIDs have been studied in newborns, and were found associated with 
harmful side effects. Furthermore, in animal models of pain the use of opioids has been 
linked with an increase in neuroapoptosis [8, 9, 14, 20].
Paracetamol (N-acetyl-p-amino-phenol; Acetaminophen; APAP) is a well-known drug 
given to children and adults worldwide to relieve fever and pain. So far it has been 
little used in very preterm infants because rectal and oral administration often was not 
feasible due to the small body size and frequent occurrence of feeding intolerance. 
Moreover, the absorption of paracetamol is unpredictable under these conditions. With 
the introduction of paracetamol for intravenous use it has now become available for 
infants of all gestational ages.
Consequently, little data are available on dosing, efficacy, safety, and the ontogeny of 
paracetamol metabolism in very preterm neonates (gestational age < 32 weeks), es-
pecially in extremely preterm infants (gestational age < 28 weeks) [1, 7, 10]. A number 
of studies documented the metabolism of paracetamol administered by oral or rectal 
route in preterm infants with a gestational age > 28 weeks to generate age-appropriate 
dosing recommendations [18, 23, 30]. There is still no literature on the optimal loading 
dose of paracetamol in extremely preterm infants with a gestational age ≤28 weeks.
In neonates paracetamol is primarily metabolized into APAP-Sulphate (APAP-Sulph) and 
to a lesser extent into APAP-Glucuronide (APAP-Gluc) due to an immature glucuronide 
conjugation system [22, 24, 30]. An even smaller part of APAP is oxidized mainly by 
cytochrome P450 iso-enzyme CYP2E1 into the toxic N-acetyl-p-benzoquinone imine 
(NAPQI). NAPQIs play a role in the paracetamol induced hepatotoxicity and are directly 
transformed into the metabolites APAP-Glutathione (APAP-Glut), APAP-Cysteine (APAP-
Cys) and APAP-N-acetyl-Cysteine (APAP-NAC) (See Figure 1).
Paracetamol dosages that result in increased, potentially toxic, NAPQI levels have never 
been reported in neonates, and the activity of CYP2E1 is still not quantified. NAPQIs 
are formed after oxidation of paracetamol and are directly converted by glutathione 
S transferase into APAP-glutathione; direct measurements of NAPQI levels are difficult, 
therefore. Whether polymorphisms of different CYP-iso-enzymes play a role in APAP-
induced hepatotoxicity is not known for any population.
The primary objective of this study was to describe paracetamol metabolism and to 
detect dose and age dependent changes in paracetamol metabolism after intravenous 
administration in very preterm infants with a gestational age <32 weeks.
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The secondary objective of this study was to determine the relation between CYP2E1 
polymorphisms and the formation of metabolites formed after conversion of NAPQI, as 
an indirect measurement for NAPQI formation.
Methods
Patients
From October 2010 until October 2013 this randomized, two-center trial was performed 
at the level 3 Neonatal Intensive Care Units (NICUs) of the Erasmus MC-Sophia Children’s 
Hospital in Rotterdam and Isala Clinics in Zwolle, both in the Netherlands. The study was 
conducted according to European Good Clinical Practice regulations.
Approval of the Ethics Review Committees of both hospitals and written informed con-
sent from parents/legal guardians were obtained prior to study initiation (MEC-2009-
250, National Trial Register 2290).
Eligible for inclusion were all preterm neonates with a gestational age ≤ 32 weeks with 
an indwelling arterial catheter already in place for clinical purposes, and undergoing 
central venous catheter (CVC) placement in the first 7 days of life. Exclusion criteria were: 
major congenital anomalies, intraventricular haemorrhage ≥ grade 3, use of neuromus-
cular blockers, and maintenance dose of analgesics or more than one loading dose of 
morphine or midazolam any time prior to this study.
Patients were randomly allocated to one of three different single doses of paracetamol 
(Perfalgan©; Bristol-Meyers Squibb): 10, 15 and 20 mg/kg bodyweight, respectively. 
Paracetamol was administered before peripheral CVC placement, which procedure 
served as the standardized painful event.
Interventions
Subjects received a single dose (10, 15, or 20 mg/kg) of paracetamol via a 15-minute 
infusion through a peripheral venous cannula. At scheduled times (see below) five 
blood samples (maximum of 200 µl/sample) were taken for pharmacokinetic analyses 
from an indwelling arterial line after the infusion of paracetamol was fully completed 
and the venous line was flushed with a 2 cc saline solution (0.9%). One additional blood 
sample (250 microliters EDTA) was taken for DNA analyses. Sparse blood sampling was 
necessary because of the low circulating blood volume. We therefore used two different 
sample schedules: samples were taken either on T = 0 (before start of paracetamol ad-
ministration), 20, 60, 240 and 540 minutes schedule 1) or on T= 15 (after the paracetamol 
infusion was completed), 30, 120, 360 and 720 minutes (schedule 2).
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Outcome measures
The primary outcome of this study included plasma concentrations of paracetamol 
and its metabolites (APAP, APAP-Sulphate, APAP-Glucuronide, APAP-Glutathione, APAP-
Cysteine and APAP-N-acetyl–Cysteine).
The secondary outcome of this study is the occurrence of CYP2E1 1* polymorphisms.
Randomization
Stratified randomization was performed for two gestational age groups (24-28 weeks 
and 281/7-32 weeks) by using sequentially numbered, sealed, opaque envelopes, con-
taining a note with the prescribed dose of paracetamol and the sampling schedule. The 
envelopes for the two different age groups were kept apart (marked A and B, respectively 
and both numbered from 1-30). For each included patient a nurse or nurse practitioner 
not involved in the care of the included patient opened the lowest numbered envelope 
for the age group in question, and prepared the indicated paracetamol dose. Patients 
could be included only once.
Blinding
The researchers as well as all nursing and medical staff taking care of included patients 
were blinded for the administered dose of paracetamol. The medication was prepared by 
a nurse or nurse practitioner from another NICU-ward. The note stating the paracetamol 
dose was then put back in the envelope, which was sealed again and locked away, 
inaccessible for the researchers. Unblinding of the study medication took place after all 
patients were included.
Analysis of APAP and Metabolites in Human Plasma
Blood samples were centrifuged directly after collection and plasma was isolated and 
stored at −80 degrees Celsius until further analyses. Paracetamol and metabolites analy-
ses were performed in the laboratory of the Department of Pharmacology & Toxicology, 
University of Utah, Salt Lake City, USA.
Reference standards, chemicals, and reagents
The following reference standards and deuterated internal standards were obtained 
from Toronto Research Chemicals Inc. (Toronto, ON, Canada). Calibration standards 
and quality control (QC) samples were prepared concurrently with study samples by 
fortification of 10 µL of analyte-free, heparinized human plasma with reference standard 
working solutions. The calibration curve ranged from 0.05 to 50 µg/mL for paracetamol 
(APAP), and its metabolites: APAP-Gluc, APAP-Sulph and 0.01 to 5 µg/mL for APAP-glut, 
APAP-Cys and APAP-NAC (See figure 1); QC samples within the quantitative ranges were 
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included for assessment of accuracy. If necessary, patient samples were diluted for 
quantifi cation within the curve range.
Sample preparation
To maintain equivalence in preparation, all study samples (10-µL aliquots) and fortifi ed 
calibration and QC samples were brought to a total volume of 110 µL with methanol-
water (1:1, v/v). Next, they were fortifi ed with 10 µL of internal standard working solu-
tion containing 0.2 and 25 µg/mL of APAP-d4 and APAP-d3-sulf in water, respectively. 
Samples were analyzed on an Agilent 1200 Infi nity Series HPLC system equipped with 
an Agilent Poroshell 120 EC-C18 column (2.1 x 100 mm ID, 2.7 µm particle size), which 
was interfaced with an Agilent 6460 triple quadrupole mass spectrometer (Agilent Tech-
nologies, Santa Clara, California, USA. Less than lower limit of quantitation (LLOQ) was 
defi ned as less than 10 (for APAP-Cys and APAP-NAC), 25 (for APAP-Glut), or 50 (for APAP, 
APAP-Sulph and APAP-Gluc) ng/mL.
Genotyping method
DNA was isolated from 250 µl EDTA blood samples according to the ‘MagNA Pure Com-
pact Nucleic Acid Isolation Kit I (Roche®)’on the MagNA Pure Compact System (Roche®). 
Figure 1. Metabolic pathway of Paracetamol. 
Metabolites: 1: APAP; 2: APAP-Sulphate; 3: APAP-Glucuronide; 4: APAP-Glutathione; 5: APAP-Cysteine; 6: 
APAP-N-Acetyl-Cysteine
Metabolism of intravenous paracetamol 75
Ch
ap
te
r 5
The CYP2E1*1A, *1C an d*1D repeats were analyzed with the PCR method, with the use 
of forward primer(F)5’–TGGTACATTGTGAGACAGTC–‘3 and reverse primer(R)5’-
ATACGGGAACACCTCGTTTG – ‘3. The PCR program started with an initial denaturation 
at 94°C during 7 minutes, followed by denaturation at the same temperature during 1 
minute. After denaturation primers were annealed at 55°C during 1 minute followed by 
elongation at 72°C during 1 minute. These steps were repeated 34 times, ending with an 
elongation at 72°C during 7 minutes. The alleles consisted respectively of 563 base pairs 
(bp), 611 bp and 707 bp products visualized with the Gel Doc™ XR+ System (Biorad®)
[19].
CYP2E1-wild type was defi ned as CYP2E1*1C/*1C and CYP2E1 mutation as CYP2E1*1D/*1D 
(homozygote) or heterozygotes CYP2E1*1C/*1D (heterozygote).
Statistical analysis
Patient characteristics are presented as median (IQR: interquartile range) in case 
of non-normally distributed variables and as mean (standard deviation) in case of 
normally distributed variables. Non-normally distributed continuous variables were 
compared between the treatment groups using the Kruskal-Wallis tests. Areas under the 
plasma concentration-time curves from time zero to time t (AUC0-t) were calculated for 
paracetamol, APAP-Sulph, APAP-Gluc, APAP-Cyst and APAP-NAC. Plasma concentrations 
of patients in sampling schedule B at T=360 and T=720 were averaged. In this way the 
AUCs were calculated for t0-t540 and t0-t550 for patients in schedule A and B, respec-
tively, and judged to be comparable.
Linear regression analyses with AUCs of APAP and its metabolites as outcome variables 
were applied using 2 dummy variables for the 3 treatment conditions) and gestational 
age group (with 0=24-28 weeks and 1=281/7 weeks to 32 weeks) and CYP2E1 polymor-
phism (0= wildtype and 1= homozygote or heterozygote) as predictor variables. Statisti-
cal signifi cance was set at p <0.05 (two-sided). Statistical data analysis was performed 
with SPSS software, version 21.0 (SPSS Inc., Chicago, USA). Data were analysed using the 
intention-to-treat-principle.
Sample size calculation
Based on the pharmacodynamics outcome, including 20 infants per treatment group 
would result in a power of 83%. This number of 20 patients per treatment group (10 
patients with the same dose in each age category) was also deemed suffi  cient for the 
planned pharmacokinetics. Thus, the total sample size was 60.
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Results
Sixty very preterm infants (N=20 per dose group) were included with an overall median 
gestational age of 27.9 weeks (IQR 3.4 weeks) and a median birth weight of 953 grams 
(IQR 398 grams). Central venous catheter (CVC) placement took place on a median post 
menstrual age of 28.6 weeks (IQR 3.2 weeks). Background characteristics for the different 
treatment groups are listed in Table 1.
Paracetamol is metabolized into APAP-Sulphate and APAP-Glucuronide and the APAP 
metabolites are formed over time. Figure 2A gives the plasma concentrations of APAP 
over time; figures 2B and 2C the plasma concentrations of APAP-Sulph and APAP-Gluc.
AUCs of APAP and its metabolites in relation to the intravenous paracetamol dose 
and gestational age are shown in Tables 2 and 3. All AUCs of APAP and its metabolites 
increased statistically significantly with increasing paracetamol doses (p-values ranged 
from p<0.001 for AUCs of APAP and APAP-Sulph to p=0.04 for AUCs of APAP-NAC 
Table 1. Background characteristics
10 mg/kg APAP
N = 20
15 mg/kg APAP
N = 20
20mg/kg APAP
N = 20
Gestational age (weeks)
Median 27.8 27.6 27.8
IQR 3.9 3.2 2.9
Birth weight (grams)
Median 970 988 885
IQR 349 430 360
SGA, n (%) 4 (20) 5 (25) 7 (35)
Sex, n (%)
Boy 10 (50) 10 (50) 8 (40)
Girl 10 (50) 10 (50) 12 (60)
Antenatal steroids, n (%) 19 (95) 18 (90) 18 (90)
PIH, n (%) 4 (20) 7 (35) 3 (15)
PPROM, n (%) 3 (15) 3 (15) 2 (10)
Apgar 1’ median 6 6 6
IQR 3.5 3.0 3.0
Apgar 5’median 7.5 8 8
IQR 2.7 2.0 2.5
PNA(days) line placement
median (IQR) 4.5 (4) 6 (1) 6 (5.7)
Abbreviations: APAP: paracetamol; SGA: Small for gestational age;
PIH: pregnancy induced hypertension; PPROM: prolonged premature rupture of membranes
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(Table 2). The AUC of APAP-Gluc for the older gestational age group was statistically 
significantly larger than that for the younger age group (Table 3). The AUC of APAP-Glut 
could not be calculated in 27 patients because APAP-Gluthation plasma levels were not 
detectable. In another 5 patients all APAP-Glut levels were measured but were below 
the threshold value of 0.00001 mg/l. In 28 patients 1 to 4 samples were obtained with a 
plasma concentration between 0.0005-0.007 mg/l.
In regression analysis with gestational age and paracetamol dose as predictor vari-
ables the AUCs-APAP were higher for the older gestational age group (281/7-32 weeks)
(p=0.001) and for the 15mg/kg and 20mg/kg treatment groups. The AUCs-Sulph were 
not predicted by gestational age group (p=0.78) but increased with an increasing dose 
of paracetamol (p<0.001).
Table 2. AUCs of APAP and APAP metabolites
Paracetamol dose
AUC (mg/l*min)
median (IQR)
10mg/kg 15 mg/kg 20 mg/kg p-value1
APAP 5614 (1151) 8574 (3688) 10811 (3007) < 0.001
APAP-Sulph 9933 (5511) 15480 (4564) 21330 (8569) <0.001
APAP-Gluc 409 (327) 767 (896) 865 (1372) 0.001
APAP-Cys 1021 (821) 1549 (869) 1659 (1372) 0.02
APAP-NAC 338 (245) 500 (339) 483 (505) 0.04
APAP: paracetamol; APAP-Sulph: paracetamol-sulphate; APAP-Gluc: paracetamol-glucuronide
APAP-Cys: paracetamol-cysteine; APAP-NAC: paracetamol-N-acetyl-cysteine
1Kruskal-Wallis tests were applied as appropriate
Table 3. AUCs of APAP and metabolites in relation with gestational age
Gestational age (weeks)
AUC (mg/l*min)
median (IQR
24-28 weeks 281/7-32 weeks p-value1
APAP 8277 (4789) 8954 (5482) 0.14
APAP-Sulph 14783 (8137) 15005 (9197) 0.78
APAP-Gluc 586 (386) 950 (1021) 0.02
APAP-Cys 1287 (1271) 1504 (11423) 0.6
APAP-NAC 446 (402) 370 (349) 0.2
APAP: paracetamol; APAP-Sulph: paracetamol-sulphate; APAP-Gluc: paracetamol-glucuronide
APAP-Cys: paracetamol-cysteine; APAP-NAC: paracetamol-N-acetyl-cysteine
1 Mann Whitney tests were applied appropriate
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The AUCs of APAP-Gluc for the youngest gestational age group were significantly 
lower than those for the older gestational age group (Figure 3). Furthermore Figure 3 
shows two outlying very high AUC of APAP-Gluc in the older gestational age group. The 
infants in question had not received co-medication capable of inducing or increasing 
glucuronidation, such as rifampicin, phenytoin or phenobarbital. AUCs of APAP-Gluc for 
the 10 mg/kg dose group were significantly lower than for the 15- and 20 mg/kg groups 
(p=0.02). Gestational age did not predict the AUCs of APAP-Cys and APAP-NAC, whereas 
the 10 mg/kg paracetamol dose led to lower AUCs of APAP-Cys (p=0.01) and of APAP-
NAC (p=0.04) than those for the other two doses in regression analyses.
NAPQIs are considered to be related to hepatotoxicity. CYP2E1 genotyping was per-
formed in samples of 58 of the 60 included patients (n=1 sample was lost and n=1 no 
specific informed consent was given for genotyping). CYP2E1-wild type (CYP2E1*1C/*1C) 
was found in 45 patients (77.6%) and CYP2E1 mutation in 13 patients (22.4%); two 
homozygotes (CYP2E1*1D/*1D) and 11 heterozygotes (CYP2E1*1C/*1D). As shown in 
Figure 4 the patients with relatively high APAP-Cys and APAP-NAC AUCs all had CYP2E1 
wild type (CYP2E1*1C/*1C) genotypes. In a multiple regression analysis with CYP2E1 
polymorphism as a predictor and controlling for gestational age and paracetamol dose, 
there was a trend towards lower AUCs of APAP-Cys for patients with the CYP2E1 poly-
morphisms (p=0.07). This trend was not found for APAP-NAC (p=0.15).
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Figure 4 AUCs for APAP-Cysteine and APAP-NAC in all patients. Outliers 
are marked for their CYP2E1 genotype.  
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# The two patients with high AUCs of APAP-Glucuronide in the 281/7-32 weeks gestation group did not re-
ceive co-medication e.g. phenobarbital that could explain increased glucuronidation.
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Discussion
In this study we affirmed that very premature born neonates are able to metabolize 
paracetamol by different pathways of sulphation, glucuronidation and oxidation. Fur-
thermore we showed that with the three used dosages these dosages the plasma levels 
of the paracetamol metabolites derived from the toxic metabolite NAPQI are rather low. 
This was as expected, as only up to 10% of paracetamol is known to be metabolized by 
oxidation.
More than 10 years ago, when intravenous paracetamol was not even on the market 
in our country, Allegaert et al. already studied the pharmacokinetics of single dose of 
intravenous propacetamol (a pro-drug of paracetamol that equals half of amount of 
paracetamol: 2 mg propacetamol = 1 mg paracetamol) [7]. They showed comparable 
volumes of distribution in preterm neonates (mean gestational age 31.4 weeks) and 
term born neonates (mean gestational age 38.5 weeks), i.e. 0.61 l/kg and 0.64l/kg, 
respectively, and with peak plasma levels above 6 mg/l and 10 mg/l for the 10 mg/
kg and 20 mg/kg paracetamol (= 20 and 40 mg/kg propacetamol), respectively. When 
corrected for paracetamol, those peak plasma levels correspond with the peak levels 
of intravenous paracetamol in our study, suggesting that the volume of distribution of 
paracetamol in the very preterm and the term infants is also comparable. In our study, 
peak plasma levels in all patients, except 3 newborns in the 10 mg/kg group, were above 
the commonly accepted target analgesic threshold level of 9 mg/l. Recently Calvier et 
al (unpublished data) compared dosing recommendations for children weighing less 
than 10 kg provided in the Dutch Kinderformularium with recommendations published 
by Palmer [25]. The latter led to paracetamol concentrations between 10 and 25mg/l. 
Thereupon Calvier et al developed new dosing recommendations leading to the con-
centration of 9 mg/l (+/-1) for infants weighing less than 1500 grams. The loading dose 
of intravenous paracetamol was predicted to be 12.5 mg/kg and 13mg/kg for infants 
weighing between 500-750 and 750-1500 grams, respectively. These new recommenda-
tions for intravenous paracetamol might explain the plasma concentrations < 9 mg/l 
we found in three patients in the 10mg/kg-dosing group in our study and confirm that 
higher doses than 10 mg/kg paracetamol are needed to reach the target concentration 
of > 9 mg/l in very preterm infants. Prospective PK/PD studies are needed to evaluate 
the population PK model based on these new dosing recommendations of intravenous 
paracetamol for infants weighing less than 1500 grams.
Allegaert et al also found much increased paracetamol half-lives as well as lower clear-
ance in preterm born neonates (mean gestational age 31.2 weeks) than in term born 
neonates (mean gestational age 38.5 weeks) [7]. This suggests that preterm born neo-
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nates would need lower paracetamol maintenance doses. Using a population PK model 
the same research group indeed showed that maintenance dosages of 20 up to 30 mg/
kg every 6 hours were needed from 28 to 36 weeks post menstrual ages, respectively 
[2]. The population PK model for intravenous paracetamol has been further expanded 
towards models that encompasses the whole human life span [5, 33]. These models 
showed that body weight is the major covariate of intravenous clearance variance in 
neonates and older patients.
Only few data about paracetamol metabolism and metabolite levels in preterm neonates 
are available in the literature. Van Lingen et al reported urinary glucuronide/sulphate ra-
tios of 0.12 and 0.28 in 28-32 weeks and 32-36 weeks old preterm neonates, respectively, 
after rectal paracetamol [31]. Allegaert et al showed increasing paracetamol glucuroni-
dation with increasing postconceptional and postnatal age [3]; this is in accordance with 
the results of our study as we also measured higher AUCs of paracetamol-Glucuronide 
for infants born between 281/7-32 weeks’ gestation compared with younger infants. The 
AUCs of APAP-Sulphate, APAP-Cysteine and APAP-NAC for the youngest infants were 
not higher than the corresponding AUCS for the older neonates, suggesting that lower 
paracetamol glucuronidation did not stimulate sulphation or oxidation with the forma-
tion of higher levels of metabolites derived from NAPQIs. Possibly the sulphation and 
glucuronidation pathways of paracetamol become saturated, on account of which a 
larger amount of APAP is excreted unchanged in the urine [27].
Based on recovered metabolite ratios in the urine, it is thought that glucuronidation 
may be upregulated upon multiple dosing [4]. Krekels et al. showed that increased 
glucuronidation in neonates and infants is more determined by developmental changes 
rather than by repeated administration of paracetamol. In our study we showed that 
next to paracetamol plasma concentrations, paracetamol-sulphate and glucuronide 
plasma levels were also higher after an increase of a single paracetamol dose, indicating 
that with the currently used single paracetamol dosages no saturation of these meta-
bolic pathways occurs. As we did not study the metabolism of multiple paracetamol 
doses in the current study, further research is needed to evaluate the effect of multiple 
paracetamol dosing regimen on the different metabolic pathways.
To the best of our knowledge, this is the first study that measured the metabolites of 
paracetamol derived from the toxic metabolite NAPQI in plasma of very preterm infants. 
Data on these metabolites in adults are predominantly derived from urine samples after 
administration of relatively high doses of paracetamol [16]. Zuppa et al published a 
population based PK study in which neonates, infants, children and adolescents were 
included receiving either 12.5 mg/kg/4 hours intravenous paracetamol (neonates as an 
exception 12.5 mg/kg/6hours) or 15 mg/kg/6 hours (neonates 15 mg/kg/8hours). Both 
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regimens were well tolerated and achieved adequate paracetamol plasma concentra-
tions[34].
Although paracetamol is considered to be safe and efficacious in adults, children and 
preterm infants > 32 weeks of gestation, accidental [12, 15, 29] or deliberate overdose 
can result in acute liver failure in adults as well as in infants and neonates. The maximum 
therapeutic dosages of paracetamol are 4 grams daily for adults and 50-75 mg/kg for 
children. A single acute ingestion exceeding 7.5 gram in adults or 150 mg/kg in children 
has been considered toxic [17]. Liver damage has been reported even after approved 
doses, and this was found associated with both genetic and epigenetic factors [11, 21]. 
Paracetamol-induced hepatotoxicity is dependent on the balance of the formation rate 
of NAPQI by CYP2E1, the elimination rate of unmetabolized paracetamol, sulphation 
and glucuronidation conjugation pathways, and the glutathione stores in the liver[6]. 
CYP2E1 levels are low at neonatal age and increase gradually during the first year of life 
[32]. It appears that young children are more resistant than are adults to paracetamol-
induced hepatotoxicity due to reduced rates of oxidation by CYP2E1 and the ability to 
replete glutathione. In our study we also found very low plasma and peak concentra-
tions of metabolites of paracetamol formed by oxidation [26]. APAP protein metabolites 
have a long elimination half-life that markedly exceeds that of the parent compound 
APAP, permitting detection of APAP toxicity long after the parent compound has been 
cleared from the blood. In adults the mean elimination half-life of APAP-metabolites 
with APAP-induced acute liver failure was 41.3 hours compared to 5.4 to 18.4 hours for 
APAP (depending on severity of acute liver failure en presence of encephalopathy) [20]. 
However, in neonates, metabolic clearance of paracetamol through sulphation matures 
more rapidly than glucuronidation, which at neonatal age is still poor. This results in 
lower clearance and slower decrease after the peak paracetamol concentration has been 
reached. Because of this lower clearance, accumulation is more likely [6]. This effect 
needs to be taken into account when prescribing a maintenance dose of intravenous 
paracetamol to very preterm infants. Moreover Calvier et al (unpublished data) gave 
dose recommendations for maintenance doses for intravenous paracetamol: 5.5 mg/
kg/6hours for preterms with a body weight of 500 to 750 grams and 6 mg/kg/6 hours 
for preterm infants weighing 750-1500 grams. Given the ongoing debate on the optimal 
dosing of intravenous paracetamol for closure of a hemodynamic relevant ductus ar-
teriosus (currently set at 15 mg/kg/6hours) prospective PK studies should evaluate the 
dose regimens used for the treatment of PDA as well as the new dose recommendations 
of paracetamol as analgesic treatment of Calvier et al.
CYP2E1 is important in the oxidation of paracetamol into NAPQIs, which are responsible 
for paracetamol-induced hepatotoxicity; these toxic metabolites are converted into the 
metabolites APAP-Cys and APAP-NAC. In the present study there is a trend of lower AUCs 
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of APAP-Cys and APAP-NAC in the presence of a polymorphism of the CYP2E1 compared 
to the wildtype of CYP2E1. These “premature” data might suggest a protective role of the 
CYP2E1 polymorphism in the formation of reactive metabolites. Our sample size was too 
small and our study underpowered, however, to draw firm conclusions but it is definitely 
a field worth exploring in future studies.
In conclusion, we showed that the AUCs of APAP and all its metabolites increased 
statistically significantly with increasing paracetamol doses in very preterm neonates. 
Gestational age was found an important determinant for glucuronidation, as the AUCs 
of APAP-Gluc in the preterm infants younger than 28 weeks were significantly lower 
than those in the older infants.
The results of this study can validly be included in a population based modelling study 
to calculate new dose recommendations for intravenous paracetamol use in infants with 
a gestational age ≥ 24 weeks.
Metabolism of intravenous paracetamol 85
Ch
ap
te
r 5
References
 1. Allegaert K, Anderson BJ, Naulaers G, de Hoon J, Verbesselt R, Debeer A, Devlieger H, Tibboel 
D (2004) Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neo-
nates. Eur J Clin Pharmacol 60: 191-197
 2. Allegaert K, Anderson BJ, Naulaers G, de Hoon J, Verbesselt R, Debeer A, Devlieger H, Tibboel 
D (2004) Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neo-
nates. European Journal of Clinical Pharmacology 60: 191-197
 3. Allegaert K, De Hoon J, Verbesselt R, Vanhole C, Devlieger H, Tibboel D (2005) Intra- and inter-
individual variability of glucuronidation of paracetamol during repeated administration of 
propacetamol in neonates. Acta Paediatrica 94: 1273-1279
 4. Allegaert K, de Hoon J, Verbesselt R, Vanhole C, Devlieger H, Tibboel D (2005) Intra- and inter-
individual variability of glucuronidation of paracetamol during repeated administration of 
propacetamol in neonates. Acta Paediatr 94: 1273-1279
 5. Allegaert K, Palmer GM, Anderson BJ (2011) The pharmacokinetics of intravenous paracetamol in 
neonates: size matters most. Arch Dis Child 96: 575-580
 6. Allegaert K, van de Velde M, van den Anker J (2014) Neonatal clinical pharmacology. Paediatr 
Anaesth 24: 30-38
 7. Allegaert K, Van der Marel CD, Debeer A, Pluim MA, Van Lingen RA, Vanhole C, Tibboel D, Dev-
lieger H (2004) Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of 
gestational age. Arch Dis Child Fetal Neonatal Ed 89: F25-28
 8. Anand KJ, Hall RW, Desai N, Shephard B, Bergqvist LL, Young TE, Boyle EM, Carbajal R, Bhutani VK, 
Moore MB, Kronsberg SS, Barton BA, Group NTI (2004) Effects of morphine analgesia in ventilated 
preterm neonates: primary outcomes from the NEOPAIN randomised trial. Lancet 363: 1673-1682
 9. Aranda JV, Thomas R (2006) Systematic review: intravenous Ibuprofen in preterm newborns. 
Semin Perinatol 30: 114-120
 10. Autret E, Dutertre JP, Breteau M, Jonville AP, Furet Y, Laugier J (1993) Pharmacokinetics of 
paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. Dev 
Pharmacol Ther 20: 129-134
 11. Bondoc FY, Bao Z, Hu WY, Gonzalez FJ, Wang Y, Yang CS, Hong JY (1999) Acetone catabolism by 
cytochrome P450 2E1: studies with CYP2E1-null mice. Biochem Pharmacol 58: 461-463
 12. Bucaretchi F, Fernandes CB, Branco MM, De Capitani EM, Hyslop S, Caldas JP, Moreno CA, Porta G 
(2014) Acute liver failure in a term neonate after repeated paracetamol administration. Rev Paul 
Pediatr 32: 144-148
 13. Carbajal R, Eriksson M, Courtois E, Avila-Alvarez A, Berger A, Lago P, Van Overmeire B, Papadouri 
T, Ilmoja M, Pölkki T, Schroth M, Sarafidis K, Tameliene R, Attard Montalto S, Simons S, Andersen R, 
Dobrzanska A, Matos C, Boyle E, Europain E, Lagercrantz H, Bergqvist L, Anand K (2014) O-103 Se-
dation And Analgesia For Neonates In Nicus Across Europe: The Europain Survey. Archives of 
Disease in Childhood 99: A64
 14. Cook SF, King AD, Chang Y, Murray GJ, Norris HR, Dart RC, Green JL, Curry SC, Rollins DE, Wilkins DG 
(2015) Quantification of a biomarker of acetaminophen protein adducts in human serum by high-
performance liquid chromatography-electrospray ionization-tandem mass spectrometry: Clinical 
and animal model applications. J Chromatogr B Analyt Technol Biomed Life Sci 985: 131-141
 15. Cuzzolin L, Antonucci R, Fanos V (2013) Paracetamol (acetaminophen) efficacy and safety in the 
newborn. Curr Drug Metab 14: 178-185
86 Chapter 5
 16. Fannin RD, Russo M, O’Connell TM, Gerrish K, Winnike JH, Macdonald J, Newton J, Malik S, Sieber 
SO, Parker J, Shah R, Zhou T, Watkins PB, Paules RS (2010) Acetaminophen dosing of humans 
results in blood transcriptome and metabolome changes consistent with impaired oxidative 
phosphorylation. Hepatology 51: 227-236
 17. Forrest JA, Clements JA, Prescott LF (1982) Clinical pharmacokinetics of paracetamol. Clin Phar-
macokinet 7: 93-107
 18. Hansen TG, O’Brien K, Morton NS, Rasmussen SN (1999) Plasma paracetamol concentrations and 
pharmacokinetics following rectal administration in neonates and young infants. Acta Anaesthe-
siol Scand 43: 855-859
 19. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M (1999) Structural and functional characteriza-
tion of the 5’-flanking region of the rat and human cytochrome P450 2E1 genes: identification of 
a polymorphic repeat in the human gene. Biochem Biophys Res Commun 263: 286-293
 20. James LP, Chiew A, Abdel-Rahman SM, Letzig L, Graudins A, Day P, Roberts D (2013) Acetamino-
phen protein adduct formation following low-dose acetaminophen exposure: comparison of 
immediate-release vs extended-release formulations. Eur J Clin Pharmacol 69: 851-857
 21. Lavonas EJ, Reynolds KM, Dart RC (2010) Therapeutic acetaminophen is not associated with liver 
injury in children: a systematic review. Pediatrics 126: e1430-1444
 22. Levy G, Khanna NN, Soda DM, Tsuzuki O, Stern L (1975) Pharmacokinetics of acetaminophen in 
the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma 
bilirubin concentration and D-glucaric acid excretion. Pediatrics 55: 818-825
 23. Lin YC (1997) Plasma concentration after rectal administration of acetaminophen in preterm 
infants. Paediatric Anaesthesia 7: 457-459
 24. Miller RP, Roberts RJ, Fischer LJ (1976) Acetaminophen elimination kinetics in neonates, children, 
and adults. Clin Pharmacol Ther 19: 284-294
 25. Palmer GM, Atkins M, Anderson BJ, Smith KR, Culnane TJ, McNally CM, Perkins EJ, Chalkiadis GA, 
Hunt RW (2008) I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J 
Anaesth 101: 523-530
 26. Pineiro-Carrero VM, Pineiro EO (2004) Liver. Pediatrics 113: 1097-1106
 27. Roberts I, Robinson MJ, Mughal MZ, Ratcliffe JG, Prescott LF (1984) Paracetamol metabolites in 
the neonate following maternal overdose. Br J Clin Pharmacol 18: 201-206
 28. Roofthooft DW, Simons SH, Anand KJ, Tibboel D, van Dijk M (2014) Eight years later, are we still 
hurting newborn infants? Neonatology 105: 218-226
 29. Van Eyken P, Nemolato S, Faa G, Ambu R (2012) Hepatic injury to the newborn liver due to drugs. 
Curr Pharm Des 18: 3050-3060
 30. van Lingen RA, Deinum JT, Quak JM, Kuizenga AJ, van Dam JG, Anand KJ, Tibboel D, Okken A 
(1999) Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neo-
nates. Arch Dis Child Fetal Neonatal Ed 80: F59-63.
 31. van Lingen RA, Deinum JT, Quak JM, Kuizenga AJ, van Dam JG, Anand KJS, Tibboel D, Okken 
A (1999) Pharmacokinetics and metabolism of rectally administered paracetamol in preterm 
neonates. Arch Dis Child Fetal Neonatal Ed 80: F59-63.
 32. Vieira I, Sonnier M, Cresteil T (1996) Developmental expression of CYP2E1 in the human liver. Hyper-
methylation control of gene expression during the neonatal period. Eur J Biochem 238: 476-483
 33. Wang CG, Allegaert K, Tibboel D, Danhof M, van der Marel CD, Mathot RAA, Knibbe CAJ (2014) 
Population Pharmacokinetics of Paracetamol Across the Human Age-Range From (Pre) term 
Neonates, Infants, Children to Adults. Journal of Clinical Pharmacology 54: 619-629
Metabolism of intravenous paracetamol 87
Ch
ap
te
r 5
 34. Zuppa AF, Hammer GB, Barrett JS, Kenney BF, Kassir N, Mouksassi S, Royal MA (2011) Safety and 
population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, chil-
dren, and adolescents with pain or Fever. J Pediatr Pharmacol Ther 16: 246-261

C hapter 6
Intravenous acetaminophen is not eﬀ ective 
for pain management during central venous 
catheter placement in very preterm infants.
Daniëlla Roofthooft
Sinno Simons
Richard van Lingen
Dick. Tibboel
John van den Anker
Irwin Reiss
Monique van Dijk
Submitted Pediatrics
90 Chapter 6
Abstract
Objectives
To determine the analgesic effects and safety aspects of different single doses of intra-
venous acetaminophen on pain from central venous catheter (CVC) placement in very 
preterm neonates.
Methods
A blinded randomized controlled trial was conducted at two level III NICU centers in the 
Netherlands. Neonates with gestational ages from 24.0 to 32.0 weeks were randomly al-
located to one of three different doses of intravenous acetaminophen (10, 15, 20 mg/kg) 
before CVC placement in the first week of life. Age-matched neonates receiving sucrose 
served as a control group. Pain was assessed with the Premature Infant Pain Profile (PIPP) 
and the COMFORTneo scale. Peak concentrations of acetaminophen (aimed target con-
centration > 9mg/l), and kidney and liver function were monitored.
Results
No statistically significant differences in pain scores were found between the acetamino-
phen treatment groups and sucrose group. The median PIPP score was 7 (IQR 6-9) for the 
15 mg/kg acetaminophen group and 8 (IQR 6-10.5) for all other groups, reflecting mild 
to moderate pain. COMFORTneo scores of 14 or higher, suggesting pain or distress, were 
assigned to 25% of infants who received sucrose and to up to 50% of infants in the 15 
mg/kg and 20 mg/kg acetaminophen groups. All subjects, except for three who received 
10 mg/kg acetaminophen, had peak plasma concentrations > 9mg/l. Kidney and liver 
function was normal in all infants.
Conclusions
We found no analgesic benefit from a single intravenous dose of acetaminophen over 
sucrose in CVC placement in very preterm neonates.
Acetaminophen is not effective during CVC placement 91
Ch
ap
te
r 6
Introduction
Today, pain assessment is an essential component of the medical care for neonates. Its 
importance is illustrated by the finding that preterm infants on average undergo many 
painful procedures, estimated at 6 to 17 procedures per day1-7. Analgesia is necessary 
to protect against the negative short and long term consequences of pain from skin 
breaking procedures such as changes in brain development8. The analgesic properties 
of sucrose to reduce procedural pain have been questioned although its administration 
is still standard of care in many NICUs9-11. Long-acting opioids, such as morphine, have 
also been shown not to be effective in reducing pain from heel sticks in preterm infants12 
The reluctance to use strong analgesic drugs in newborns is triggered by studies in ro-
dents showing accelerated neuronal apoptosis and other morphological changes in the 
developing brain after administration of commonly used opioids, benzodiazepines and 
general anaesthetics13-15. These findings warrant studies on the effectiveness and safety 
of other analgesics, such as acetaminophen.
Acetaminophen (acetyl-para-aminophenol, APAP) is the most used analgesic drug to 
relieve mild to moderate pain in children and adults, with proven safety and efficacy. Its 
safety and efficacy after intravenous administration have not yet been proven, however, 
in extreme preterm neonates. Besides, there are no dosing guidelines for preterm infants 
with gestational ages of less than 28 weeks16,17. A population pharmacokinetic study of 
acetaminophen including subjects older than gestational age of 27 weeks found that an 
acetaminophen concentration of > 9 mg/l should be aimed for18.
Pain assessment is an indispensable component of pain management; acute pain in 
preterm infants is often assessed with the Premature Infant Pain Profile (PIPP) basis.
In our quest for ‘new’ pharmacological agents we performed a study on the effective-
ness of acetaminophen administered before central venous catheter (CVC) placement 
in very preterm infants.
The objective of the study was to determine the analgesic effect of different doses of ac-
etaminophen. A group of age-matched neonates who underwent the same procedure 
after administration of sucrose only, served as control group.
Material and Methods
Design, Patients and Setting
This multicenter, blinded and randomized controlled trial was performed from October 
2010 until October 2013 at the level III NICUs of the Erasmus MC-Sophia Children’s 
Hospital in Rotterdam and the Isala Clinics in Zwolle, the Netherlands. Subjects were 
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randomly allocated to one of three different single doses of acetaminophen (Perfalgan©; 
Bristol-Meyers Squibb) (10, 15, 20 mg/kg) given before peripheral CVC placement.
Inclusion criteria were the following: gestational age between 24 and 32 weeks, an 
indwelling arterial catheter already in place for clinical purposes, and CVC placement 
in the first 7 days of life. Exclusion criteria were the following: receiving a maintenance 
dose of analgesics, and/or receiving morphine or midazolam prior to the study interven-
tion. NSAIDs used for patent ductus arteriosus closure were allowed and were accurately 
documented for each patient. The study was conducted according to European Good 
Clinical Practice regulations and registered in the Dutch Trial Registry (Trial number: 
2290); Ethics Review Board approval from both hospitals and written informed consent 
from parents or legal guardians was obtained prior to study initiation (MEC-2009-250).
Because this study was a pharmacological dose finding trial, the Ethics Review Board did 
not allow including patients treated with oral sucrose as control group. Instead, after fin-
ishing this trial, and with approval of the Erasmus MC Ethics Review Board (MEC-2014-386), 
we applied the same pain assessment instruments to a group of age-matched patients 
who were given oral sucrose before CVC placement.
Pain assessment instruments
Pain during CVC placement was assessed with two assessment tools. First, the Pre-
mature Infant Pain Profile (PIPP), which is a multidimensional tool that has been well 
validated to assess procedural pain in preterm and term neonates19,20. The PIPP rates 
seven indicators (gestational age, behavioural state, heart rate and oxygen saturation 
changes, occurrence of brow bulge, eye squeeze and nasolabial furrow) on a 4-point 
scale from 0 to 3 (total score range 0 to 21). A total PIPP score of < 7 is taken to reflect 
no or minimal pain and a score ≥ 7-12 mild to moderate pain; scores > 12 reflect severe 
pain20,19,21. Because the recently revised PIPP22 also assigns points to drops in heart rate 
as an indicator of pain after completion of the study we analysed how inclusion of heart 
rate change would have affected PIPP assessment.
PIPP scores were assigned by the researchers only, who had been trained to this purpose 
and all showed sufficient inter-rater reliability (assessed with a linearly weighted Cohen’s 
kappa > 0.65) in 10 bedside assessments.
Second, the COMFORTneo scale, which was found to have good psychometric qualities6. 
It consists of 6 behavioural items: alertness, calmness, respiratory response (used in 
mechanically ventilated patients) or crying (used in spontaneously breathing patients), 
physical movements, muscle tone and facial tension (total score range 6-30). The 
COMFORTneo scale was applied by trained nurses with sufficient inter-rater reliability 
(a linearly weighted Cohen’s kappa >0.65) as determined with 10 bedside assessments. 
A COMFORTneo score between 14 and 30 indicates ‘pain or distress’ (sensitivity of 0.81 
and specificity of 0.90)6.
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Interventions
CVC placement was selected as intervention in this study because nurses and physicians 
of the NICUs in the two participating centers rated its painfulness 8 on a 0 to 10 scale,1.
In the separate sucrose study, sucrose 24% (EPMC Pharma, Belgium) was administered 
in the buccal cavity together with the use of a pacifier 2 minutes before CVC placement; 
i.e. 0.5 cc if body weight was lower than1000 grams, and 1.0 cc if body weight was 1000 
grams or more.
From subjects who received acetaminophen, five blood samples (maximum of 200 µl/
sample) were taken from an indwelling arterial line at set times after infusion of the allocated 
acetaminophen single dose. Peak plasma levels were determined for the current study.
The attending ICU nurse applied the COMFORTneo scale 15 minutes before CVC place-
ment while the researchers assessed the two PIPP baseline items ‘behavioral state’ and 
‘gestational age’ simultaneously. Next, acetaminophen was administered for 15 minutes 
as a single intravenous dose through a peripheral venous cannula that was already in 
place. The total volume administered was 2 cc (acetaminophen supplemented with NaCl 
0.9%) in the 24-28 weeks gestational age group and 4 cc in the group of 281/7-32 weeks.
While the attending physician or nurse practitioner inserted the CVC, one of the research-
ers assigned the PIPP score after 30 seconds observation. In addition, the attending ICU 
nurse assigned the COMFORTneo score during the intervention. Subjects in the control 
group receiving sucrose were assessed in exactly the same way.
Study Outcomes
PIPP score was the primary outcome; COMFORTneo score was the secondary outcome. 
Furthermore, changes in heart rate and oxygen saturation during CVC placement were 
analysed, as well as blood urea nitrogen (BUN), creatinine, ASAT, ALAT and total – and direct 
bilirubin levels before administration of the loading dose of acetaminophen and 12 – 24 
hours after (if blood sampling was required as standard care). The following reference values 
were considered: BUN < 15 mmol/l, creatinine 27-88 µmol/l, ALAT < 52U/l, ASAT <120 U/l, 
total bilirubin according to curves23,24 and conjugated bilirubin < 5% of total bilirubin.
Randomization
Stratified randomization was performed for two gestational age groups (24-28 weeks 
and 281/7-32 weeks) by using sequentially numbered, sealed, opaque envelopes, 
containing a note with the prescribed dose of acetaminophen. The envelopes for the 
different age groups were kept apart (marked A and B, respectively and both numbered 
from 1-30). A nurse or nurse practitioner not involved in the care of the included patient 
opened the first envelope for the applicable age group, containing the allocated dose of 
acetaminophen. For each new patient the next subsequently numbered envelope was 
opened. Patients could be included only once.
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Blinding
Both the researchers and all nursing and medical staff taking care of the subjects were 
blinded for the administered dose of acetaminophen. The medication was prepared 
by a nurse or nurse practitioner from another NICU-unit. The slip of paper stating the 
acetaminophen dose was then put back in the envelope, which was sealed again and 
locked away, inaccessible for the researchers. Unblinding of the study medication took 
place after all subjects were included.
Statistical analysis
Patient characteristics are presented using descriptive statistics. Categorical data were 
compared between the treatment groups using Fisher’s exact tests.
Non-normally distributed continuous variables were compared between the treatment 
groups using the Kruskal-Wallis tests. Linear regression analysis with PIPP scores as out-
come variable was applied to determine the effects of the treatment (using 3 dummy 
variables for the 4 treatment conditions) as predictor variable. In addition administra-
tion of ibuprofen or indomethacin (as patent ductus arteriosus (PDA) treatment) within 
24 hours before the procedure was added as covariate. Statistical significance was set 
at p <0.05 (two-sided). Data were analysed with SPSS software, version 21.0 (SPSS Inc., 
Chicago, USA) using the intention-to-treat-principle.
Sample size calculation
With 20 infants per treatment group the power to detect differences in the mean PIPP 
scores of 1 point equals 83%. This calculation is based on the reported SD of PIPP scores 
assigned for a skin breaking procedure, i.e. 1.3 points20. Thus the total sample size was 
80 subjects including 20 in the sucrose control group.
Results
In total we assessed 266 patients for eligibility and included 60 patients in the acet-
aminophen trial (see Figure 1 flowchart); thirty patients in the gestational age group 
of 24-28 weeks and thirty patients in the 281/7-32 weeks group. Twenty age-matched 
patients who received only sucrose as analgesic treatment formed the control group. 
Background characteristics of all subjects are shown in Table 1. Clinical outcome data 
are listed in Table 2.
Table 3 shows PIPP scores for the three different acetaminophen dose groups and con-
trol group treated with sucrose. Regression analysis showed that PIPP scores were not 
significantly different between the 4 treatment groups Treatment with indomethacin/
ibuprofen added as covariate did not significantly affect the PIPP scores (p=0.60) either. 
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Figure 1. Participant flowchart
Table 1. Background characteristics
Characteristics 10 mg/kg APAP
N = 20
15 mg/kg APAP
N = 20
20mg/kg APAP
N = 20
Sucrose
N = 20
Gestational age (weeks)
Median 27.8 27.9 28.8 27.9 
Range 24.0 to 31.1 24.2 to 30.4 24.2 to 30.3 24.1to 31.4 
Birth weight (grams)
Median 970 988 885 898 
Range 462 to 1550 475 to 1440 630 to 1380 520 to 1330 
SGA, n (%) 4 (20) 5 (25) 7 (35) 8 (40)
Sex, n (%)
Boy 10 (50) 10 (50) 8 (40) 10 (50) 
Girl 10 (50) 10 (50) 12 (60) 10 (50) 
Antenatal steroids, n (%) 19 (95) 18 (90) 18 (90) 18 (90)
PIH, n (%) 4 (20) 7 (35) 3 (15) 5 (25)
PPROM, n (%) 3 (15) 3 (15) 2 (10) 1 (5)
Apgar 1’ median 6 6 6 7.5 
IQR 4.3-7.8 5.0-8.0 5.0-8.0 4.3-9.0 
Apgar 5’median 7.5 8 8 9 
IQR 6.3-9.0 7.0-9.0 6.5-9.0 8.0-9.0 
PNA(days) line placement     
median (IQR) 4.5(2-6) 6(5-6) 6 (1.3-7) 3 (1-7) 
Abbreviations: APAP: acetaminophen; SGA: small for gestational age; PIH: pregnancy induced hyperten-
sion; PPROM: prolonged premature rupture of membranes
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Figure 2 shows boxplots of the PIPP scores broken down by acetaminophen dose and 
gestational age group.
After a single dose of 10, 15 and 20 mg/kg acetaminophen median plasma peak con-
centrations were 10.6 mg/l (IQR 9.5-11.6), 16.5 mg/l (IQR 14.9-19.6) and 21.3 mg/l (IQR 
Table 2. Clinical outcome data
Characteristics APAP 10mg/kg
n = 20
APAP 15 mg/kg
n = 20
APAP 20 mg/kg
n = 20
Sucrose 24%
n = 20
IRDS: n (%)
Mechanical 
Ventilation: n (%)
Surfactant: n (%)
PDA: n (%)
Treatment indomethacin
Treatment ibuprofen
Surgery: n (%)
Sepsis: n (%)
NEC: n (%)
FIP: n (%)
Surgery NEC: n (%)
IVH: n (%)
Dead: n (%)
Kidney function:
BUN1 before APAP (n)
median (IQR)
BUN1 after APAP (n)
median (IQR)
Creatinine2 before APAP (n)
median (IQR)
Creatinine2 after APAP (n)
median (IQR)
Liver enzymes &bilirubin 
ASAT3 before APAP (n)
Median (IQR)
ASAT3 after APAP (n)
Median (IQR)
ALAT3 before APAP (n)
Median (IQR)
ALAT3 after APAP (n)
Median (IQR)
Tot. Bili4. before APAP (n)
Median (IQR)
Tot. Bili4. After APAP (n)
median (IQR)
Dir.Bili4. before APAP (n)
median (IQR)
Dir. Bili4. After APAP (n)
median (IQR)
15 (75)
15 (75)
14 (70)
  8 (40)
  3 (15)
  2 (10)
  5 (25)
  9 (45)
  1 (5)
  0 
  0
  2 (10)
  0
18
8.3 (6.4-12.1)
17
7.5 (5.9-10.2)
17
63 (59-76)
17
56 (49-68)
3
98 (15-98)
4
46 (10-153)
2
50 (16-50)
3
36 (5-36)
19
102 (81-131)
17
82 (72-141)
2
1 (1)
2
3 ( 2-3)
16 (80)
16 (80)
15 (75)
  7 (35)
  2 (10)
  3 (15)
  2 (10)
  9 (45)
  1 (5)
  2 (10)
  1 (5)
  5 (25)
  4 (20)
17
7.7 (5.7-9.1)
14
6.8 (5.6-9.2)
18
55 (50-70)
13
47 (40-62)
5
29 (18-38)
5
38 (17-46)
4
5 (5-8)
5
5 (5-8)
18
100 (76-128)
18
93 (65-110)
5
1 (1)
6
1 (1-15)
13 (65)
14 (70)
14 (70)
12 (60)
  5 (25)
  4 (20)
  4 (20)
10 (50)
  2 (10)
  2 (10)
  3 (15)
  6 (30)
  2 (10)
16
7.4 (5.4-9.4)
15
6.4 (5.2-8.8)
13
67 (56-77)
12
57 (46-69)
5
19 (14-50)
1
32 
5
5 (5)
1
10 
18
95 (79-125)
4
86 (68-104)
5
1 (1)
3
1 (1)
14 (70)
13 (65)
13 (65)
  8 (40)
  0
  8 (40)
  1 (5)
12 (60)
  1 (5)
  0 
  1 (5)
  4 (20)
  2 (10)
Abbreviations: APAP: acetaminophen; PDA: patent ductus arteriosus; NEC: necrotizing enterocolitis; FIP: 
focal intestinal perforation; IVH: intraventriculair hemorrhage
1 BUN levels in mmol/l; 2 creatinine levels in µmol/l; 3 ASAT/ALAT levels in U/l; 4 Total and Direct bilirubin values 
in µmol/l
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18.5-22.1), respectively (p< 0.001, Kruskal-Wallis test). All subjects, except for three who 
received 10 mg/kg acetaminophen, had a peak plasma concentration > 9mg/l.
The COMFORTneo scores are also shown in table 3. The median COMFORTneo scores 
were higher in the 15 and 20 mg/kg acetaminophen groups with a median of 14 (IQR 
11-19.8 and 11-20) versus median 11 (IQR 10-13.8) and 12 (IQR 10-14.8), respectively, in 
the sucrose and 10 mg/kg group. This diff erence was not statistically signifi cant (p=0.17, 
Kruskal-Wallis test).
Table 3. PIPP and COMFORTneo scores during CVC placement
Pain assessments 
during procedure
APAP 10mg/kg
n = 20
APAP 15 mg/kg
n = 20
APAP 20 mg/kg
n = 20
Sucrose 24%
n = 20
p-value3
PIPP
 Median
  IQR
8 
6-10.5
7 
6-9
8 
6-10
8 
6.3-10 0.97
PIPP Score < 71
 n (%) 9 (45) 11 (55) 8 (40) 9 (45) 0.81
PIPP Score 7 – 12
 n (%) 10 (50) 8  (40) 10 ( 50) 11(55)
PIPP Score > 12
 n (%) 1 (5) 1  (5) 2 (10) -
COMFORTneo
 Median 
  IQR
12 
10-14.8
14
11-19.8
14 
11-20
11 
10-13.8 0.17
COMFORTneo 14-302 
 n (%) 6 (30) 10 (50) 10 (50) 4 (25) 0.28
1 PIPP < 7 no to mild pain; 7-12 moderate pain; ³13 severe pain
2  a COMFORTneo score between 14 and 30 suggests pain and/or distress
3 Fisher exact tests and Kruskal-Wallis tests were applied as appropriate
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Figure 2 PIPP scores during CVC placement (n=10 in each box) 
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Figure 3 gives the boxplots for the peri-intervention changes in heart rate and oxygen 
saturation for the groups separately. In most subjects the heart rate increased (76%) or 
remained unchanged (4%) but it dropped in 16 subjects (20%): 2 in the sucrose group, 
6 in the 10 mg/kg acetaminophen group and 4 in both the 15mg/kg and 20 mg/kg 
acetaminophen groups.
BUN, creatinine, aspartaat-aminotransferase (ASAT), alanine-aminotransferase (ALAT), 
total- and direct bilirubin values after acetaminophen administration were available 
for 46 (77%), 42 (70%), 10 (17%), 9 (15%), 39 (65%) and 11(18%) patients, respectively. 
BUN and creatinine values (refl ecting kidney function) and transaminases and bilirubin 
values (refl ecting liver function) were not statistically signifi cantly diff erent between the 
three acetaminophen treatment groups (p=0.54 for BUN, p=0.12 for creatinine, Kruskal-
Wallis test) (see Table 2).
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Figure 3 Peri-intervention changes in heart rate (left panel) and oxygen saturation 
(right panel)    
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Figure 3. Peri-intervention changes in heart rate and oxygen saturation
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Discussion
Pain scores assigned to preterm newborns during CVC placement did not signifi cantly 
diff er between the three groups receiving a diff erent dose of iv. acetaminophen. This 
procedure is considered very painful, and in most cases the scores still refl ected mild to 
moderate pain. Comparison with an oral sucrose control group showed that acetamino-
phen was not more eff ective than sucrose.
Comparative studies of diff erent acetaminophen doses in infants are lacking. Allegaert 
et al showed a signifi cant reduction of the Leuven Neonatal Pain Score after a single 
intravenous loading dose of 20 mg/kg acetaminophen in preterm and term neonates 
suff ering from delivery trauma25. The available pharmacokinetic (PK) studies on intrave-
nous acetaminophen in preterm infants also suggest that a loading dose of 20 mg/kg 
intravenous acetaminophen for neonates with postconceptional ages of 28-32 weeks and 
body weights above 1.5 kilograms is suffi  cient for pain relief17,26. Our study population was 
younger, both in gestational age and postnatal age. We compared outcome in terms of 
pain scores after a single dose of 20 mg/kg intravenous acetaminophen with that after 10 
and 15 mg/kg doses to fi nd the optimal dose to provide proper and safe analgesia.
While there are data from PK studies16,17,27, the pharmacodynamics (PD) of acetaminophen 
in neonates are poorly described. Therefore it is not known if we can simply extrapolate 
the available PK observations (concentration/time profi le) to dosing regimens, assuming 
that there is no age-dependent diff erence in PD (concentration/eff ect or level of analgesia). 
PK/PD data in older infants showed that an eff ect compartment concentration of >9 mg/l 
acetaminophen will achieve the target eff ect18. Our study showed median plasma peak 
concentrations of acetaminophen > 9 mg/l in 95% of all subjects across the three acetamin-
ophen treatment groups. As a consequence, the lack of diff erences of PIPP scores between 
acetaminophen treatment groups cannot be explained by too low acetaminophen doses.
On the other hand, it is well possible that acetaminophen, which has been found suitable 
to relieve mild to moderate pain, does not relieve severe pain associated with acute skin 
breaking procedures. Thus, other medications, such as fentanyl and remifentanil, need 
to be considered27. Remifentanil, for example, is a short acting drug with highly suitable 
analgo-sedative qualities for acute procedural interventions. On the other hand, how-
ever, short acting opioids can cause adverse eff ects such as respiratory insuffi  ciency and 
chest rigidity. Before repeated or continuous use can be advocated, further studies on 
hyperalgesia, tolerance and long term neurodevelopmental outcome are also needed.
Exposure to stressful procedures and procedural pain without analgesia is associated 
with alterations in brain development of very preterm infants. This is due to reduced 
maturation of white matter and subcortical grey matter shown on MRI scans, assessed 
at term equivalent age8, and reduced brain size in the frontal and parietal regions28. The 
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necessity of pain relief in very preterm infants is beyond any doubt, but the best drug for 
that purpose has yet to be found.
Pain assessment in very preterm neonates is a challenge; numerous pain assessment instru-
ments are available but only a few take gestational age into account, such as the PIPP used 
in our study. The PIPP includes changes in heart rate and oxygen saturation, which might 
better reflect acute pain. Other than the originally published PIPP, the revised PIPP22 takes 
both a rise and a drop in heart rate into account. The fact that 20% of our patients showed a 
drop in heart rate proves the usefulness of the revised PIPP score in future studies.
Several limitations of this study should be addressed. First, numbers of patients in each 
dose group per gestational age group were relatively small. However, like in all studies 
in neonates it is very difficult to obtain larger sample sizes because participating in a 
trial is not the first priority for parents of these very young and generally severely ill 
infants. Second, seven patients received NSAIDs for PDA treatment, reflecting standard 
clinical care of very preterm neonates. These patients were not excluded, but the use of 
NSAIDs was added as covariate in our analyses. Third, to avoid infusion site discomfort 
the acetaminophen was administered over 15 minutes. This time period may not have 
been long enough to reach optimal analgesia. Still, the peak plasma levels seemed to be 
adequate if compared to studies in older infants. Fourth, we were not able to check liver 
and kidney function before and after administration of acetaminophen in all patients. It 
is not part of the routine care in both centers and we were not allowed to withdraw extra 
blood for sampling. Moreover the study had not enough power to determine the overall 
safety of acetaminophen in extreme preterm infants.
Conclusion
In our quest for efficient pain medication before acute painful procedures we performed 
a study on the use of acetaminophen. We did not show a benefit of doses higher than 
10 mg/kg acetaminophen for pain relief during central venous catheter placement in 
preterm infants. Besides, acetaminophen was not more effective than sucrose. In view 
of our findings it is quite likely that acetaminophen is not the drug of choice for this or 
other skin breaking procedures in preterm infants; whether it could be suitable for mild 
or more prolonged pain needs to be further elucidated.
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Abstract
Finding the optimal pharmacological treatment of a patent ductus arteriosus (PDA) in 
preterm neonates remains challenging. There is a growing interest in paracetamol as a 
new drug for PDA closure.
In this prospective observational cohort study we evaluated the effectiveness of intrave-
nous paracetamol in closing a PDA in very low birth weight infants with a hemodynami-
cally significant PDA who either did not respond to ibuprofen or had a contra-indication 
for ibuprofen. They received high dose paracetamol therapy (15mg/kg/6h intravenous) 
for 3-7 days. Cardiac ultrasounds were performed before and 3 and 7 days after treat-
ment. Thirty-three patients were included with a median gestational age of 251/7 weeks 
(IQR 1.66), a median birth weight of 750 grams (IQR 327) and a median post-natal age of 
14 days (IQR 12). Paracetamol was ineffective in 27/33 patients (82%). Even more, after 
previous exposure to ibuprofen this was even 100%.
Conclusions
In this study paracetamol after ibuprofen treatment failure was not effective for PDA 
closure in VLBW infants. From the findings of this study, paracetamol treatment for PDA 
closure cannot be recommended for infants with a postnatal age >2 weeks. Earlier treat-
ment with paracetamol for PDA might be more effective.
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Introduction
The ductus arteriosus fails to close after birth in 30 to 60% of prematurely born infants 
[16]. This condition – patent ductus arteriosus (PDA) – is associated with a prolonged 
ventilation need and carries an increased risk of morbidity (i.e., necrotizing enterocolitis, 
chronic lung disease) and even mortality [10, 15, 18]. Pharmacological closure with 
non-steroidal anti-inflammatory drugs (NSAIDs), mainly ibuprofen and indomethacin, is 
currently the standard of care [27]. NSAIDs are not effective in around 30% of patients, 
however, and can have side-effects such as gastrointestinal bleeding and perforation, 
diminished platelet aggregation, hyperbilirubinemia and transient renal function 
impairment [22, 23]. Moreover, NSAIDs are contra-indicated in a considerable propor-
tion of newborns, notably those with renal failure, intracerebral hemorrhage, gastro-
intestinal problems and thrombocytopenia. If NSAIDs fail or are contra-indicated, the 
only currently available solution is surgical ligation, which is associated with the risks of 
cardiothoracic surgery and impaired neurological outcome [17]. Therefore, alternative 
pharmacological interventions are needed.
Paracetamol has been suggested as an alternative drug for PDA closure [21]. More 
than 10 observational and retrospective studies have described oral or intravenous 
high-dose paracetamol treatment with varying effectiveness [1, 8, 9, 11, 12, 19, 21, 26, 
29](see Table 1). Two recent prospective randomized controlled trials comparing oral 
paracetamol with ibuprofen both showed a slightly favorable effect of paracetamol 
(closure rate 81.2% versus 78.8% for ibuprofen) [5]. The other trial by Oncel et al. even 
showed a higher closure success rate in the paracetamol group (97.5% versus 95% in 
the ibuprofen group) after a maximum of two courses of ibuprofen or paracetamol [20].
After publication of the first studies on paracetamol and PDA closure we added intra-
venous paracetamol to our PDA treatment guideline. However, the results in the first 
patients did not match the high closure rates of other studies and only 20% of patients 
did not need further PDA treatment after paracetamol [24]. Based on the promising 
results of other published studies we decided to continue paracetamol treatment for 
PDA closure in preterm infants with ibuprofen contra-indications or ibuprofen treat-
ment failure.
In the current study we describe the evaluation of the efficacy of intravenous 
paracetamol on PDA closure in very low birth weight (VLBW) infants admitted to our 
hospital.
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Methods
In a prospective observational, single center study performed from December 2012 un-
til September 2014 at the level III NICU of the Erasmus MC-Sophia Children’s Hospital in 
Rotterdam, the Netherlands, we included all neonates with a gestational age of less than 
28 weeks and a birth weight of less than 1500 grams diagnosed with a hemodynami-
cally significant patent ductus arteriosus (hsPDA) using clinical and cardiac ultrasound 
evaluation. Findings in the first 9 patients in the current study were also presented in a 
preliminary report in 2014 [4].
The first drug of choice in our department for PDA treatment was intravenous ibuprofen 
(Neobrufen♥; Pedea ©), a single daily dose for 3 days (10 mg/kg on first day, 5 mg/kg 
on second and third days), and a repeated 3-day course if closure was not yet obtained. 
Paracetamol (Perfalgan©; Bristol-Meyers Squibb) was given if two courses of ibuprofen 
had no effect or if ibuprofen was contra-indicated. Intravenous paracetamol 15 mg/
kg every 6 hours (60 mg/kg/day) was administered for a minimum of three days and a 
maximum of 7 days.
Based on the indication for paracetamol, we created three groups. Group A: ibuprofen 
contra-indicated and paracetamol as first drug of choice (primary contra-indication); 
Group B: development of a contraindication for ibuprofen during treatment with ibu-
profen as first choice and switch to paracetamol (incomplete ibuprofen); and Group C: 
two complete courses of ibuprofen failed to achieve closure and switch to paracetamol 
(complete ibuprofen). (See figure 1).
Contraindications for ibuprofen treatment were active intracerebral hemorrhage, throm-
bocytopenia or other known clotting disorders, severe sepsis, suspected or confirmed 
necrotizing enterocolitis (NEC), intestinal perforation, liver and kidney function disorders 
(oliguria < 1.0 ml/kg/h, serum creatinine > 110 µmol/l) and severe hyperbilirubinemia.
Echocardiographic examination was performed by the echocardiosonographer or 
pediatric cardiologist before the start of paracetamol treatment, after three days and 
after 7 days. Measurements included ductus diameter, PDA diameter/LPA (left pulmo-
nary artery) diameter, and LA/Ao (left atrial to aortic root) ratio. Two-dimensional color 
Doppler echocardiography was performed using a Vivid-S6 (GE Health Care) ultrasound 
system equipped with a 10MHz transducer.
Cardiac ultrasound studies were done at the bed side by different echocardiosonogra-
phers, and measurements were checked by one pediatric cardiologist (I.M. v B). HsPDA 
closure was defined as no flow through the duct. An open duct with diameter < 1.5 mm, 
without significant left-to-right shunt, PDA:LPA diameter < 0.5 and LA/Ao ratio smaller 
than < 1.4 was defined as small PDA and not hemodynamically significant. HsPDA was 
defined as a ductal diameter of > 2.0 mm, PDA:LPA diameter > 0.8 and/or LA/Ao ratio > 
1.6.
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Table 2. background characteristics 
Characteristics Group A
N = 13
Group B
N = 8
Group C
N = 12
Gestational age (weeks); median
Range
IQR
25.2
24.0-26.4
0.8
24.3
24.0-26.3
0.7
25.8
23.6-26.6
1.0
Birth weight (gr): median
Range
IQR
650
400-1130
360.0
730
365-820
305.0
868
480-990
231.3
Small for gestational age: n (%) 5 (38.5) 3 (37.5) 2 (16.7)
Gender
Male: n(%)
Female: n(%)
9 (69.2)
4 (30.8)
4 (50)
4 (50)
6 (50)
6 (50)
Died: n (%)
Post natal age: median/IQR
4 (30.8)
51/24.5
4 (50)
30/34.3
0 (0)
Antenatal steroids: n (%) 11(84.6) 8 (100) 12(100)
PIH; n (%) 3 (23.1) 2 (25) 2 (16.7)
Cesarean section: n (%) 9 (69.2) 5 (62.5) 7 (58.3)
Mechanical ventilation: n (%) 12(92.3) 7 (87.5) 11(91.7)
Surfactant treatment 10(76.9) 7 (87.5) 11(91.7)
Diuretics 11(84.6) 4 (50) 11(91.7)
Fluid restriction 9  (69.2) 3 (37.5) 8  (66.7)
PNA start PCM:median (days)
IQR
12.0
11.5
12.5
14.75
16.5
10.75
Paracetamol treatment
days in total (median/IQR)
6.0
3
6.5
2.75
5.5
4
Surgical ligation: n(%) 5 (38.5) 6 (75.0) 12 (100)
PDA measurements
PDA diam. before start PCM 
(mm): median/IQR 2.4/1.30 1.9/1.13 2.4/0.83
PDA diam. after 3 days PCM
(mm): median/IQR 1.9/0.90 2.1/1.13 2.1/1.08
PDA diam. after 7 days PCM
(mm): median/IQR 1.8/1.28 2.0/0.40 2.6/1.60
PDA:LPA ratio before start PCM
median/IQR 0.85/0.55 0.85/0.45 0.90/0.30
PDA:LPA ratio after 3 days PCM
median/IQR 0.90/0.60 0.80/0.15 0.95/0.50
PDA:LPA ratio after 7 days PCM
median/IQR 0.75/0.58 0.80/0.30 0.85/0.28
LA/Ao ratio  before start PCM
median/IQR 1.6/0.30 1.7/0.53 1.75/0.30
LA/Ao ratio after 3 days PCM
median/IQR 1.64/0.60 1.7/0.70 1.8/0.55
LA/Ao ratio after 7 days PCM
median/IQR 1.4/0.55 1.9/0.40 1.7/0.65
NT-proBNP (pmol/l)¥: median
IQR
1097
3849.3
2102
5832.0
3078
4981.8
Pregnancy induced hypertension syndrome (PIH); Postnatal age (PNA); Paracetamol (PCM);
Left pulmonary artery (LPA); Left atrium-Aorta (LA-Ao)
N-terminal pro-Brain natriuretic Peptide (NT-proBNP); ¥: all NT-proBNP values were determined on day 3 PNA
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Statistical analysis
Patient characteristics are presented as medians (IQR: Inter Quartile Range) in case of 
non-normally distributed variables and as means (standard deviations) in case of nor-
mally distributed variables. PDA diameters, PDA:LPA ratio and LA/Ao ratio before, during 
and after treatment with paracetamol were compared using paired t-tests. Fisher exact 
tests were used in case of categorical variables. Data analyses were performed with SPSS 
version 21.0 (SPSS Inc.). A p-value of 0.05 was set as statistically significant.
Results
A total of 33 VLBW infants with a median gestational age of 251/7 weeks (range 236/7-
266/7, IQR 1.66) and a median birth weight of 750 grams (range 365-1130, IQR 327) were 
included. Intravenous paracetamol was started at a median postnatal age of 14 days 
(IQR 12). Background characteristics and clinical outcome are shown in Table 2.
Median duration of paracetamol treatment was 6 days (IQR 3); the median cumulative 
dose was 360 mg (IQR 180). Ductal closure or no hsPDA after treatment was achieved 
in 6 of the 33 patients (18%). In total 23 patients (76.7%) needed surgical ligation for a 
hsPDA with clinical symptoms. Findings in the three different groups (see Figure 1) are 
detailed below.
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Figure 2 Change in ductus arteriosus diameter after 3 to maximum 7 days of 
intravenous PCM treatment for the 3 different groups (Group A: primary 
contraindication for ibuprofen; Group B: paracetamol after early stop of ibuprofen; 
Group C paracetamol after complete ibuprofen treatment). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Change in ductus arteriosus diameter after 3 to maximum 7 days of intravenous PCM treatment 
for the 3 different groups (Group A: primary contraindication for ibuprofen; Group B: paracetamol after 
early stop of ibuprofen; Group C paracetamol after complete ibuprofen treatment).
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Patients in Group A (=primary contra-indication for ibuprofen; N=13, 39.4%) received the 
first dose of paracetamol after a median of 12 (IQR 11.5) postnatal days and the median 
duration of the course was 6 (IQR 3) days. In six patients (46%) the ductus arteriosus was 
closed or not hemodynamically significant after paracetamol and further treatment was 
not indicated. Two of the seven patients who did not respond to paracetamol treatment 
were successfully treated with ibuprofen (one and two courses, respectively) afterwards 
because the contra-indication for ibuprofen had disappeared. Surgical ligation was 
performed in the other five (54%).
Patients in group B (= incomplete ibuprofen; N= 8, 24.2%) received the first dose of 
paracetamol after a median of 12.5 (IQR14.75) postnatal days and the median duration 
of the course was 6.5 (IQR 2.75) days. Two patients died on the 24th and 34th postnatal 
day (i.e., sepsis with extension of bilateral intraventricular hemorrhage with venous in-
farction, gram-negative bacterial infection) after paracetamol treatment (started on day 
8 and 13 respectively) before a decision could be made to treat the persistent PDA with 
surgical closure. Paracetamol treatment was ineffective in the six remaining patients and 
all underwent surgical closure of the duct.
Patients in group C (= complete ibuprofen; N=12, 36.4%) received paracetamol for a 
median of 5.5 days (IQR 4) after two courses of ibuprofen. At start of paracetamol treat-
ment their median postnatal age was 16.5 (IQR10.75) days. Paracetamol treatment was 
ineffective in all patients and consequently they all underwent surgical ligation.
Both the surgical ligation rate and the mortality rate differed between the three groups. 
Surgical ligation was performed in 5/13 (38.5%) in group A; 6/8 (75%) in group B; and 
12/12 (100%) in group C (Fisher exact test for surgical ligation p=0.001). In total 8 pa-
tients died (Fisher exact test for death p=0.025), 4/13 (31%) in group A (median 51 days; 
IQR 24.5); 4/8 (50%) in group B (median 30 days; IQR 34.3); and none in group C. Two 
of the 4 non-survivors in group B died from the consequences of NEC before surgical 
closure of the PDA could be performed.
Cardiac ultrasound studies showed a statistically significant decrease in ductal diameter 
after paracetamol treatment only in group A, from median 2.4 mm to 1.8 mm after 7 
days treatment (p=0.035, paired T-test). (Figure 2)
All pre- and post-treatment measurements of kidney function (urea and creatinine) and 
liver function (transaminases, conjugated bilirubin) were normal.
Discussion
In this study, high dose intravenous paracetamol for the treatment of hsPDA in VLBW 
infants was overall effective in only 18%. Looking at subgroups of patients, paracetamol 
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treatment was completely ineffective after previous ibuprofen treatment failure. 
However, it was effective in 46% of the newborns with primary contraindications for 
ibuprofen.
Variability in success rates this paracetamol therapy for PDA closure is hard to explain. 
Other studies reported success rates of 0% [7] up to 100% [12, 19]. Success rates in two 
RCTs comparing oral paracetamol versus oral ibuprofen were 81% [5] and 94% [20], 
respectively, thus much higher than in our study. Still, in all but one of those studies 
the same dosing regimen of 60 mg/kg/24h paracetamol was used. In the study by Tek-
gunduz et al. the dose was lowered to 30 mg/kg/day after a patient showed elevated 
transaminases [13]. The duration of paracetamol treatment in our study was 6.0 days 
compared to 4.1 days [29] and 3.9 days [19] in the studies with high success rates.
In previous studies, except the 2 RCTs [5, 20], the indication for paracetamol was the same 
as in our study (treatment failure or contraindication for ibuprofen). The interpretation 
of different studies on this subject seems to be hindered by the lack of an international 
guideline on the definition of hsPDA and cutoff values for a small, medium or large PDA 
(cardio ultrasound measurements).
It is remarkable that Oncel et al. reported a 100% success rate of PDA closure with 
intravenous paracetamol[19], the same administration route as in our study. Although 
unlikely, the route of administration could in part explain the variety in success rates: 
as long as data on bioavailability of the drug in the different routes and enterohepatic 
recirculation are lacking, we cannot tell which route of administration is superior. Still, 
ibuprofen studies also tend to find better results with oral administration [27]. Intrave-
nous therapy probably leads to high peak plasma levels, but on the other hand also to 
a relatively fast decrease in levels. Oral therapy might result in lower, but more steady 
plasma levels. It can be hypothesized that PDA closure relies more on continuous pros-
taglandin inhibition than on intermittent high paracetamol or NSAIDs levels.
The relatively late start of paracetamol administration might be the most important 
explanation for our disappointing results compared to other studies. A second likely 
reason is the low gestational ages in our study. Other studies with better results [12, 19, 
21, 29] included older infants with gestational ages > 28 weeks. PDAs in this age group 
are generally less hemodynamically significant and tend to close spontaneously and 
respond better to pharmacological treatment.
Ibuprofen therapy failure was previously found to be 17% in infants with gestational 
ages of 26-27 weeks versus 62% in 23 to 25-week-old infants [6]. PDAs in more preterm 
born infants are probably less responsive to cyclooxygenase inhibitors due to higher 
expression of prostaglandin receptors [3]. Next to gestational age and postnatal age, 
clinical factors such as the amount of fluids given, incidence of infections or sepsis, type 
of respiratory support, and use of co-medication might be influential factors for PDA 
closure success in extreme preterm infants.
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Third, selection bias may have occurred in that we included patients in whom ibu-
profen therapy had failed prior to paracetamol treatment. As NSAIDs are more potent 
prostaglandin synthesis inhibitors than paracetamol [8], resulting in lower peripheral 
PGE2 levels as is shown in orthodontic studies [25] the a priori probability of success of 
paracetamol in this group of patients was already relatively low.
Pharmacokinetics and pharmacodynamics of paracetamol for PDA closure have been 
hardly studied. Consequently, the effective plasma level of paracetamol to achieve PDA 
closure is unknown. The currently used dosages are already much higher than recom-
mended for analgesia, and might be unsafe. Increasing the dose to improve closure 
rates is unadvisable. In a study by Kessel et al. plasma levels of paracetamol (15 mg/
kg 6 hourly by nasogastric tube) did not exceed the recommended plasma levels of 
10-20 mg/l for pain and fever control [14]. Based on predictive modeling, plasma levels 
will accumulate with the 15 mg/kg 6 hourly regimen, reaching peaks of nearly 25 mg/
kg after four doses [1]. In very preterm infants and murine studies the effectiveness of 
paracetamol on PDA closure was suggested to depend on dosing, duration of treatment 
(>2 days course) and mode of administration [8].
Likewise, safety of paracetamol in very preterm infants (gestational age <28 weeks) has 
been little studied. Allegaert et al. showed no hemodynamic alterations during and fol-
lowing an intravenous loading dose of paracetamol and afebrile neonates maintained 
normothermia [2]. Paracetamol-induced hepatotoxicity is the most important concern; 
this is caused by the formation of a highly active metabolite N-acetyl-p-benzoquinone 
imine (NAPQ1) by the hepatic cytochrome P-450 dependent CYP 2E1 enzyme system 
[28]. The formation of NAPQ1 is suggested to be low due to the immaturity of the he-
patic enzymes, although increased susceptibility to toxicity from supratherapeutic of 
paracetamol is described in infants and younger children with fever [13]. CYP 2E1 activ-
ity has not yet been quantified in neonates and the correlation between paracetamol 
concentration and increased NAPQ1 production is unknown.
Several limitations of this study should be addressed. First, this was an observational 
single center study with relatively few patients per group, without a matched control 
group to rule out spontaneous PDA closure. Firm statements are therefore difficult to 
make. Second, the echocardiosonographer and pediatric cardiologist were not blinded 
for the PDA treatment. Third, only patients were included in our study after ibuprofen 
failure or with a primary or secondary contraindication for ibuprofen; this selection bias 
might have contributed to our results.
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Conclusions
In view of the findings from this study, we do not recommend the use of intravenous 
paracetamol for hsPDA closure in VLBW infants after ibuprofen failure. Still, as we did not 
rule out effectiveness of paracetamol as early PDA treatment, it might be recommended 
when started in the first week of life. On the other hand, as long as data on long term 
safety are lacking, high dosages of paracetamol should be used with caution. Better 
designed PK/PD studies are needed to shed a light on safety aspects and the optimal 
dose-concentration-effect relationship. PK modeling of available data on PDA treatment 
with paracetamol in different gestational age groups can lead to different dosing recom-
mendations per age group; a trial with these dose recommendations of paracetamol for 
PDA is also an option for future research.
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Introduction
After revealing publications by Anand in the late eighties on the necessity of pain 
treatment in newborns, in particular in view of the preventive effect of peri-operative 
analgesia on mortality1, we have now reached a new era in which pain is seen as the 
fifth vital sign, as suggested by the American Pain Society. It is generally accepted that 
prematurely born neonates are able to feel pain and that any pain must be adequately 
treated but, better still, prevented in the first place. The questions how and when to 
measure pain in these vulnerable newborns or how analgesics should be used with 
regards to dosage, timing and drug of first choice are still difficult to answer.  
Worldwide 15 million premature neonates are born yearly. Advances in neonatal care 
and medical technology over the past two decades have led to a 31% increase in survival 
among infants born at 23 weeks’ gestation2,3, albeit at the expense of significant morbid-
ity. In several countries the limit of viability is trending down and in the Netherlands the 
current limit for active treatment is 24 weeks’ gestation. Other countries, such as the 
USA, Japan and Sweden, are already treating preterm infants with gestational ages of 22 
weeks. As a consequence, the number of preterm infants who will be exposed to painful 
procedures in the NICU setting is rising.
Caution is needed as the growing pain awareness even led to overtreatment. In 
the 1990s, many centers started to use strong opioids such as morphine or fentanyl, 
sedatives like midazolam or even muscle relaxants, as standard of care during invasive 
ventilation in newborns. Then, Anand and colleagues showed in a large placebo con-
trolled trial (Neopain study) that morphine had no effects on short term outcome. Even 
relatively high dosages of 20-30 mcg/kg/hour instead of the generally accepted 10 mcg/
kg/hour4 had inadequate analgesic effects in ventilated preterm neonates between 28 
and 32 weeks of gestation. A trial from our own research group in which the neonates 
received 10 mcg/kg/hour morphine or placebo, irrespective of gestational age, was the 
first to conclude that routine administration of morphine in ventilated preterm infants is 
unnecessary5. A meta-analysis of the NEOPAIN study combined with other comparable, 
smaller trials confirmed this conclusion 6. 
Furthermore, after a Cochrane review concluded that midazolam seemed associated 
with an increased risk of intraventricular hemorrhages, its use was almost completely 
abolished from neonatal intensive care units7,8. Data from animal studies suggesting 
that many analgesics and anesthetics9 cause excessive cell death in the developing 
brain further increased clinicians’ reluctance to use pharmacological agents to treat 
neonatal pain. Today, as is shown in this thesis (chapter 4), NICU stay is a stressful affair 
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for these vulnerable newborns and is associated with an enormous number of painful 
procedures10. The Europain Survey has shown wide variation in the use of analgesics and 
sedatives for neonates in NICUs across Europe – from 81.5% of ventilated infants,  17.8% 
of non-invasively  ventilated infants to 9.3% of those with spontaneous ventilation11.
Neonatal pain
Pain response
Although numerous questions concerning pain still remain unanswered, much has 
been learned about pain perception, pain response and pain assessment. Pain percep-
tion requires awareness of a noxious stimulus and development of pathophysiological 
pathways of pain12. 
Nociceptive cutaneous receptors start developing from 7.5 weeks gestational age13 and 
nociceptive fibers from 22-23 weeks of gestation14.  The nociceptive receptors in the skin 
are connected with specialized peripheral sensory neurons transmitting the pain signal 
to the cortex and vice versa. These pathways are fully developed at 30 weeks of gesta-
tion and the degree of myelinisation determines the speed of the conducted signal15. 
Reflexes mediated in the spinal cord as a response to mechanical skin stimulation are 
exaggerated in young infants compared with adults, with lower thresholds  resulting in 
more synchronized, longer-lasting reflex muscle contractions16. This might be caused by 
immaturity of the inhibitory descending pain pathways.  Slater et al showed that pre-
maturely born infants who have experienced at least 40 days of intensive care, have an 
increased neuronal response to noxious stimuli compared with healthy newborns at the 
same corrected age17. This means that even the most extreme preterm neonates born 
at the limits of viability are capable to respond to painful stimuli with a pain response 
expressed as changes of physiologic parameters and behavior. These pain responses 
are comparable between preterm and term infants; even extremely low gestational age 
infants have similar, though dampened pain responses as older infants18.
Some additional factors play a role in the extent and the way preterm newborns respond 
to pain. First, previous painful procedures can affect pain responses: in a cross-sectional 
comparative study, preterm infants who spent postconceptional weeks 28 through 32 
in a NICU had a less mature pain response than premature infants born after 32 weeks’ 
postconceptional age19. The infants exposed to frequent invasive procedures showed 
fewer behavioral manifestations of pain, but larger changes in heart rate during heel 
sticks than those of the same postconceptional age who were just born 19. Furthermore, 
severity of illness may affect the way neonates express pain. For example, an infant with 
(suspected) necrotizing enterocolitis may show little behavioral pain expression, but the 
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estimated extensiveness of tissue inflammation and bowel ischemia may point at pain 
that should be treated. 
Painful procedures
In 2003, the mean number of painful procedures per neonate per day on our NICU was 
14 (SD 4), which figure compares agreeably with the 16 painful procedures per day of 
hospitalization in other international NICUs (EPIPPAIN study)20. After the introduction 
of a pain management protocol the mean number of painful procedures per neonate 
per day in our NICU went down to 11.2 (SD 5.7). A further reduction is unlikely as the 
NICU population has changed over the last years to include more preterm neonates 
with lower gestational ages and birth weights as well as more critically ill term infants. 
Insertions of lines, catheters and endotracheal tubes often need more than one attempt 
to succeed and are considered painful (chapter 4). With respect to line insertion there 
is room for improvement, however, which could be achieved by simulation training in 
skills labs with suitable manikins, by setting up an intravenous access team, training 
programs for senior neonatal nurses and residents  and by introducing new support 
devices such as the translumination devices based on cold near-infrared LEDs. 
Most of the suitable pain assessment instruments have been validated for acute pain, 
for example the pain experienced from heel lancing. Heel lancing is less time consuming 
and easier to perform than venous puncture, which is proven to be less painful21,22. Opt-
ing for venous puncture could obviously reduce the amount of pain. However, in some 
cases heel lancing is unavoidable, and then it is important to use an appropriately-sized 
heel lance and to perform the procedure in the correct way. To assess how correctly this 
is done in our unit, we observed how many squeezes of the heel (considered even more 
painful than the heel prick itself ) were needed to obtain blood (unpublished study). In 
150 newborns a median of 19 squeezes (IQR 9 to 32) were needed, which makes one 
think that there is room for improvement.  Apart from pharmacological pain control, 
non-pharmacological interventions can help reduce pain. Weissman et al showed that 
any method of pain control is better than none.  Of the  non-pharmacological interven-
tions they studied, nonnutritive sucking, skin-to-skin holding by the mother, oral glucose 
solution, and breastfeeding during heel lancing were found to be the most effective23. 
Ultimately, our goal will be to determine how multiple stressful and painful interven-
tions in the NICU can be minimized, thereby improving clinical, behavioral and develop-
mental outcomes of our patients.
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Pain assessment
Routinely performed pain assessments have become quite common in the daily care 
for newborn infants although practices vary between European NICUs. There still seems 
to be room for improvement: the Europain Survey showed that pain assessments were 
performed in 58.5% of endotracheally ventilated and 45.0% of non-invasively ventilated 
neonates24. Still in many centers in the world pain assessment instruments are used as a 
research tool only and their use had not been integrated in pain management protocols.
The gold standard of pain assessment is self-report but for obvious reasons this is not
possible in nonverbal neonates. Pain assessment should go further than simply apply-
ing one of the many pain assessment instruments in the neonatal ICU.  One important 
aspect is knowledge of the pain source or sources (including exposure duration and 
type of stimulus). For example, the insertion of a chest tube in case of a pneumothorax 
is extremely painful without the proper analgesic therapy and maintenance analgesic 
treatment is needed as long as drainage is necessary. 
Another aspect should be taken into account is the infant’s ability to respond to the nox-
ious stimulus, level of consciousness, especially in the very preterm infants, and severity 
of illness.25 Furthermore, current behavioral state and the amount of pain exposure prior 
in life are relevant: a study in preterm newborns showed that those who were more 
premature, asleep, and had undergone a painful event more recently, less likely demon-
strated behavioral and physiologic indicators of pain during a heel stick26.  Most research 
focuses primarily on acute pain, like in procedural interventions or surgery. In the clinical 
setting, assessing prolonged or persisting pain is also an important challenge, which 
so far has received only little attention because major methodological issues regarding 
scoring of chronic pain have not yet been solved.
Numerous pain assessment instruments have been developed since 1987 and there 
seems to be no limit to the introduction of new instruments (see Figure 1). This is un-
fortunate because the newer instruments show significant overlap with the older ones 
with respect to the indicators used. In the absence of a ´gold standard´ instrument, it 
remains hard to determine which is the best of the other instruments. Most pain assess-
ment instruments are based on behavioral indicators such as facial expression, cry and 
body movements. This would explain why ‘new’ instruments are highly correlated with 
the existing ones and supposedly show good construct validity. However, this is rather 
a case of “old wine in new bottles”. Some instruments, however, such as the N-PASS 
for prolonged pain and PIPP for acute pain, include physiological parameters, next to 
behavioral indicators, heart rate, oxygen saturation and blood pressure27-29.
General discussion 127
Ch
ap
te
r 8
Unfortunately most authors do not provide data about the correlation between these 
physiological indicators and the behavioral indicators but an average correlation of 0.3 
between these two classes of measures has been reported. This leaves the question 
which of the two types of indicators is more valid for pain assessment. 
In our department we have chosen for the COMFORT behavior scale, which we adapted 
from an instrument originally developed to assess the degree of sedation in ventilated 
infants between 0 and 18 years of age30. We further modified and validated it for use in 
neonates in a NICU31 and named this modified version the COMFORTneo scale (chapter 
2). It is intended to monitor prolonged pain and rather not to assess acute pain.  One 
of its assets is that low scores can indicate oversedation and thus alert NICU staff to 
consider tapering of opioids or sedatives. 
Validation is an ongoing process and it will be worthwhile to validate the COMFORTneo 
scale in other settings and relate it with physiological indicators and other instruments, 
which is especially relevant for the extreme premature neonates.
Possibly more objective indicators of pain have been explored, such as technology-
based autonomic, brain-oriented, and bio hormonal indices, including heart rate 
variability32-34, skin conductance35-37, electroencephalogram (EEG)38 and cerebral near-
infrared spectroscopy (NIRS)39,40. 165 
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Heart rate variability 
Studies by the group of Lindh showed that heart rate increased and that the total heart 
rate variability – the variation in the interval between heart beats – decreased in term 
and preterm infants during lancing and squeezing of the heel32,33. Although heart rate 
variability seems a good indicator for acute pain, so far it has only been tested in heel 
lancing and mechanical ventilation, predominantly in term infants. The feasibility of its 
bedside use is still questionable. New advanced measurement devices are promising, 
however, as they can compare subtle heart rate variations measured multiple times per 
second. 
Skin conductance
Skin conductance activity has been first validated as a physiological measure of the 
emotional state in full term infants, based on changes in the palmar and plantar sweat 
glands. These changes in conductance are due to the activity of the sympathetic ner-
vous system, which responds to the emotional state by secreting acetylcholine in the 
postganglionic synapses37,41.  The technique has been hardly tested in preterm infants 
and a study showed that even in children without evident pain, skin temperature was 
correlated with changes in skin conductance activity41. A study by Valkenburg et al sug-
gested that sympathetic neural control of vital functions to maintain homeostasis (such 
as autoregulation of skin temperature) results in skin conductance peaks42. It has also 
been reported that oral glucose administration before heel lancing influences skin con-
ductance peaks43. This finding impacts the specificity of the instrument because these 
peaks are seen in non-stressful or non-pain situations as well. As the majority of NICU 
patients are in incubators in which the temperature is continuously adjusted, and as 
they standardly are given oral sucrose before heel lancing, skin conductance measure-
ments seem less suitable for the NICU population. 
Electroencephalogram (EEG) 
Painful stimuli in preterm infants elicit specific hemodynamic responses in the so-
matosensory cortex, caught on EEG, implying conscious sensory perception38. It may 
be difficult to distinguish increased cortical somatosensory activity from that related to 
motor activity, especially in the smallest infants. A study by Fabrizi et al was the first to 
map the maturation of tactile and nociceptive activity in the developing human brain 
from the extremely preterm stage (28 weeks) through full-term birth (>37 weeks). It 
was found that specific neural circuits necessary for discrimination between touch and 
nociception emerge from 35–37 weeks gestation in the human brain44. In a response 
to a painful stimulus, infants generally evoke parallel cortical and behavioral responses 
but pain may be processed at the cortical level without deflecting detectable behavioral 
changes. It is thus possible that a low score on a pain assessment instrument based 
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on behavioral indicators does not necessarily imply little or no pain45. Multi-modal pain 
assessment is needed, therefore, for example a behavioral pain assessment instrument 
combined with a newer technology-based instrument. 
Near-Infrared Spectroscopy
Near-infrared spectroscopy (NIRS) works through the differential absorption of infrared 
light by hemoglobin and cytochrome aa3, with changes in hemoglobin absorption 
reflecting changes in cerebral blood flow. The hemodynamic changes caught by NIRS 
in the absence of visible behavioral changes in response to pain might support the idea 
that more conventional pain assessment instruments underestimate the pain response 
in infants17. Unfortunately NIRS also reacts on changes in blood pressure, drug treatment, 
respiratory changes and movement, which limits it clinical use as a pain assessment 
instrument. Still this technique might be interesting for research purposes. Evaluation 
of the frontal cortex oxygen consumption is measured with NIRS, and it is hard to see a 
relation with the projections of the nociceptive fibers in the specific “pain” areas of the 
brain. Further studies in which the oxygen consumption is measured at different places 
simultaneously are needed to determine the value of NIRS for pain assessment. 
Multimodal pain assessment
Overall, little is known about threshold- and reference values, interfering factors and the 
applicability of these newer non-conventional markers for pain in (extreme) preterm 
infants. Furthermore, most have not been validated for pain assessment in neonates 
and the bedside utility is questionable at this moment. Still it could be worthwhile to 
explore their applicability as an adjunct to other such tools or to a validated pain scale. 
For example, multimodal pain assessment combining EEG, EMG with NIRS has been 
studied during heel lancing in 6 infants46. The combined measurements proved reliable 
and reproducible, but applicability in preterm and extreme preterm neonates needs to 
be elucidated. Besides, applying all these instruments simultaneously on the fragile skin 
of the extreme preterm infant is not only a technical but also a logistic challenge.
Stress hormones
Recently, salivary biomarkers such as salivary chromogranin and salivary amylase have 
been used to assess stress in adults47,48 and older infants49,50. A study in healthy newborns 
enrolled 3-4 days after birth showed no change in salivary biomarkers before and after 
heel lancing and concluded that these biomarkers are not objective indices for assess-
ing newborn pain51. Salivary and serum cortisol levels are determined to assess acute 
stress. Hair cortisol level is a possible biomarker for chronic stress in neonates, seeing 
that hospitalized term and preterm infants had significantly higher hair cortisol levels 
than healthy term infants (p=0.004). A subgroup analysis of term NICU infants showed a 
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statistically significant association between total number of ventilator days and hair cor-
tisol levels. For every extra day on the ventilator, hair cortisol levels increased on average 
by 0.2 nmol/g (p = 0.03)52. The clinical relevance of this finding is limited as the need for 
ventilator support is determined by the infant’s respiratory condition. Furthermore, it 
will take some time to receive test results of cortisol levels from the laboratory, which 
makes this method impractical for bedside real time pain assessment with subsequent 
acute therapeutic decisions. In addition we do not have the necessary knowledge at this 
moment to assure that stress hormone levels are really associated with repeated painful 
procedures. 
Compliance with guidelines
Pain management by protocol has not always been the case. We know, for example, that 
some 30 years ago many neonates were not given analgesics during and after surgery53. 
The management of pain, agitation, and sedation had thus far been based on caregivers’ 
subjective evaluations of the patient’s condition. On the other hand, the many neonatal 
pain assessment instruments developed since then were not always effectively used in 
daily practice54. 
There is much to say for the idea that pain treatment should be guided by the pain 
scores. Treatment guidelines should therefore specify the pain scores that indicate the 
need to taper down or increase analgesic dosing. Achieving good compliance with new 
guidelines requires much more, however, than simply telling staff one day that we are 
going to work differently. Well planned implementation is needed, as well as a dedicated 
multidisciplinary pain team that keeps on propagating the importance of adequate pain 
management and assessment.
After implementing a pain management protocol in our NICU in 2005, in the year 2011 
we prospectively recorded COMFORTneo scores and all prescribed analgesics and seda-
tives (chapter 3). We found that for 90% of patients fewer than the stipulated 3 assess-
ments per day were done. Deindl et al reported their successful multilayer approach of 
developing and implementing a neonatal pain management and sedation protocol55. 
They concluded that the success was owed to medical staff education using interac-
tive video-based tutorials, bedside teaching, questionnaires, regular assessments with 
defined responses, reassessments and feedback. From our experience we know that 
the electronic patient data management system is helpful in this respect, as it provides 
information about procedures performed, pain scores and subsequent administered 
analgesics. Still, we need to achieve better documentation of protocol violations and of 
reassessments performed after adjustment of treatment56
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Long term consequences of untreated pain
To leave pain untreated is not an option from an ethical perspective and besides carries 
risks of short and long term sequelae. Studies in animals and humans have shown a 
significant risk of neurological impairment, as well as long term learning, cognitive and 
behavioral effects when neonatal pain was left untreated57-59. Furthermore, a study by 
Taddio et al found that pain scores for vaccination at the age of 4-6 months were highest 
for term neonates circumcised without pain treatment in the neonatal period compared 
with those for pretreated circumcised- and uncircumcised infants60. There is growing 
evidence that preterm infants whose clinical condition necessitates prolonged NICU 
stay undergo numerous painful procedures and not always receive analgesics11. As a 
consequence they may show altered brain development in terms of reduced maturation 
of white matter and subcortical grey matter shown on MRI scans at term equivalent 
age61, and reduced brain size in the frontal and parietal regions62. Thus, we need to be 
aware that leaving painful interventions untreated can have far-reaching consequences 
for these neonates at later age.
Consequences of pharmacological treatment
Analgesic treatment of pain is also not without consequences: studies in rodents show 
accelerated neuronal apoptosis and other morphological changes in the developing 
brain after administration of commonly used opioids, benzodiazepines and of general 
anaesthetics63-65. Especially morphine administration in animals at neonatal age led to 
increased hypersensitivity66 , impaired learning67 and decreased cell division within the 
hippocampus, with possible  neurobehavioral deficits in adulthood68. Other studies in 
rats have suggested, however, that morphine (at higher doses) may have a protective 
role as well69,70. Morphine can act as a modulator of cell proliferation and protect astro-
cytes against apoptosis71.  In mice high doses of propofol and low doses of ketamine may 
provide a certain degree of neuroprotection but the underlying mechanism remains 
unclear72. Programmed cell death, apoptosis, has been described also in in vitro studies 
in human fetal brain cells exposed to morphine73 . 
Neonatal pain treatment
Non-pharmacological interventions
The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) 
has become standard of care in many NICUs worldwide although a systematic review 
concluded that there is no evidence that NIDCAP improves long-term neurodevelop-
mental or short-term medical outcome74. NIDCAP embraces a range of interventions 
and behavioral changes, and levels of interventions have not been standardized, which 
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makes it difficult to study the effects. These interventions include skin-to-skin care, also 
during painful procedures75, reduction of noise and light exposure, and providing con-
tainment of the infant by having procedures performed by two nurses. A positive effect 
on long-term medical outcome has been proven, as NIDCAP care was found associated 
with a better daily weight gain, a shorter hospitalization, and an increase in Bayley 
Scale of Infant Development scores at 9 months74.The analgesic properties of sucrose 
to reduce procedural pain have also been questioned although it is still standard of 
care in many NICUs76-78. According to Slater et al40, reduction in clinical observational 
scores should not be seen as pain relief as their data on EEG suggested that oral sucrose 
does not significantly affect activity in the neonatal brain and spinal cord nociceptive 
circuits. But the question remains if the lack of nociceptive-specific brain activity dur-
ing a painful procedure for which patients are given sucrose reflects the absence of 
pain. Is it the nociception or the subsequent cortical pain response that leads to long 
term sequelae? New approaches to increase comfort are continually being introduced: 
for example, Mimo, a pillow system embedded with sensing and actuating functions 
providing  comfort through mediation of a parent’s physiological features (heartbeat) 
to the distressed neonate 79. Again, the applicability of such approaches needs to be 
investigated as well as the practical use and possible effects on short term and long term 
outcomes for critically ill infants.
Pharmacological interventions
Opioids are the most commonly used drugs in the treatment of pain in adults and 
children. A follow-up study of 5-year-old children who as ventilated newborns par-
ticipated in a morphine-placebo controlled trial, found no impairment of cognitive and 
behavioral development. Still it was found that morphine infusion in the first week of 
life [(10 mcg/kg/hour with extra median dosages of 3.0 mcg/kg/hour (IQR 1.30-6.8 mcg/
kg/hour) open-label morphine on suspicion of pain or distress)] may negatively affect 
response inhibition, a domain of executive functions80. Studying these patients again at 
the age of 8-9 years demonstrated that the morphine given during the neonatal period 
had not harmed general functioning and may even have had a positive influence on 
executive functions at 8 to 9 years81. This positive result is in contrast with the results of 
a pilot study on preemptive morphine analgesia in preterm infants (a subset of subjects 
previously enrolled in the NEOPAIN trial) which reported a smaller head circumference, 
lower body weight, less social behavior and longer response latencies in early childhood 
in those children treated with morphine compared with the placebo group82. 
Paracetamol, a non-selective cyclooxygenase inhibitor, is a fairly old drug, known for 
its antipyretic and analgesic effect, and is sold over-the-counter worldwide. Although 
frequently used by people of all ages, this drug is also not without side effects. Hepato-
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toxicity is described after intentional but also unintentional overdosing of paracetamol, 
but adverse effects are also described after proper dosing in children with myopathies83. 
The possible relationship between maternal use of paracetamol during pregnancy and 
wheezing or asthma in the offspring was first  suggested by Shaheen et al84. So far, 
seven additional studies have been published on this subject but the evidence that any 
such association is causal is inconclusive. The Generation R study, a large cohort study 
involving 3184 pregnant women in the Netherlands, showed that intrauterine exposure 
to mild analgesics, primarily paracetamol, during the period in pregnancy when male 
sexual differentiation takes place, increases the risk of congenital cryptorchidism (odds 
ratio 2.12)85. In one animal study, paracetamol administration during neonatal brain 
development negatively affected cognitive function and altered the analgesic and anx-
iolytic response of these animals at adult age86. These findings are reasons for caution 
and suggest that simply extrapolating PK/PD data of paracetamol in older children and 
adults to neonates is not the way to go. Safety studies on paracetamol in fetal and pre-
term infants and even in term infants are therefore needed, although they are difficult 
to perform in these age groups. If the expected incidences of certain side effects are 
expected to be low, a large sample size is needed which is hard to achieve. Furthermore, 
many environmental factors might contribute to altered cognitive function on adult age 
after drug administration in the neonatal period of life87.
Still, cautious interpretation and extrapolation of the results of animal studies towards 
humans is warranted. Not only are there important differences in pharmacokinetics, 
pharmacodynamics and pharmacogenetics between humans and animals, but also the 
used dosages of analgesics in human and animal studies are different.
Paracetamol and pain
Considering the limited PK/PD data available for adequate and safe dosing guidelines, 
pharmacological pain treatment for neonates is still in its infancy. Furthermore, in 
neonatology the use of unlicensed or off-label medications is quite common: these are 
given to up to 93% of neonates treated at NICUs and include analgesics and sedatives88.
We are the first to provide single PK data of intravenously administered paracetamol and 
all its metabolites in very preterm infants (chapter 5). Three different doses of intrave-
nous paracetamol were studied (10-, 15- and 20 mg/kg), administered as a single dose 
before placement of a central venous catheter, which is a painful procedure (chapter 6).
PK/PD data in older infants showed that an effect compartment concentration of  >9 
mg/l paracetamol will achieve the target effect89. Our study showed median plasma 
peak concentrations of paracetamol > 9 mg/l in 95% of all subjects across the three 
paracetamol treatment groups (p < 0.001)(chapter 5). Our PD data, expressed as PIPP- 
and COMFORTneo scores, showed no beneficial analgesic effect of the three different 
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doses of paracetamol over sucrose (chapter 6). What does this mean? Is paracetamol not 
effective in relieving acute pain or was the effect compartment concentration of >9 mg/l 
too low for very preterm neonates to reach the target effect, which was the case in older 
neonates? Alternatively, as also probably holds true for the use of morphine, we may 
have been measuring in the wrong body compartment and should have investigated 
the effect directly at receptor level – which probably is the way to go for the use of 
morphine. We do not know yet if this also holds true for the use of paracetamol because 
its mechanism of action is not fully understood. Endogenous binding sites or receptors 
for paracetamol are unknown, but it has been suggested that paracetamol stimulates 
activity of descending 5-HT pathways that inhibit nociceptive signal transmission in the 
spinal cord90.
A maintenance dose of paracetamol – as a single analgesic – is probably more effec-
tive in relieving prolonged pain than acute pain. Paracetamol as adjuvant therapy in 
combination with other analgesics is another field to explore. In term infants after major 
non-cardiac surgery, postoperative use of intermittent intravenous paracetamol result-
ed in a lower cumulative morphine dose over 48 hours than did continuous morphine 
administration. 91 This observation is worth further investigation, as dose reduction of 
opioids is quite relevant in view of possible adverse effects of opioids administration.
Paracetamol and PDA
The association of paracetamol exposure and closure of the patent ductus arteriosus 
(PDA), a serendipity type of observation by Hammermann and colleagues92, has led to 
widespread use of high doses of paracetamol in observational and intervention studies 
on PDA closure, without any dose finding study with pharmacokinetic data as evidence 
to support this finding. Placebo controlled trials are lacking.
More than 10 observational and retrospective studies on this subject have been pub-
lished92-100 (see chapter 7). In addition, two prospective randomized controlled trials 
compared oral paracetamol with ibuprofen in relation to PDA closure – both showing 
a slightly favorable effect of paracetamol (PDA closure rate 81.2% versus 78.8% for 
paracetamol and ibuprofen, respectively101 and  97.5% versus 95%102). Our own study 
(chapter 7) could not confirm these high closure rates with paracetamol and the effect of 
paracetamol after ibuprofen failure treatment was even non-existent. This observation 
raises the question in what way paracetamol might add to PDA closure if ibuprofen and 
indomethacin, which are more potent non-selective cyclo-oxygenase (COX) inhibitors, 
are also not always successful? It has been suggested that paracetamol, like ibuprofen, 
exerts inhibitory activity on prostaglandin synthesis. There are no data on the effect of 
paracetamol and ibuprofen on prostaglandin synthesis in young infants and neonates 
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and the scarce data in older humans are often derived from orthodontic procedures as 
the classical test situation103. From these available data it was concluded that ibuprofen 
inhibits PGE2 synthesis more than does paracetamol.  One study in term mice suggested 
a dose/’effect’ (i.e. in vitro constriction), but  paracetamol doses were up to 100 mg/l 
(10x higher than commonly used in humans), and constriction was more pronounced in 
the more mature ductus arteriosus samples, suggesting an age related effect 99. Again, 
the pharmacokinetics of paracetamol in relation to PDA closure in extreme preterm 
neonates has not been comprehensively studied and data on target or effect concentra-
tions of paracetamol needed for PDA closure are missing. The results of our study can 
partly be explained by the fact that we included only very low birth weight infants with 
a gestational age < 28 weeks. Studies from other groups included older infants in whom 
spontaneous PDA closure cannot be ruled out (chapter 7).
It might be worthwhile to also focus on dose regimens and route of administration of 
available drugs for PDA treatment. A population PK/PD study by Hirt et al in 2008 showed 
already that ibuprofen doses used worldwide are too low and should be adjusted to 
postnatal ages104. Furthermore, in that study oral administration of ibuprofen was found 
as effective as intravenous administration.  
What have we learned so far?
• Neonates of all ages can feel pain, although the more preterm infants may show less 
explicit pain behavior105. 
• Neonates admitted to a NICU undergo many painful procedures per day (chapter 
4). By introducing a pain management protocol integrated with a pain treatment 
decision-tree, we were able to reduce the number of painful procedures from 14 to 
11.2 (SD 5.7) (chapter 4). 
• Analgesic treatment decreased even more over the last decade when studies 
showed that routine administration of opioids to ventilated newborns was not 
beneficial. Further concerns arose with the adverse effects of certain analgesics 
and anesthetics on brain development in animals. Sinner et al reviewed the current 
literature of animal experiments, and nicely put together the possible transfer of 
experimental data to humans and the current clinical data106: the timing of anes-
thetic exposure as well as the frequency, duration and dose play a key role in the 
development of toxicity.
• Multiple pain assessment instruments have been developed, but a gold standard 
instrument useful for neonates of all ages and all types of pain (acute, prolonged 
or recurrent pain) is still lacking. We tested the COMFORTneo scale, a modified ver-
sion of the COMFORT-behavioral scale tailored for use in premature neonates for its 
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psychometric qualities and its usefulness in measuring prolonged pain (chapter 2). 
Pain assessment is inseparable from pain treatment.
• Introducing new guidelines does not imply that medical and nursing staff will fully 
comply with these guidelines: we learned that documentation of protocol violations 
and reassessments after adjustment of analgesic/sedative treatment are points of 
improvement for the future (chapter 3). 
• Intravenously administered paracetamol has become available in the Netherlands 
and is suggested to have fewer side effects than the predominantly used opioids 
so far. Paracetamol is metabolized in the liver mostly into APAP-sulphate, to a lesser 
extent into APAP-glucuronide due to an immature glucuronide conjugation system. 
Only a small portion is oxidized into the toxic metabolites (chapter 5). 
• Intravenously administered paracetamol is not effective in relieving acute pain, for 
example, pain associated with placement of a central venous catheter (chapter 6). 
• The use of paracetamol to achieve PDA closure is debatable; administration of 
paracetamol after incomplete or complete ibuprofen treatment is useless (chapter 
7). 
Future perspectives 
In terms of expanding our knowledge on neonatal pain management, assessment and 
treatment we have come a long way. Still numerous questions remain unanswered. Find-
ings from research settings combined with clinical experience should be incorporated 
into new pain management guidelines used in the daily care of critically ill neonates. 
Repeated monitoring of compliance with the guidelines is potentially more important. 
Effectiveness of these new guidelines should be evaluated and adjustments should be 
made, if necessary, to prevent that nurses develop pain assessment ‘fatigue’. 
Instead of developing more and newer pain assessment instruments it is worthwhile 
to further evaluate the existing instruments that have been validated for only a spe-
cific painful procedure or patient group. For example, specificity and sensitivity of 
the COMFORTneo scale in the extreme preterm infants should also be tested during 
sleep and skin-to-skin care. Exploring the applicability of novel methods, such as NIRS 
and biomarkers like hair cortisol, should also be included in future research on stress 
in neonates of all gestational ages. Note, however, that only studies in which relevant 
differences in stress levels are expected will be of any help. 
In this thesis we found that paracetamol is not suitable to relieve acute pain. The role 
of fentanyl or remifentanil herein could be a field for future research. Paracetamol as 
an adjuvant to other analgesics is also a field to explore. A possible reduction of opioid 
needs post- operatively by adding paracetamol or replacing morphine with paracetamol 
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is certainly worth investigating. For example, in preterm neonates after surgical liga-
tion or surgery for NEC or focal intestinal perforation. Future research should also take 
safety measures into account: data on the effects of high doses or prolonged use of 
paracetamol treatment on the short term (considering liver and kidney function) and on 
the long term (neurodevelopment) are still scarce.
We should not ignore the lack of PK/PD data as well as safety aspects and blindly copy 
the dose regimen of a newer drug established in other studies that only focused on 
positive effects. The use of paracetamol in PDA treatment is a good example of this. 
Future research should, at least include a randomized controlled trial in a population of 
patients with different gestational ages comparing paracetamol (15 mg/kg/6 hour) with 
placebo to rule out cases of spontaneous PDA closure. 
The next step logical step would be a PK/PD study investigating the relationship be-
tween the dose-concentration-effect of paracetamol on PDA closure. Large samples 
are needed to investigate the safety of the used doses of paracetamol, but it is worth 
attempting so as to deal with this issue for once and for all.
PK modeling of available data on PDA treatment with paracetamol in different gesta-
tional age groups can lead to different dosing recommendations per age group. A proof 
of principle study with dose recommendations of paracetamol for PDA is another option 
for future research.
Our search for effective and safe analgesics suitable for even the extreme preterm in-
fants will continue as the use of paracetamol did not answer all our research questions. 
Both the role of paracetamol in multimodal analgesic treatment and the indications 
for maintenance paracetamol treatment need to be elucidated. Meanwhile we should 
also focus on improving pain assessment. Instead of developing new instruments, the 
area of technology-based pain assessment instruments probably in combination with 
a validated pain assessment instrument is a promising field to explore. These new in-
struments should be ideally non-invasive, easy to use and applicable for infants of all 
gestational ages. Although critically ill infants need to undergo painful procedures in 
the context of intensive care, and pain prevention obviously is preferable, with proper 
pain assessment - and consequently adequate pain treatment - we can contribute to 
their survival with bright prospects for their future.
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“Pain is inevitable; suffering is optional”. This phrase by Haruki Murakami summarizes 
what we have learned in the past three decades where far-reaching changes took place 
in pain perception and pain management of newborns. For example, the misconception 
that preterm infants cannot feel pain due to an immature central nervous system was 
corrected. Furthermore, it was demonstrated that untreated pain can have acute, short 
term but also long-lasting physiologic and neurodevelopmental negative outcomes. 
Advances in technology made it possible to treat and keep the very ill and extremely 
preterm infants alive. They have to endure numerous painful procedures on their way 
to survival, however, and adequate and effective pain management is therefore an 
indispensable part of their treatment.
Research in the past years led to profound interest in improving and optimizing pain 
assessment, prevention and treatment. This thesis presents various facets of pain assess-
ment and management in newborn infants and of our search for effective and safe an-
algesics, suitable even for extreme preterm infants. This search focused on paracetamol, 
which worldwide has various applications including the treatment of fever and control 
of mild-to moderate pain as a single agent or as part of multimodal analgesia.
Pain should be considered the fifth vital sign according to the American Pain Society 
and proper pain assessment tools are indispensable for adequate dosing of analgesics 
in neonates. A wide selection of multidimensional pain measurement instruments is 
available, many of which combine behavioral items (facial expression, movements) with 
physiological parameters like change in heart rate and oxygen saturation. The majority 
of these instruments target acute procedural pain whereas prolonged pain, such as that 
induced by mechanical ventilation, is much more difficult to assess. In a clinical obser-
vational study described in Chapter 2, we tested a modified version of the COMFORT-
behavioral scale, called the COMFORTneo scale, for its psychometric qualities in the 
NICU setting. Nurses assessed patients with the COMFORTneo scale and Numeric Rating 
Scales (NRS) for pain and distress. The COMFORTneo scale showed good interrater reli-
ability (median weighted Cohen κ 0.79). COMFORTneo cut off scores of 14 or higher had 
good sensitivity (r=0.81) and specificity (r=0.90) using NRS-pain and NRS-distress scores 
of 4 or higher as criterion. No major differences were found in cut-off values for low birth 
weight, small for gestational age, neurological impairment risk levels or gender.
In 2005 a pain management protocol was implemented in our NICU including individual 
pain assessments and pain treatment guidelines with an accompanying decision tree for 
treatment. The pain management protocol demanded that nurses assess pain with the 
COMFORTneo scale in all patients three times every 24 hour (once every 8-hour shift). 
Extra COMFORTneo assessments were required in case of suspected pain or distress, after 
148 Chapter 9
an acute painful procedure, in case of suspected oversedation and in case of administra-
tion of analgesics and/or sedatives for five days or longer. Chapter 3 describes to what 
extent the medical and nursing staff complied with this pain protocol in calendar year 
2011. The majority of pain scores (86%) suggested that patients were comfortable, with 
scores between 9 and 14. The requirement of pain assessments three times daily was 
not always complied with. Compliance with pain assessment and treatment was far from 
perfect generally. In cases of high pain scores (>=14), the required reassessment within 
60 minutes took place in 31% of cases and in 40% treatment was started or adjusted. In 
cases of low pain scores (<=8) during treatment, 13% of the 457 assessments were reas-
sessed within 120 minutes and in 17% a dose reduction was performed. There is room 
for improvement with respect to reassessments after adjustment of analgesic/sedative 
treatment. Lastly we recommended justified and individualized adaptation of pain pro-
tocols to increase compliance and get rid of useless and time-consuming procedures 
not resulting in adjustment of treatment. Tailoring the number of pain assessments to 
the individual patient could also contribute to better compliance.
In a prospective observational study reported in Chapter 4, we counted the total num-
ber of notably painful procedures 175 neonates admitted to our NICU were subjected to 
in the first two weeks of life. We also registered the number of attempts needed for cer-
tain painful procedures and quantified analgesic therapy used in these patients. From a 
study performed in 2001 it appeared that in our NICU neonates underwent a mean of 14 
painful procedures per day and that pharmacological analgesic therapy was given to no 
more than 60.3% of neonates per study day. After this study we introduced sucrose and 
NIDCAP on our ward, placing a focus on non-pharmacological pain management. New 
pain guidelines and a decision tree for pharmacological treatment were implemented 
at the same time. This new study brought to light that neonates still had to endure a 
mean number of 11 painful procedures per day in the first two weeks of life and that no 
more than 36.6% received analgesics, most likely because more non-pharmacological 
pain- or stress reducing strategies like NIDCAP and sucrose were applied. As further 
reduction of the number of painful procedures is unlikely we should apply more non-
pharmacological interventions and explore newer pharmacological agents.
We therefore focused on the metabolism of intravenous paracetamol in Chapter 5. The 
use of paracetamol in very preterm infants is limited due to the lack of data on dosing, 
efficacy and safety. We conducted a multicenter, blinded and randomized trial in 60 very 
preterm infants (n= 60) with a gestational age between 24 and 32 weeks. They were ran-
domly allocated to one of three different single doses of intravenous paracetamol (10, 
15, 20 mg/kg) before central venous catheter placement in the first week of life. Plasma 
concentrations of paracetamol and its non-toxic and toxic metabolites were determined. 
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In neonates paracetamol is primarily metabolized into APAP-Sulphate (APAP-Sulph) and 
to a lesser extent into APAP-Glucuronide (APAP-Gluc) due to an immature glucuronide 
conjugation system. An even smaller part of APAP is metabolized via oxidation with iso-
enzymes CYP2E1, 1A2 and 3A4 of Cytochrome P450 into the toxic metabolite NAPQI. 
The enzyme gluthatione S transferase converts NAPQIs into APAP-Gluthatione (APAP-
Glut), which is metabolized into APAP-Cysteine (APAP-Cys) and APAP-N-acyl-Cysteine 
(APAP-NAC). All AUCs of APAP and its metabolites increased statistically significantly 
with increasing paracetamol doses, with p values ranged from p<0.001 for AUCs of APAP 
and APAP-Sulph to p=0.04 for AUCs of APAP-NAC.
Gestational age determines the glucuronidation pathway of paracetamol as AUC of 
APAP-Gluc for the older gestational age group was statistically significantly larger than 
that for the younger age group
Whether polymorphisms of different CYP-isoenzymes play a role in APAP-induced hepa-
totoxicity is unknown. Still, paracetamol-induced hepatotoxicity caused by N-acetyl-p-
benzoquinone imine (NAPQI) formation produced by the oxidative enzyme CYP2E1 has 
been described. We therefore determined the relation between CYP2E1 polymorphism 
and the formation of oxidized metabolites of APAP as an indirect measurement for 
NAPQI formation. In 58 patients we performed DNA sampling and CYP2E1-wild type 
was found in 45 patients (77.6%) and in 13 patients (22.4%) a polymorphism for CYP2E1: 
2 homozygous and 11 heterozygous, respectively. In a multiple regression analysis 
with CYP2E1 polymorphism as a predictor and controlling for gestational age and 
paracetamol dose, there was a trend towards lower AUCs of APAP-Cys for patients with 
the CYP2E1 polymorphisms (p=0.07). This trend was not found for APAP-NAC (p=0.15). 
These “premature” data might suggest a protective role of the CYP2E1 polymorphism in 
the formation of reactive metabolites. This finding is in line with limited literature avail-
able in adults, where a similar decrease of the proteins as well as the catalytic activity of 
this CYP2E1 variants was found suggesting that polymorphism of CYP2E1 iso-enzymes 
leads to less protein formation or less stable proteins.
Besides the pharmacokinetic properties of paracetamol we also studied the pharma-
codynamics of paracetamol in the same study population in Chapter 6. The objective 
of the study was to determine the analgesic effect of different doses of paracetamol, 
and a group of age-matched neonates who underwent the same procedure after 
administration of sucrose only, served as control group. Pain during central venous 
catheter placement was assessed with two pain assessment tools: the Premature Infant 
Pain Profile (PIPP), a multidimensional tool that has been well validated to assess pro-
cedural pain in preterm and term neonates. As second assessment tool we used the 
COMFORTneo scale, which had good psychometric qualities in our NICU (chapter 2). No 
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statistically significant differences in pain scores were found between the paracetamol 
treatment groups and the sucrose group. The median PIPP score was 7 for the 15 mg/
kg paracetamol group and 8 for all other treatment groups, reflecting mild to moderate 
pain. COMFORTneo scores of 14 or higher, suggesting pain or distress, were assigned to 
25% of infants who received sucrose and to up to 50% of infants in the 15 mg/kg and 
20 mg/kg paracetamol groups. None of the infants showed abnormal kidney or liver 
function after treatment with a single dose of paracetamol, but the number of patients 
in this study is too limited to draw conclusions about safety of paracetamol in general.
The phrase “Old medication with a new indication” applies to Chapter 7. The ductus ar-
teriosus fails to close after birth in 30 to 60% of prematurely born infants. This condition 
– patent ductus arteriosus (PDA) – is associated with a prolonged ventilation need and 
carries an increased risk of morbidity (i.e., necrotizing enterocolitis, chronic lung disease) 
and even mortality. Pharmacological closure with non-steroidal anti-inflammatory drugs 
(NSAIDs), mainly ibuprofen and indomethacin, is currently the standard of care and was 
found effective in around 70% of patients. Moreover, NSAIDs are contra-indicated in a 
considerable proportion of newborns, notably those with renal failure, intracerebral 
hemorrhage, gastro-intestinal problems and thrombocytopenia. If NSAIDs fail or are 
contra-indicated, the only currently available solution is surgical ligation, which is as-
sociated with the risks of cardiothoracic surgery and impaired neurological outcome. 
Paracetamol has been suggested as an alternative drug for PDA closure. More than 10 
observational and retrospective studies have described oral or intravenous high-dose 
paracetamol treatment with varying effectiveness. Two recent prospective randomized 
controlled trials comparing oral paracetamol with ibuprofen both showed a slightly fa-
vorable effect of paracetamol. We conducted a prospective observational cohort study 
in which we evaluated the effectiveness of intravenous paracetamol in closing a PDA in 
very low birth weight infants with a hemodynamically significant PDA who either did 
not respond to ibuprofen or had a contra-indication for ibuprofen. They received high 
dose paracetamol therapy (15mg/kg/6h intravenous) for 3-7 days. Cardiac ultrasounds 
were performed before and 3 and 7 days after treatment. We included 33 patients with 
a median gestational age of 251/7 weeks (IQR 1.66), a median birth weight of 750 grams 
(IQR 327) and a median post-natal age of 14 days (IQR 12). Paracetamol was ineffective 
in 27/33 patients (82%). This percentage even rose to 100% after previous exposure 
to ibuprofen. Patients with a primary contra-indication for ibuprofen (n=13; 39.4%) 
received the first dose of paracetamol after a median of 12 (IQR 11.5) postnatal days and 
the median duration of the course was 6 (IQR 3) days. In six patients (46%) the ductus 
arteriosus was closed or not hemodynamically significant after paracetamol and further 
treatment was not indicated.
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In view of the findings from this study, we do not recommend the use of intravenous 
paracetamol for hemodynamic significantly PDA closure in VLBW infants after ibuprofen 
failure. Still, as we did not rule out effectiveness of paracetamol as early PDA treatment, 
it might be recommended when started in the first week of life. On the other hand, as 
long as data on long term safety are lacking, high dosages of paracetamol should be 
used with caution. Better designed PK/PD studies are needed to shed a light on safety 
aspects and the optimal dose-concentration-effect relationship of paracetamol and 
PDA closure.
In Chapter 8 the results of our studies are discussed and recommendations for future 
perspectives and research are given.
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“Pijn is onvermijdelijk, lijden is een keuze”. Deze uitspraak van de schrijver Haruki Mu-
rakami verwoordt goed wat we hebben geleerd in de afgelopen drie decennia, waarin 
grote veranderingen hebben plaatsgevonden in onze inzichten over pijn en het pijnbe-
leid bij pasgeborenen. De eerdere opvatting dat te vroeg geboren kinderen geen pijn 
kunnen voelen omdat hun centraal zenuwstelsel zich nog moet ontwikkelen is inmiddels 
weerlegd. Verder is aangetoond dat onbehandelde pijn negatieve effecten kan hebben 
op de ontwikkeling van het kind, zowel op de korte als de lange termijn. Tegenwoordig 
is het technisch beter mogelijk om ernstig zieke en extreem prematuur (=veel te vroeg) 
geboren kinderen te behandelen en in leven te houden. Hun medische behandeling in 
de eerste weken na de geboorte brengt echter talrijke pijnlijke handelingen met zich 
mee, en het is uiteraard belangrijk om de pijn goed te bestrijden.
Er is in de afgelopen jaren al veel onderzoek gedaan naar betere pijnmeting, -preventie 
en –behandeling in het algemeen. Dit proefschrift gaat in op deze facetten met betrek-
king tot pasgeboren kinderen, en in het bijzonder op onze zoektocht naar effectieve 
pijnstillers die zelfs geschikt zijn voor veel te vroeg geboren kinderen. We hebben ons 
voornamelijk gericht op paracetamol, een geneesmiddel dat wereldwijd wordt gebruikt 
voor de behandeling van koorts en lichte tot matige pijn. 
Volgens de American Pain Society zou pijn beschouwd moeten worden als de vijfde 
vitale functie en zijn goede pijnmeetinstrumenten onmisbaar om pijnmedicatie bij 
pasgeborenen goed te kunnen doseren. Veel van de geschikte en gebruikte pijn-
meetinstrumenten voor pasgeborenen combineren zogenaamde gedragsindicatoren 
(bijvoorbeeld gelaatsexpressie en bewegingen) met lichamelijke kenmerken zoals 
veranderingen in de hartslag en zuurstofverzadiging. De meeste pijnmeetinstrumenten 
zijn bedoeld om acute pijn te meten, zoals bijvoorbeeld van een hielprik. Langdurige 
pijn, bijvoorbeeld door mechanische ventilatie, is veel moeilijker te beoordelen. 
Hoofdstuk 2 beschrijft een onderzoek in onze NICU naar de sensitiviteit en specificiteit 
van een aangepaste versie van de COMFORT-gedragsschaal, genaamd de COMFORTneo 
schaal. Verpleegkundigen beoordeelden pijn en onrust van de pasgeborenen met zowel 
de COMFORTneo schaal als de Numerieke Rating Schaal (NRS). Voor toepassing van de 
COMFORTneo schaal werd goede overeenkomst gevonden tussen de verschillende 
beoordelaars (mediaan gewogen Cohen k 0.79). Bij afkapwaarden van de COMFORTneo 
schaal van 14 of hoger hebben een goede sensitiviteit (r=0.81) en specificiteit (r=0.90) 
met als criterium een NRS-pijn en NRS-onrust score van 4 of hoger. Geboortegewicht, 
dysmaturiteit (=te laag geboortegewicht voor de zwangerschapsduur), neurologische 
ontwikkeling of geslacht speelden hierbij geen rol.
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In 2005 werd op onze NICU een protocol voor pijnbeleid ingevoerd dat voorziet in 
verplichte pijnmetingen en richtlijnen geeft voor de behandeling van pijn aan de hand 
van een beslisboom. De verpleegkundigen worden geacht bij alle patiënten minstens 
drie keer per 24 uur (1 maal per 8-uurs dienst) pijn te beoordelen met de COMFORTneo 
schaal. Extra metingen moeten worden uitgevoerd bijvoorbeeld bij verdenking op pijn 
of onrust, na een pijnlijke handeling, of bij verdenking op te veel sedatie of in geval van 
langdurige toediening (5 dagen of meer) van pijnstillers al dan niet in combinatie met 
sedatie. Hoofdstuk 3 beschrijft de mate waarin de medische en verpleegkundige staf 
dit pijnprotocol opvolgden in het kalenderjaar 2011. De meerderheid van de pijn scores 
(86%) waren tussen de 9 en 14 wat suggereert dat patiënten comfortabel waren. De 
pijnmeting met de COMFORTneo schaal drie keer per dag werd niet altijd nageleefd. 
Ook werd in geval van hoge pijnscores (>=14) maar in 31% van de gevallen de verplichte 
herbeoordeling binnen 60 minuten gedaan en werd maar in 40% van de gevallen 
waarin dit op grond van de beoordeling nodig was, behandeling van pijn gestart of 
aangepast. In geval van lage pijn scores (<=8) gedurende de behandeling werd in 13% 
een herbeoordeling gedaan binnen 120 minuten en in 17% werd de dosering verlaagd. 
De ruimte voor verbetering ligt in het uitvoeren van herbeoordelingen na aanpassingen 
van de medicatie. Ook kan het afstemmen van het aantal pijnmetingen op de individu-
ele patiënt bijdragen tot een betere naleving van het protocol.
Hoofdstuk 4 beschrijft een prospectieve observationele studie naar het totaal aantal 
pijnlijke procedures die 175 pasgeborenen op onze NICU moesten ondergaan in de 
eerste twee levensweken. Verder hebben we ook het aantal pogingen genoteerd die 
nodig waren voor een bepaalde pijnlijke procedures zoals intubatie, inbrengen van 
navellijnen en centrale lijnen en het prikken van een perifere arterielijn. Verder is ge-
noteerd welke en hoeveel pijnstillende medicatie is gegeven aan deze patiënten in die 
eerste twee levensweken. Uit een soortgelijke eerdere studie in 2001 op onze NICU, was 
een gemiddeld aantal van 14 pijnlijke procedures per kind per dag naar voren gekomen; 
ook bleek dat niet meer dan 60,3% van de pasgeborenen pijnmedicatie kreeg. Naar 
aanleiding van die studie hebben we de toediening van sucrose voor pijnlijke proce-
dures en NIDCAP- als niet-farmacologische pijnbestrijding ingevoerd op onze NICU; 
een nieuw pijnprotocol met een beslisboom voor farmacologische pijnbehandeling 
werd tegelijkertijd geïntroduceerd. Onze nieuwe studie, uitgevoerd in 2009, liet zien 
dat pasgeborenen gemiddeld nog steeds 11 pijnlijke procedures per dag ondergaan 
in de eerste twee levensweken en dat maar 36.6% van hen pijnstillers heeft gekregen, 
waarschijnlijk omdat niet-farmacologische pijn- en stress reducerende strategieën zoals 
NIDCAP en sucrose werden toegepast. Aangezien een verdere vermindering van het 
aantal pijnlijke procedures per patiënt per dag onwaarschijnlijk is, zullen we meer niet-
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farmacologische interventies moeten gaan toepassen en op zoek moeten gaan naar 
nieuwere farmacologische middelen.
Het gebruik van paracetamol bij veel te vroeg geboren kinderen is beperkt ten gevolge 
van het gebrek aan data over dosering, effectiviteit en veiligheid. In Hoofdstuk 5 heb-
ben we ons gefocust op het metabolisme van intraveneus toegediende paracetamol 
en beschrijft een gerandomiseerde, geblindeerde studie bij 60 pasgeborenen met een 
zwangerschapsduur tussen de 24 en 32 weken. Ze werden willekeurig toegewezen aan 
een van de drie verschillende doseringen van intraveneus toegediende paracetamol (10, 
15 of 10 mg/kg) voorafgaande aan het plaatsen van een centraal veneuze katheter, dat 
een pijnlijke handeling is. Plasma concentraties van paracetamol en de metabolieten 
werden bepaald in het bloed. Bij pasgeborenen wordt paracetamol primair gemetabo-
liseerd in APAP-Sulfaat (APAP-Sulph) en in mindere mate in APAP-Glucuronide (APAP-
Gluc) ten gevolge van een onrijp glucuronide conjugatie systeem. Een nog kleiner 
deel van de paracetamol wordt via oxidatie met iso-enzymen CYP2E1, 1A2 en 3A4 van 
Cytochroom P450 omgezet in de toxische metaboliet N-acetyl-p-benzoquinone imine 
(NAPQI). Het enzym glutathion S transferase zet NAPQIs direct om in APAP-Glutathion 
(APAP-Glut), dat vervolgens wordt gemetaboliseerd in APAP-Cysteine (APAP-Cys) en 
APAP-N-acetyl-Cysteine (APAP-NAC). Alle ‘area’s under the curve’ van paracetamol en 
de metabolieten namen statistisch significant toe met een hogere dosis paracetamol 
dosis, met p-waardes variërend van p<0.001 voor APAP en APAP-Sulph tot p=0.04 voor 
APAP-NAC.
Of polymorfisme van de verschillende CYP-iso-enzymen een rol spelen in de door 
paracetamol veroorzaakte hepatotoxiciteit (leverschade) is onbekend. Hoewel hepa-
toxiciteit veroorzaakt door de vorming van NAPQIs uit paracetamol door het oxidatieve 
enzym CYP2E1 wel beschreven is. We hebben onderzoek gedaan naar polymorfismen 
van CYP2E1en de vorming van toxische metabolieten van paracetamol. DNA sampling 
bij 58 van de 60 patiënten gaf als resultaat dat 45 patiënten (77.6%) het CYP2E1 wild 
type hadden en 13 patiënten (22.4%) een polymorfisme voor CYP2E1: 2 homozygoot 
en 11 heterozygoot. In een multipele regressieanalyse met CYP2E1 polymorfisme als 
predictor, en gecontroleerd voor zwangerschapsduur en paracetamol dosis, was er een 
trend naar lagere ’area’s under the curve’ voor APAP-Cys voor patiënten met het CYP2E1 
polymorfisme (p=0.07). Deze trend werd niet gevonden voor APAP-NAC (p=0.15). Deze 
‘premature’ data zouden kunnen wijzen op een beschermende rol van CYP2E1 poly-
morfismen bij de vorming van reactieve metabolieten. Deze bevinding komt overeen 
met de beperkte beschikbare literatuur bij volwassenen, waar zowel een vergelijkbare 
daling van de gevormde metabolieten als een verlaagde de katalyserende activiteit van 
deze CYP2E1 varianten was gevonden; Dit wijst er op dat polymorfismen van CYP2E1 
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iso-enzymen kunnen leiden tot minder metaboliet formatie of tot minder stabiele 
metabolieten. 
Naast de farmacokinetische eigenschappen van paracetamol hebben we ook de farma-
co-dynamiek bestudeerd van paracetamol bij de kinderen beschreven in Hoofdstuk 6. 
Het doel van de studie was het bepalen van het pijnstillende effect van verschillende 
doseringen paracetamol en een groep leeftijd-gematchte pasgeborenen die dezelfde 
procedure moesten ondergaan maar met sucrose als pijnstilling fungeerde als controle 
groep. Pijn tijdens het plaatsen van een centraal veneuze katheter werd gemeten met 
twee pijnmeetinstrumenten: de eerder genoemde COMFORTneo schaal (hoofdstuk 2) 
en de Premature Infant Pain Profile (PIPP), een multidimensioneel instrument dat ge-
valideerd is voor de beoordeling van acute procedurele pijn bij prematuren en terme 
pasgeborenen. Er werden geen statistisch significante verschillen in pijnscores gevon-
den tussen de verschillende paracetamol doseringen en de sucrose groep. De mediane 
PIPP score was 7 voor de groep kinderen die 15 mg/kg paracetamol hadden gekregen 
en 8 voor de overige groepen, duidend op mild tot matige pijn. COMFORTneo scores 
van 14 of hoger, wijzend op pijn of onrust, werden gevonden bij 25% van de kinderen 
die sucrose hadden gekregen en bij maximaal 50% van de kinderen die of 15mg/kg of 
20mg/kg paracetamol hadden gekregen. Geen van de kinderen vertoonde nier- of le-
verfunctiestoornissen als gevolg van de behandeling met een enkele dosis paracetamol, 
maar het aantal patiënten in dit onderzoek is te klein om conclusies te mogen trekken 
over de veiligheid van paracetamol in het algemeen.
De uitdrukking “Oude medicatie met een nieuwe indicatie’ zou goed kunnen passen bij 
Hoofdstuk 7. Bij 30 tot 60% van de te vroeg geboren kinderen sluit de ductus arteriosus 
niet spontaan na de geboorte, wat wel het geval zou moeten. De ductus arteriosus is een 
bloedvat dat de longslagader verbindt met de lichaamsslagader. Dit bloedvat is vooral 
belangrijk tijdens het intra-uteriene leven van een foetus. Als dit bloedvat open blijft na 
de geboorte, is langdurige mechanische ventilatie nodig en is er grote kans op ernstige 
aandoeningen, zoals necrotiserende enterocolitis en chronische longziekte, en zelfs op 
overlijden. De huidige standaardtherapie is toediening met zogenaamde NSAIDs, vooral 
ibuprofen en indomethacine, maar dit werkt slechts bij ongeveer 70% van de patiënten. 
Bovendien kunnen deze medicijnen niet worden gegeven aan kinderen met aandoenin-
gen zoals nierfalen, hersenbloedingen, maagdarmklachten en trombocytopenie. Dan 
blijft alleen chirurgische sluiting als behandelmogelijkheid voor een open ductus over, 
maar deze operatie draagt ook risico’s met zich mee met een verhoogde kans op ook 
een slechtere neurologische uitkomst.
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Paracetamol wordt genoemd als alternatief medicijn voor het sluiten van een open 
ductus. Meer dan 10 observationele en retrospectieve studies hebben de orale of intra-
veneuze hoog gedoseerde paracetamol behandeling voor een open ductus beschreven 
met wisselende effectiviteit. In twee recente prospectieve, gerandomiseerde, gecon-
troleerde trials waarin paracetamol werd vergeleken met ibuprofen bleek paracetamol 
een iets gunstiger effect te hebben op het sluiten van de ductus. Wij hebben een pros-
pectieve, observationele cohortstudie verricht waarin we gekeken hebben in hoeverre 
intraveneuze toediening van paracetamol effectief was om een open ductus arteriosus 
te sluiten. Het ging hierbij om 33 kinderen met een geboortegewicht < 1500 gram 
met een open ductus die aanleiding gaf tot klinische symptomen (= hemodynamisch 
significante ductus) en waarvoor ibuprofen behandeling faalde of gecontra-indiceerd 
was. Ze kregen 3 tot maximaal 7 dagen een hoge dosis paracetamol (15 mg/kg/6 uur 
intraveneus) toegediend, en echo’s van het hart werden gemaakt voorafgaande aan de 
behandeling met paracetamol en 3 en 7 dagen daarna ter controle van de sluiting. 
De paracetamol was ineffectief bij 27 van de 33 kinderen (82%). Dit percentage was 
zelfs 100% bij de kinderen die voorafgaande aan de paracetamol een behandeling met 
ibuprofen hadden gekregen. Van de 33 kinderen hadden er 13 een contra-indicatie 
voor een behandeling met ibuprofen en zij kregen primair paracetamol. In 6 van deze 
13patiënten (46%) was na behandeling met paracetamol de ductus arteriosus gesloten 
of niet meer hemodynamisch significant dat verdere behandeling nodig was.
Gezien het hoge percentage kinderen bij wie een behandeling met intraveneuze parace-
tamol niet leidde tot sluiting van een hemodynamisch significante ductus zien wij geen 
reden om dit toe te passen bij kinderen met een geboortegewicht < 1500 gram als ibu-
profen eerder al niet effectief was gebleken. We sluiten de effectiviteit van paracetamol 
voor de vroege open ductus behandeling in de eerste levensweek niet uit. Niettemin is 
voorzichtigheid geboden in het gebruik van hoge doseringen paracetamol zolang er 
weinig bekend is over de veiligheid op de lange termijn. Weldoordachte PK/PD studies 
kunnen inzicht geven in de veiligheidsaspecten en de optimale dosis- concentratie- ef-
fect relatie van paracetamol om sluiting van de ductus arteriosus te bewerkstelligen.
In Hoofdstuk 8 zullen de resultaten van onze studies bediscussieerd worden en aanbe-
velingen gedaan worden voor toekomstig onderzoek. 
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List of abbreviations
ALAT  Aspartaat-aminotransferase
APAP  Acetyl-para-aminophenol
APAP-Cys APAP-Cysteine
APAP-Gluc APAP-Glucuronide
APAP-Glut APAP-Glutathione
APAP-NAC APAP-N-acetyl-cysteine
APAP-Sulph APAP-sulphate
ASAT  Alanine-aminotransferase
AUC  Area Under the Curve
BUN:  Blood Urea Nitrogen
CI  Confidence Interval
CPAP  Continuous Positive Pressure Ventilation
CRIB  Critical Risk Index for Babies
CVC:  Central venous catheter
EDIN  Echelle Douleur Inconfort Nouveau-Né
EEG  Electroencephalogram
ELBW  Extreme Low Birth Weight
GA  Gestational Age
hsPDA  hemodynamically significant Patent Ductus Arteriosus
IQR  Interquartile range
IRDS  Infant Respiratory Distress Syndrome
i.v.  Intravenous
IVH  Intraventriculair hemorrhage
LA/Ao ratio Left Atrial to Aortic Root ratio
LLOQ  lower limit of quantification
LPA  Left Pulmonary Artery
mg  Milligram
NAPQI  N-acetyl-p-benzoquinone imine
NEC  Necrotizing Enterocilitis
NI  Neurologic Impairment
NICU  Neonatal Intensive Care Unit
NIDCAP  Newborn Individualized Developmental Care and Assessment Pro-
gram
NIRS  Near-infrared Spectroscopy
N-PASS  Neonatal Pain, Agitation and Sedation Scale
NPT  Nasopharyngeal Tube
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NRS  Numeric rating Scale
NSAID  Non-Steroidal Anti-Inflammatory Drug
PD  Pharmacodynamic
PDA  Patent Ductus Arteriosus
PDMS  Patient Data Management System
PICU  Pediatric Intensive Care Unit
PIPP  Premature Infant Pain Profile
PK  Pharmacokinetic
ROC  Receiver Operator Characteristic
SD  Standard Deviation
SDM  Standardized Mean Difference
SGA  Small for Gestational Age
SPSS  Statistical Package for the Social Sciences
VLBW  Very Low Birth Weight
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Dankwoord
Alles zelf doen is optellen, samenwerken is vermenigvuldigen. 
Deze zin is zeker van toepassing op de totstandkoming van mijn proefschrift want met 
de steun en hulp van velen is de eindstreep gehaald. Een hele opgave voor iemand 
wiens hart ligt bij de klinische patiëntenzorg en het reilen en zeilen van de afdeling 
Neonatologie. Het voltooien van dit proefschrift is voor mij dan ook zeker een mijlpaal 
die me veel voldoening geeft en bovendien een beetje trots maakt. Dit had ik nooit allen 
gekund en ik ben allen dankbaar die een bijdrage geleverd hebben aan dit werk.
Allereerst gaat mijn oprechte dank uit naar alle kinderen en ouders/verzorgers die 
mee gewerkt hebben aan de studies waar dit proefschrift op gebaseerd is. Door jullie 
deelname aan wetenschappelijk onderzoek zijn we in staat de behandeling voor veel 
te vroeg geboren kinderen aan te passen en te optimaliseren met als doel een beter 
toekomstperspectief. Dit proefschrift is voor en door jullie tot stand gekomen.
Mijn promotoren Prof. dr. Tibboel en Prof. dr. van den Anker. Beste Dick, om onderzoek 
te doen op het gebied van de farmacologie kan je je geen betere plek wensen en jouw 
begeleiding, kritisch en analytisch vermogen, snelle respons en je gedrevenheid heb ik 
zeer gewaardeerd. Vol trots kan ik ook zeggen dat ik je 94ste promovendus ben. 
Beste John, toen jij mij op een congres een fellowship Neonatologie aanbood in het 
Sophia Kinderziekenhuis twijfelde ik geen seconde. Mijn grootste wens ging hiermee 
in vervulling. Jouw input, ondersteuning en bruikbare suggesties voor dit proefschrift, 
vanuit Amerika en Bazel, zijn heel belangrijk geweest. Daarnaast heb je me ook laten 
zien dat je naast een hele goede klinische dokter ook waardevol wetenschappelijk 
onderzoek kan doen. Ik zal me de komende twintig jaar niet gaan vervelen!
Mijn copromotor Dr. Van Dijk, lieve Monique, wat moest ik zonder jou? Ik ben ondertussen 
Endnote de baas maar jouw SPSS gegoochel geeft me nog steeds een minderwaardig-
heidscomplex. Ik kan je niet genoeg bedanken voor je hulp, wijze en soms opbeurende 
woorden maar bovenal je nooit aflatende energie en positiviteit. Het is voor mij een eer 
dat je mijn copromotor wilde zijn.
Prof. dr. Allegaert, Prof. dr. Knibbe en Prof. dr. Reiss, beste Karel, Catherijne en Irwin, dank 
voor jullie constructieve bijdrage, suggesties en ondersteuning in de diverse studies. Te-
vens dank voor jullie bereidheid om plaats te nemen in de kleine commissie en voor de 
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beoordeling van mijn proefschrift. Mijn speciale dank gaat uit naar Irwin, ‘Grote-kleine 
Baas’ voor de tijd, de mogelijkheden, je steun en vertrouwen die je me gegeven hebt om 
dit proefschrift te schrijven. Met alle andere neonatologie-spelers tezamen vormen we 
een afdeling die ‘Champions League’-waardig is.
Daarnaast wil ik de overige leden van de promotiecommissie, Dr. van Lingen, Dr. Simons 
en Prof. dr. Carbajal danken voor de bereidheid om plaats te nemen in de grote com-
missie.
Dr. R van Lingen, beste Richard, helemaal los van Rotterdam en paracetamol kom je niet. 
Ik wil je ook enorm bedanken voor je participatie in de multicenter studies. Wellicht 
zullen we in de toekomst nieuwe samenwerkingsverbanden aan gaan met Zwolle.
Dr. Simons, beste Sinno, eens mocht ik jou helpen bij je promotieonderzoek en nu waren 
de rollen omgekeerd. Dank voor alles en eigenlijk had ik gewoon twee copromotoren. 
Straks zal ik meehelpen om farmacologisch onderzoek te promoten en uit te voeren op 
onze afdeling.
Prof. dr. Carbajal, dear Ricardo, I am truly honored that you would like to participate in 
my PhD committee.
Prof. dr. van Goudoever, beste Hans. Jij was het die tegen mij zei dat ik iedere vijf jaar een 
nieuwe uitdaging in mijn vak moest zoeken en dat iets doen dat je niet makkelijk afgaat 
maar veel moeite en energie kost, je uiteindelijk meer voldoening zal geven. Je had 
helemaal gelijk! Dank voor het scheppen van de mogelijkheden om dit promotietraject 
te starten in 2009. Op de goede afloop zullen we zeker samen een glaasje drinken.
Speciale dank gaat uit naar alle co- auteurs waar ik de afgelopen jaren mee samen 
gewerkt heb en die ik nog niet bij naam en toenaam heb genoemd.
Research doen zonder een team is onmogelijk. Lieve Annelies Bos, ik wil je daarom heel 
erg bedanken voor je inzet, hulp en enorme flexibiliteit. Daarnaast ook voor de gezellige 
koffie momenten, films en etentjes. We gaan gewoon zo door. Liesbeth Groot Jebbink, 
enorme dank voor de ondersteuning en uitvoering van het onderzoek in Zwolle.
Beste Ko Hagoort, jij toverde mijn engelse artikelen om tot nog fraaiere versies. Je 
maakte altijd tijd en werkt echt snel (helemaal niet slakkerig dus) en ik kan je niet vaak 
genoeg bedanken voor je bijdrage en hulp.
Dankwoord 175
Ch
ap
te
r 1
0
Annemarie van Dick, Karin van Irwin en Wendy van Yvonne, lieve dames wat moest ik 
zonder jullie hulp en ondersteuning? Formulieren, handtekeningen, telefoontjes en 
ontcijferingen van handgeschreven correcties. Mijn dank is groot.
Alle (oud) collega’s van de afdeling Neonatologie van het Erasmus MC-Sophia; leiding-
gevenden, neonatologen, fellows, verpleegkundig specialisten, art-assistenten, ver-
pleegkundigen, zorg assistenten en ondersteunende diensten, ik dank jullie allen voor 
de steun, hulp maar ook voor het samen creëren van een fijne werkomgeving waar ik 
heel graag werk en trots op ben. Zonder iemand te kort te willen doen dank ik in het 
bijzonder Andre, mijn trouwe en liefste roommate. Ik denk dat we een goed duo vormen 
ondanks dat jij voor Ajax bent en ik voor Feijenoord. Projecten en uitdagingen genoeg 
waar we samen met de andere collega’s de schouders onder kunnen zetten.
Ook kan ik het niet laten om nogmaals te zeggen dat ik zo ontzettend trots ben op 
de verpleegkundig specialisten op de neonatologie. Ik zie het als een voorrecht dat 
ik heb mogen meedenken en invullen van deze functie op de afdeling samen met de 
verpleegkundig specialisten van het eerste uur. Jullie zijn een waardevolle, onmisbare 
speler geworden in de zorg rondom zieke pasgeborenen en wees daar maar ‘fier’op.
Onmisbaar zijn ook mijn paranimfen, en zeker op een dag als deze.
Lieve Sabrina, lief zuske. Wat ben ik blij dat jij vandaag naast mij staat, deze dag is zo 
compleet. De ‘zusjes’ blijft een begrip waar we nooit meer van af komen maar daar ben 
ik gewoon trots op. 
Lieve Milène, vriendinnetjes vanaf eerste klas van de middelbare school en nu al 36 jaar. 
Superfijn dat jij vandaag naast mij staat.
Dank aan alle vrienden voor jullie geduld, steun en het begrip dat ik helaas niet bij alle 
gebeurtenissen van de partij kon zijn. Maar die tijd is voorbij!! Er kunnen weer eindeloos 
cappucinootjes gedronken worden, de stad onveilig gemaakt worden, etentjes, films, 
borreltjes, en andere leuke uitjes afgesproken gaan worden. Verder beloof ik hierbij aan 
mijn Vlietlijn-vrienden dat ik weer trouw 2 keer per week in de roei-les zal zitten.
Lieve Schultheisjes, allen dank voor het warme welkom in jullie familie, ik voelde me 
meteen thuis.
Lieve Roofthooftjes in Groningen: Marc, Sylvia, en mijn liefste neefjes Joep, Gijs en Pim. 
Ik geef toe broertje, niet zo’n dik proefschrift als het jouwe maar hopelijk ben je net zo 
trots op mij als ik op jou. De tijd voor nog meer leuke dingen is weer aan gebroken.
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Lieve pappa en mamma, dank voor jullie onvoorwaardelijke steun, liefde en vertrouwen. 
Wat hebben wij,  Sabrina, Marc en ik, het goed en heerlijk gehad om in zo’n veilige en 
fijne omgeving op te mogen groeien waarin we alle kansen kregen van jullie. Stelling 11 
zou ook moeten zijn ‘in alles wat wij doen zit een Roofthooft-gehalte’ en daar is niets mis 
mee. Ik ben dankbaar dat we deze dag samen kunnen vieren.
Som-hi tots-♥ Dave
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